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ABSTRACT  
 
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) have been identified as 
an independent, causal risk factor for coronary heart disease. Lp(a) resembles low-density 
lipoprotein (LDL), but is distinguished by the covalent addition of apolipoprotein(a) 
(apo(a)) to the apolipoproteinB-100 (apoB-100) moiety of LDL. Apo(a) shares homology 
with the zymogen plasminogen and Lp(a)/apo(a) can inhibit plasminogen activation to 
the serine protease plasmin on the fibrin surface. In addition, apo(a)/Lp(a) can inhibit 
fibrinolysis through attenuation of Glu
1
-plasminogen to Lys
78
-plasminogen conversion: a 
key positive feedback mechanism in accelerating plasmin formation. Cellular receptors 
for Lp(a)/apo(a) are suggested to contribute to the pathophysiological mechanisms of 
Lp(a) such as inhibition of pericellular plasminogen activation as well as Lp(a) clearance 
from plasma. The roles and identities of these receptors, however, remain elusive. The 
work in this dissertation evaluates the roles of receptors implicated in the ability of 
apo(a)/Lp(a) to inhibit pericellular plasminogen activation as well as in Lp(a) clearance 
by hepatocytes. Apo(a)/Lp(a) was found to potently inhibit pericellular plasminogen 
activation on vascular and blood cells through attenuating Glu
1
- to Lys
78
-plasminogen 
conversion. For both these effects, critical roles for the strong lysine binding site in 
kringle IV type 10 as well as the kringle V domain within apo(a) were identified; there 
was also no dependency on apo(a) isoform size. We found that the urokinase receptor and 
integrins αMβ2 and αVβ3 all contribute to plasminogen activation and apo(a) mediated 
inhibition of plasminogen activation on the cell surfaces of vascular and blood cells, with 
only a minor role for receptors containing carboxyl-terminal lysines. In vivo evidence 
suggests a potential role for proprotein convertase subtilisin/kexin type 9 (PCSK9) in 
Lp(a) clearance through an unidentified receptor. Effects on the number of LDL-receptor 
(LDLR) molecules were found to underlie the ability of PCSK9 to modulate Lp(a) 
catabolism in hepatic cells and fibroblasts. This process was dependent on the apoB-100 
component of Lp(a) and on clathrin-mediated endocytosis. Taken together, our data 
contribute importantly to our understanding of the mechanisms of Lp(a) pathogenicity 
with regard to inhibition of pericellular plasminogen activation and highlight a novel role 
for PCSK9 activity and the LDLR in modulating Lp(a) catabolism. 
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1.1 LIPOPROTEIN(a) 
Lipoprotein(a) (Lp(a)) is an enigmatic lipoprotein that has been identified as a 
causal risk factor for coronary heart disease (CHD) [1,2]. Recent evidence suggests that 
Lp(a) is the strongest genetic risk factor for CHD [Reviewed in ref. 3]. Lp(a) is a 
complex lipoprotein that resembles low-density lipoprotein (LDL) in both lipid 
composition and the presence of apolipoproteinB-100 (apoB-100); however, Lp(a) is a 
unique lipoprotein class that contains a highly glycosolayted hydrophilic component 
called apolipoprotein(a) (apo(a)) (Fig. 1.1) [4]. Glycosylation accounts for approximately 
28% of apo(a) by mass, with both N- and O-linked glycans present on the molecule [5]. 
Apo(a) is predominantly synthesised in the liver [6], after which it becomes covalently 
attached to apoB-100 through a single disulfide bond to form an Lp(a) particle [7] (see 
Section 1.1.3).  
Analysis of the sequence of apo(a) in 1987, following cloning of apo(a) from 
liver, revealed striking similarities to the fibrinolytic zymogen plasminogen [8]. Apo(a) 
consists of multiple copies of a plasminogen-like kringle IV (KIV) domain, followed by 
single copies of plasminogen kringle V (KV) and protease-like domains (Fig. 1.2) [8,9]. 
Unlike plasminogen, the protease domain of apo(a) is inactive [10]. The apo(a) KIV 
domain is further classified into 10 distinct subtypes (KIV1 to KIV10) based on amino 
acid sequence [8]. Isoform size heterogeneity is observed within the population based on 
differing numbers of identically repeated copies of the sequence encoding KIV2 in LPA, 
the gene encoding apo(a) [11-13]. The number of KIV2 domains can vary from 3 to 
greater than 30 identically repeated copies [13].  
3 
 
The similarities between apo(a) and plasminogen represent a potential link 
between the areas of atherosclerosis and thrombosis. Plasmin, the active form of the 
zymogen plasminogen, is a key enzyme involved in fibrinolysis. Therefore, the 
plasminogen-like apo(a) moiety of Lp(a) has been linked to thrombotic events. On the 
other hand, the atherogenic LDL-like component of Lp(a) can contribute to the 
development and progression of atherosclerosis. However, many physiological/ 
pathophysiological proposed functions of Lp(a) have also been shown to be unique to this 
class of lipoprotein independent of its similarities to the LDL- and plasminogen-like 
properties.  
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Figure 1.1: Representation of the structure of Lp(a). Lipoprotein(a) (Lp(a)) resembles 
low-density lipoprotein (LDL) in both lipid composition and presence of 
apolipoproteinB-100 (apoB-100), but is distinguished from LDL by the presence of 
apolipoprotein(a) (apo(a)). The LDL-like moiety is composed of a central core containing 
triglycerides (TG) and cholesteryl esters (CE), surrounded by an outer shell of 
phospholipids (PL) and free cholesterol (FC). Apo(a) consists of multiple copies of a 
plasminogen-like kringle IV (KIV) domain, followed by single copies of a plasminogen-
like kringle V (KV) and protease (P) domains. KIV domains in apo(a) can be further 
classified into 10 distinct subtypes (KIV1 to KIV10) based on amino acid sequence with 
the number of identically repeated KIV2 domains varying in the population from 3 to 
>30. Lysine binding sites (LBSs) in KIV7 and KIV8 play a key role in non-covalent 
association with two Lys residues in the amino-terminal region of apoB-100. This initial 
non-covalent interaction between apo(a) and apoB-100 allows for disulfide bond 
formation between a free cysteine in KIV9 of apo(a) and apoB-100. Adapted from 
reference 4. 
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Figure 1.2: Structural similarities between plasminogen and apo(a). Plasminogen 
consists of an amino terminal tail sequence (T) followed by five kringle domains (KI-
KV) and a serine protease domain (P). Apo(a) contains a number of repeated domains 
which are highly similar to that of plasminogen kringle IV (KIV), followed by single 
copies of a plasminogen kringle V (KV) and protease-like (P) domains. Kringle IV 
domains of apo(a) can be grouped into 10 distinct types on the basis of amino acid 
sequence with each present in a single copy except for KIV type 2 (KIV2). The number of 
KIV2 domains ranges from 3 to greater than 30 identically repeated copies which gives 
rise to the Lp(a) isoform size heterogeneity observed in the population. Unlike 
plasminogen, the protease domain of apo(a) is catalytically inactive. The weak lysine 
binding sites (LBSs) and strong LBS of apo(a) (indicated with circles and asterisks 
resepctively) are important for many physiological interactions between apo(a) and 
various substrates. The cysteine (SH) present in KIV9 of apo(a) is required for disulfide 
bond formation to the C-terminal region of apoB-100. Adapted from reference 9. 
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Apo(a) consists of multiple kringle units that are tri-looped structures containing 
three invariant intramolecular disulfide bonds [9]. Kringle domains are generally found in 
many coagulation and fibrinolytic proteins and are recognized as binding motifs. Apo(a) 
KIV5-8 each contain “weak” lysine binding sites (LBS) whereas KIV10 contains a “strong” 
LBS based on its ability to bind to free lysine or lysine analogues [14]. Apo(a) also 
contains a weak LBS in the KV domain. The LBS acts as a pocket that allows for 
effective binding to lysine or lysine analogues. The pocket contains a cationic and anionic 
subsite at either end that acts by stabilizing the carboxylate and ammonium group of 
lysine respectively, separated by a hydrophobic trough [15]. The hydrophobic trough of 
the LBS pockets found in plasminogen and apo(a) are  generally composed of Trp or Phe 
and act to stabilize the aliphatic backbone of lysine [15]. The LBS present in the KIV10 
domain of apo(a) bears the greatest sequence similarity to that of plasminogen KIV [15]. 
The only exception is a conservative substitution of Arg
35
 in plasminogen KIV to Lys
35
 in 
apo(a) KIV10 [8]. Key amino acids in KIV10 that mediate binding to lysine include Arg
35
, 
Asp
54
, Phe
62
, and Asp
56
 [15]. Key amino acid substitutions in each of the KIV5-8 domains 
result in a lower affinity of these kringles for lysine and its analogues compared to KIV10. 
For example, KIV7 of apo(a) contains a Tyr at amino acid position 62 compared to a Phe 
at the corresponding position in KIV10. This results in a unique network of electrostatic 
interactions and hydrogen bonding in KIV7 leading to reduced flexibility and adaptability 
in accommodating lysine and its analogues compared to KIV10 [16]. Plasminogen not 
only contains a strong LBS present in KIV but also in KI (two orders of magnitude 
greater than KIV for lysine affinity) and a weak LBS present in KV [15, 17]. The LBSs 
present in plasminogen KI and KIV are generally responsible for binding to fibrin [15].  
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Plasma Lp(a) levels vary widely within the population from nearly undetectable 
to greater than 100 mg/dL [18]. The majority of apo(a) is found associated with Lp(a) 
particles in the plasma with very little free apo(a) detected [19]. The greater than 1000-
fold variation in plasma levels of Lp(a) observed in the population is predominantly 
determined (up to 90%) by the LPA gene [20]. The largest contributor (up to 60%) of this 
variation resides in the genetically determined isoform size heterogeneity of Lp(a) 
observed within the population [reviewed in ref. 3]. A general inverse relationship exists 
between Lp(a) plasma levels and apo(a) size [21, 22]. This phenomenon is due in part to 
less efficient secretion of larger apo(a) isoforms from hepatocytes [21]. This occurs as a 
result of the longer retention time for larger apo(a) species within the endoplasmic 
reticulum (ER) due to the additional time required to fold these species compared to 
smaller isoform sizes [23, 24]. The longer retention time results in increased quality 
control mediated degradation within the ER, leading to reduced secretion efficiency [23, 
24].  
Currently, there is no accepted pharmaceutical agent that can consistently or 
specifically lower elevated plasma Lp(a) levels. Of note, plasma Lp(a) levels are 
primarily dictated by the rate of production rather than catabolism. Currently, however, 
the route of catabolism of Lp(a) from the circulation is unclear. Understanding the 
catabolic fate of Lp(a) may prove vital in potentially lowering elevated plasma levels of 
the proatherogenic and antifibrinolytic/prothrombotic Lp(a) particle.  
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1.1.1 Lp(a) pathophysiology: potential mechanisms of action  
 The pathophysiological mechanism of how elevated Lp(a) levels contribute to 
atherothrombotic diseases remains largely speculative. Elevated levels of Lp(a), greater 
than 30-50 mg/dL, confer risk for a variety of atherosclerotic disorders including CHD 
[reviewed in ref. 2, 25], ischemic stroke [26-28], and peripheral vascular disease [29]. 
Lp(a) has been proposed to contribute to not only proatherogenic but also 
prothrombotic/antifibrinolytic processes (Fig. 1.3). Elevated levels of plasma Lp(a) result 
in accumulation of Lp(a) within the arterial wall at sites of atherosclerotic lesions [30]. 
Lp(a)/apo(a) can be retained within atherosclerotic lesions through interactions with 
components of the extracellular matrix (ECM) including fibronectin, fibrinogen, 
tetranectin, proteoglycans and DANCE [31, 32].  
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Figure 1.3: Proposed proatherogenic and prothrombotic mechanisms of Lp(a) action. 
Lp(a) has been identified as an independent risk factor for CHD as well as purely 
thrombotic events such as stroke and venous thromboembolism (VTE). Illustrated here 
are some processes that may be mediated by Lp(a) based on in vitro and in vivo studies. 
The mechanisms are categorized as either proatherogenic, illustrated in red on the left, or 
prothrombotic, illustrated in blue on the right.  PL, phospholipids; SMC, smooth muscle 
cells; EC, endothelial cells; TFPI, tissue factor pathway inhibitor; PAI-1, plasminogen 
activator inhibitor-1. Adapted from reference 33. 
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1.1.1.1 Development of atherosclerosis  
 
Atherosclerosis is a progressive, inflammatory disease resulting in the 
accumulation of lipids and fibrous elements in arteries [reviewed in ref. 34]. The 
progression of atherosclerotic lesions initially occurs through subendothelal lipoprotein 
retention. Accumulation of the retained lipoproteins is greater in individuals with 
elevated levels of circulating LDL and Lp(a). Lipoproteins in the subendothelium can 
interact with the ECM and are subsequently retained. The retained lipoproteins undergo 
modifications such as oxidization, aggregation, or lipolysis. The oxidized lipoproteins 
trigger a response from endothelial cells (ECs) resulting in the production of pro-
inflammatory molecules that recruit monocytes and lymphocytes to the arterial wall. In 
this milieu, monocytes are subsequently differentiated into macrophages and can engorge 
oxidized lipoproteins leading to foam cell formation [34]. Over time, foam cell death 
occurs resulting in formation of a necrotic core, which is evident in late stages of 
atherosclerosis. Macrophages can also release various cytokines and growth factors 
which promote smooth muscle cell (SMC) migration and proliferation. The SMCs 
undergo phenotypic switching from a quiescent to a proliferative state leading to 
migration from the medial layer to the intima. In the intima, SMCs synthesize ECM 
proteins, resulting in the formation of a fibrous cap over the plaque [35]. The plaque may 
become vulnerable over time through events including a reduction in SMCs proliferation 
and production of ECM proteins, secretion of proteases from macrophages, and by the 
calcification of advanced lesions. The weakening of the fibrous cap predisposes the 
lesion to plaque rupture or erosion leading to acute thrombosis and vascular occlusion. 
This, in turn, causes a myocardial infarction, unstable angina, or stroke due to reduced 
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blood flow [34].  High-density lipoprotein (HDL) has been shown to be protective against 
atherosclerosis through removal of excess cholesterol from peripheral tissues or by 
protecting lipoproteins from oxidation [34].  
 
1.1.1.2 Proposed proatherogenic/prothrombotic properties of Lp(a)   
 
The accumulation of Lp(a) at the site of atherosclerotic lesions can have many 
consequences for the process of lesion development. Lp(a) can be retained within the 
subendothelium to a greater extent than LDL as the apo(a) component of Lp(a) can 
contribute to binding to arterial wall components as mentioned above. Lp(a) can be 
readily oxidized in atherosclerotic lesions and engulfed by macrophages to form foam 
cells [36]. The apo(a) component of Lp(a) contains unique functions that promote 
atherogenesis that are not related to plasminogen or LDL homology, such as the ability to 
bind to oxidized phospholipids.  
Pro-inflammatory oxidized phospholipids have been shown to preferentially bind 
to Lp(a) compared to LDL [37]. It has been speculated that Lp(a) deposition at sites of 
lesions results in the targeting of pro-inflammatory oxidized phospholipid species to 
developing plaques. The site of oxidized phospholipid addition to apo(a) has been 
previously shown to occur in the KV domain potentially through covalent attachment to a 
lysine within this domain [38]. However, a later study determined that oxidized 
phospholipids are present upon removal of the KV domain of apo(a) [39]. Removal of the 
strong LBS in KIV10 of apo(a) abolishes the ability to bind to oxidized phospholipids 
[39]. The exact location and mechanism of addition for the oxidized phospholipid 
covalent attachment to apo(a) remains elusive. Interestingly, the KV domain of apo(a) 
can also stimulate macrophages to produce and secrete the pro-inflammatory cytokine 
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interleukin (IL)-8 [38]. The importance of oxidized phospholipids present on apo(a) in 
mediating this process is unknown. In addition, the oxidized phospholipid moiety on 
apo(a) can induce apoptosis in ER-stressed macrophages through a CD36-TLR2-
dependent mechanism which may contribute to plaque necrosis [40]. Overall, these 
findings illustrate that oxidized phospholipids associated with Lp(a) may contribute to the 
process of atherosclerosis.  
 Lp(a) can also contribute to endothelial dysfunction through multiple 
mechanisms. Endothelial dysfunction, in which the normal endothelium exhibits 
increased permeability as well as pro-coagulative and pro-inflammatory properties, is 
implicated in the early stages of atherosclerosis [41]. It has been demonstrated that Lp(a) 
can contribute to endothelial dysfunction through its ability to elicit cytoskeletal 
rearrangement in human umbilical vein endothelial cells (HUVECs) [42]. The 
rearrangement of the cytoskeleton results in the loss of cell-cell contact and subsequent 
increase in EC permeability [43]. This process may, in turn, result in increased LDL and 
Lp(a) deposition in the arterial wall. Furthermore, apo(a) can elicit independent pro-
inflammatory effects through stimulation of the nuclear translocation of β-catenin, 
resulting in increased prostaglandin synthesis, and stimulating the expression of pro-
inflammatory mediators such as cell adhesion molecules [44, 45]. Lp(a) can also impair 
vasodilation through reducing nitric oxide (NO) availability by inhibiting eNOS 
expression [46].  
Angiogenesis, which is the process of development of new blood vessels, is also a 
key contributor to the development of atherosclerosis. An important regulator of this 
process is the ability of various enzymes, such as matrix metalloproteinases (MMPs) and 
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plasmin, to degrade the ECM in order for remodeling to occur. The role of Lp(a) in 
angiogenesis remains controversial with a number of conflicting reports. For example, 
Lp(a)/apo(a) was able to stimulate EC growth and migration through decreasing the total 
and active transforming growth factor-β (TGF-β) levels secreted by these cells [47]. The 
ability of apo(a) to mediate this effect was shown to be dependent on the presence of the 
LBS in KIV10 of apo(a). In this study, the activation of the ECs was dependent on the 
integrin αVβ3 [46]. Conversely, Lp(a) can inhibit in vitro tube formation through 
inhibition of plasmin formation by apo(a) KV [48]. Further work is needed to explore the 
potential distinct mechanism of how Lp(a) elicits its affects on EC migration/proliferation 
and tube formation in vivo.  
As noted above, SMC migration and proliferation is also a key step in the 
development of atherosclerosis. Lp(a) has been found to be colocalized with 
macrophages and SMCs in patients with coronary atheroma [49]. Human apo(a) 
transgenic rabbits were found to promote SMC proliferation and dedifferentiation [50]. 
This study determined that the accumulation of SMCs in advanced atherosclerotic lesions 
was often associated with Lp(a) deposition [50]. Further, it has been demonstrated that 
apo(a)/Lp(a) can stimulate SMC migration and proliferation through the apo(a) KIV9 
domain [51]. The KIV9 domain inhibits the activation of TGF-β resulting in increased 
SMC migration and proliferation [51]. The ability of apo(a) to inhibit this process was 
dependent on the presence of plasminogen, suggesting that apo(a) may inhibit pericellular 
plasmin formation. 
The ability of apo(a) to inhibit plasminogen activation is directly correlated with 
prothrombotic/antifibrinolytic properties of Lp(a). A number of studies have shown that 
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apo(a)/Lp(a) can inhibit fibrinolysis and contribute to thrombus formation [52-56]. 
Apo(a) shares a high degree of structural similarity to plasminogen and therefore it is 
possible that apo(a) may bind to plasminogen receptors and result in a decrease in 
plasmin formation. More detail on the mechanism of how apo(a)/Lp(a) inhibits 
fibrinolysis and potentially pericellular plasminogen activation can be found in Section 
1.2.3. It has been shown that the apo(a) component of Lp(a) can interact with the 
plasminogen receptor αMβ2 resulting in the recruitment of inflammatory cells to 
atherosclerotic plaques [57]. Further work will be needed to identify the role of other cell 
surface plasminogen receptors in mediating apo(a)/Lp(a) pathogenicity.  
Mechanistically, there is some evidence to suggest that small apo(a) (<22 KIV 
domains) isoform sizes may in fact confer increased CHD risk (reviewed in ref. 1). Small 
apo(a) species have been shown to be associated more readily with small, dense LDL 
particles which are more atherogenic than larger, less dense LDL species [58]. There is 
also an inverse relationship between apo(a) size and fibrin binding affinity [53]. The 
increased affinity of smaller apo(a) isoforms to bind to fibrin may result in an increased 
risk for thrombotic events. Furthermore, an inverse relationship exists between small 
apo(a) isoforms and oxidized phospholipid binding which may contribute to the 
atherogenicity of these species [59].  
 Taken together, there is the potential for Lp(a)/apo(a) to contribute to the 
development and progression of atherosclerosis through multiple mechanisms that affect 
vascular cell phenotype. Lp(a)/apo(a) may also be implicated in purely thrombotic 
processes as demonstrated by its ability to inhibit fibrinolysis.  
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1.1.2 Lp(a) pathophysiology: evidence from clinical studies  
 Retrospective case-control studies consistently have shown that elevated levels of 
plasma Lp(a) are a risk factor for CHD [60-63]. However, these studies were criticized 
since they cannot be interpreted to prove a causal role for Lp(a) in CHD, rather than 
simply a marker for the process. Stronger evidence in this regard has come from 
prospective studies [reviewed in ref. 1, 2]. A large meta-analysis encompassing 36 
prospective studies and over 125,000 patients demonstrated that elevated plasma Lp(a) is 
an independent risk factor for CHD [60]. This study indicated that elevated Lp(a) 
concentrations are continuously associated with CHD risk and that risk is primarily 
associated with vascular outcomes [60]. This is in contrast to the previously held notion 
for the risk threshold of above 30 mg/dL for Lp(a) levels [3]. 
 Genetic studies have shown that elevated plasma Lp(a) levels are a causal risk 
factor for CHD [62, 63]. For example, a Mendelian randomization study design has been 
utilized to definitively demonstrate causality [63]. A Mendelian randomization study is a 
method used to measure the random variation in genes from parents to offspring and to 
estimate a casual effect from observational data generated by random assignment [63]. 
The Mendelian randomization study by Kamstrup and coworkers [63] demonstrated that 
small LPA allele size is strongly associated with both elevated Lp(a) levels and increased 
risk for myocardial infarction (MI), thereby demonstrating that elevated Lp(a) levels are a 
causal risk factor for CHD.   
Genome-wide linkage and association (GWA) studies further emphasized that the 
LPA gene is a major determinant for Lp(a) plasma levels [64, 65]. The association 
between gene variants and CHD in these GWA studies suggest that genetic variation in 
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LPA is the strongest predictor of CHD [66]. The major determinant of elevated Lp(a) 
levels is the number of KIV2 repeats encoded by LPA, and single nucleotide 
polymorphisms (SNPs) present in LPA. Clarke and colleagues [62] identified two SNPs 
that are strongly associated with both an increased risk for CHD as well as Lp(a) levels 
[62]. The SNPs identified were rs3798220, corresponding to an Ile to Met substitution at 
position 4399 in the protease domain of apo(a), and rs10455872, which is intronic [62]. 
The I4399M mutation was found to be strongly associated with elevated oxidized 
phospholipids [67] and individuals with this mutation showed greater benefit from aspirin 
treatment for the prevention of CHD [68]. The relationship of the SNPs identified with an 
increase in Lp(a) concentration as well as risk for CHD also support a causal role for 
elevated Lp(a) levels and CHD risk.  
It is clear that small Lp(a) isoform sizes (<22 KIV domains) confer risk for CHD. 
However, the relationship between apo(a) isoform size and risk for CHD independent of 
Lp(a) concentration remains controversial. Conflicting results have been reported on the 
risk associated with small LPA allele size independent of elevated plasma Lp(a) 
concentration. A meta-analysis of over 58,000 participants suggested that small isoforms 
of apo(a) (<22 KIV2 repeats) are associated with an increased risk for vascular disease, 
although an independent role for isoform size could not be concluded [26]. In fact, the 
only clinical study that demonstrated an independent role for Lp(a) isoform size and risk 
was the Bruneck study [reviewed in ref. 1]. Conversely, the two recent genetic studies 
described above revealed that the risk association for CHD in these specific studies was 
abolished following adjustment of LPA allele size to plasma concentration [62, 63]. 
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Taken together, it is still unclear if small LPA allele size confers risk for atherogenic or 
thrombogenic processes independent of plasma Lp(a) levels.  
  Interestingly, elevated Lp(a) levels have been shown to confer increased risk for 
thrombotic events such as venous thromboembolism (VTE) [69, 70] and ischemic stroke 
[26-28]. A more recent prospective population study revealed that Lp(a) was associated 
with coronary artery disease (CAD) but not with ischemic stroke [29]. However, an 
increased risk for reoccurrence of ischemic stroke was determined in patients with 
elevated Lp(a) levels [28]. Elevated levels of plasma Lp(a) (>30 mg/dL) have been 
shown to be a risk factor for VTE in children, with a small population size of 186 patients 
in this study [70]. Also, Lp(a) levels >300 mg/dL were found to be an independent risk 
factor for VTE in adults, again in a small study of 603 patients [69]. However, larger 
studies revealed that elevated plasma Lp(a) levels are not a risk factor for primarily 
thrombotic phenotypes including VTE [71-73]. Most recently, analysis of 21,483 women 
indicated no risk of VTE in patients with elevated plasma Lp(a) levels, except for those 
with Lp(a) concentrations in the top 1% [73].   
The role of elevated plasma Lp(a) levels has also been directly correlated with 
coronary artery calcification (CAC), which is an atherosclerotic process, and aortic valve 
stenosis (AVS), which is not an atherosclerotic process. However, the role for elevated 
Lp(a) levels as a risk factor for CAC remains controversial, with evidence both for [74, 
75] and against [76, 77] such a relationship. Three recent genetic studies revealed a clear 
causal association between elevated plasma Lp(a) levels and AVS [78-80]. Interestingly, 
a threefold increased risk of AVS was not only associated with small LPA allele size, but 
also with SNPs rs10455872 and rs3798220 [79]. The mechanism by which elevated 
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Lp(a) levels contribute to CAC and development of AVS is poorly understood and 
remains a subject for future investigation.  
Overall, current evidence suggests that elevated Lp(a) levels are an independent 
causal risk factor for CHD, with a more disputed role in purely thrombotic processes in 
vivo. The exact pathophysiological contribution of Lp(a) to the development and 
progression of CHD remains unclear, with recent evidence also suggesting a role for 
elevated plasma Lp(a) levels in the development of CAC and AVS. The role of apo(a) 
isoform size as an independent contributor to risk for atherothrombotic disorders also 
remains to be conclusively determined.  
 
1.1.3 Lp(a) assembly 
It is generally accepted that Lp(a) assembly occurs via a two-step mechanism [81, 
82]. First, an initial non-covalent interaction occurs between the weak LBS present in 
apo(a) and N-terminal lysine residues in apoB-100 [81, 82]. Using point mutations to 
systematically abolish the weak LBS in apo(a), it was identified that the weak LBS in 
KIV7 and KIV8 were essential in mediating the non-covalent step in Lp(a) assembly [81]. 
The non-covalent interaction is required to facilitate the disulfide linkage between the 
free cysteine in KIV9 of apo(a) and apoB-100 through correct alignment of the two 
molecules [81]. 
These preponderance of evidence suggests that Lp(a) assembly occurs 
extracellularly [7, 83-84], rather than within the cell [85-88]. For example, a previous 
study indicated that extracellular Lp(a) formation occurred within the medium of hepatic 
cells (HepG2) and that apo(a) was not associated covalently with apoB-100 within the 
cell [7]. Furthermore, extracellular Lp(a) assembly was demonstrated in primary cultures 
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of baboon hepatocytes, perhaps on the cell surface, with no indication of intracellular 
Lp(a) formation [83]. The latter study also identified the importance of LBS in assembly 
as the process was inhibited by the addition of the lysine analogue ε-aminocaproic acid 
(ε-ACA) to the cells [83].  
Spontaneous disulfide bond formation occurs extremely slowly in vitro between 
purified apo(a) and LDL despite the high affinity of the non-covalent interaction between 
apo(a) and apoB-100 [84]. However in the presence of a putative Lp(a) oxidase secreted 
by hepatic cells, the ability of apo(a) to form a disulfide bond with apoB-100 is greatly 
accelerated [84]. Interestingly, apo(a) adopts a closed conformation that becomes more 
open upon binding to lysine analogs which allows for more rapid disulfide bond 
formation between apo(a) and apoB-100 [84]. It is possible that non-covalent interaction 
between apo(a) and apoB-100 occurs within the cell followed by extracellular disulfide 
bond formation either on hepatic cell surface, in space of Disse, or within the plasma.  
The prevailing view of extracellular assembly of Lp(a) particles is difficult to 
reconcile with Lp(a) kinetic data generated in humans using stable isotope labeling. An 
early kinetic study reported that production rates for apo(a) and apoB-100 in Lp(a) are 
identical, and that Lp(a) is formed from newly-synthesized apo(a) and apoB-100, rather 
than the association of newly-synthesized apo(a) with circulating LDL as suggested by 
the extracellular Lp(a) assembly model [85]. A recent kinetic study in human subjects 
reported that the production rate of apoB-100 associated with Lp(a) particles is very 
different from apoB-100 associated with LDL or very-low-density lipoprotein (VLDL), 
but similar to the production rate of apo(a) itself [86]. This has been taken as evidence for 
intracellular assembly of Lp(a), which has not been directly observed except for a study 
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using a very small and non-physiological isoform of apo(a) [87]. However, the kinetic 
studies cannot exclude the possibility that Lp(a) forms extracellularly from a special pool 
of newly-synthesized apoB-100 containing lipoprotein. It is also possible that a pool of 
apoB-100 containing lipoprotein assembles non-covalently with apo(a) intracellularly and 
that the covalent complex forms upon secretion. Further studies are required to re-visit 
the site of Lp(a) assembly in the context of in vivo human kinetic data.
 
 
1.1.4 Lp(a) catabolism  
The mechanism of Lp(a) catabolism remains unclear despite many studies 
directed at studying how Lp(a) is cleared from plasma. Various reports have suggested 
that the liver plays a crucial role in catabolising Lp(a) with a more minor role for the 
kidney. A study by Cain [89] and coworkers determined that Lp(a) was found to be 
cleared predominantly by the liver (34.6%) with only a small fraction detected within the 
kidney (1.3%). These findings coincide with a previous report indicating that Lp(a) 
clearance in a rat model was 28.5% by the liver and 0.5% by the kidney indicating a clear 
role for hepatic rather than renal cells in the clearance of Lp(a) [90]. However, patients 
with renal disease have been shown to have elevated Lp(a) plasma levels [91, 92]. 
Frischmann and coworkers [93] used an in vivo turnover study in hemodialysis patients 
and determined that the increase in plasma Lp(a) levels observed is due to the rate of 
Lp(a) catabolism rather than production. Overall, these results indicate that the kidney 
plays an indirect role in Lp(a) clearance from plasma with potentially a more significant 
role in patients with kidney disease.  
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Of note, plasma Lp(a) levels have been shown to be dictated primarily by the rate 
of production rather than catabolism [94]. A study by Rader and coworkers determined 
that the catabolic rate of different isoforms of apo(a) were similar in vivo, whereas the 
production rate was significantly greater for the smaller isoform compared to the larger 
isoform of apo(a) [94]. Understanding how Lp(a) is cleared from the plasma presents a 
useful strategy to potentially lower elevated plasma Lp(a) levels.  
  
1.1.4.1 Potential receptors for Lp(a) catabolism  
A variety of receptors have been proposed to be involved in Lp(a) clearance likely 
through the apo(a) or the apoB-100 components of Lp(a)  [89, 95-109]. Initially, 
clearance of Lp(a) was assumed to occur in a similar manner to that of LDL through the 
LDL-receptor (LDLR). This is because Lp(a) contains an LDL-like moiety and therefore 
it was assumed that Lp(a) can be catabolised through binding of the apoB-100 component 
of Lp(a) to the LDLR similar to what is observed with LDL. However, statin therapy, 
which increases the number of hepatic LDLRs, generally has little to no effect on the 
clearance of Lp(a), but has a significant effect on LDL removal from plasma [reviewed in 
ref. 9]. Therefore, presence of the apo(a) component in Lp(a) may interfere with the 
binding of apoB-100 to the LDLR. This hypothesis was validated using a mouse model in 
which excess apo(a) was able to compete for clearance of radiolabeled Lp(a); this was 
interpreted to suggest that Lp(a) clearance is predominantly driven by the apo(a) rather 
than the apoB-100 component of Lp(a) [89]. However, a study by Tam and coworkers 
[95] determined that apo(a) complexed with LDL can bind to HepG2 cells via high and 
low affinity receptors. The results demonstrated that the apo(a) component was 
responsible for binding to low affinity plasminogen receptors on these cells, whereas the 
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apoB-100 component of Lp(a) appeared to mediate binding to the higher affinity LDLR 
[95]. Further studies need to be conducted to determine the physiological route of Lp(a) 
catabolism in plasma.  
In addition to the LDLR [95-103] and plasminogen receptors [53, 95], a number 
of other possible receptors have been identified which may play a role in Lp(a) 
catabolism. These include the low-density lipoprotein-related protein (LRP-1) [101], 
VLDL-receptor (VLDLR) [107], megalin/glycoprotein 330 (gp330) [108], and scavenger 
receptor class B type I (SR-BI) [109]. As noted above, the liver is the predominant organ 
which clears plasma levels of Lp(a) with only a minor role for the kidney [89, 90]. Only 
the LDLR, LRP-1, and SR-BI are prominently expressed in the liver which suggests a 
relatively minor role for the VLDLR and megalin/gp330 receptor in Lp(a) clearance in 
vivo [89, 109].  
  
1.1.4.2 The role for the LDLR in Lp(a) catabolism  
 The main physiological role for the LDLR is to bind and internalize LDL from the 
circulating plasma into hepatic cells. The LDLR is traditionally divided into five 
domains; (1) the ligand-binding domain (composed of seven cysteine-rich domains, R1-
R7); (2) two epidermal growth factor (EGF) subunits (EGF-A and EGF–B), a six-bladed 
β-propeller, and an EGF-C domain; (3) an O-linked sugar domain; (4) a transmembrane 
domain; (5) and a cytoplasmic tail (Fig 1.4) [110]. The ligand binding domain can bind to 
various lipoproteins through interactions with apoB-100 and apolipoprotein E (apoE) 
[111]. The apoB-100 component of LDL binds to the LDLR and the complex undergoes 
clathrin-mediated internalization [112]. In the acidic environment of sorting endosomes, 
the LDLR adopts a closed conformation which weakens the LDLR:LDL interaction 
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[112]. Subsequently, LDL is released from the LDLR and is transported to lysosomes for 
degradation, whereas the LDLR is recycled back to the cell membrane [112].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Representation of the domains of the LDLR. The LDLR is divided into five 
domains; (1) the ligand-binding repeats (composed of seven cysteine-rich domains, R1-
R7); (2) an EGF precursor homology domain (composed of an EGF-A and EGF–B, a six-
bladed β-propeller, and an EGF-C domain); (3) an O-linked sugar domain; (4) a 
transmembrane domain; and (5) a cytoplasmic tail. The ligand binding domain can bind 
to apoB-100 and apoE. The EGF-A domain is required for binding to PCSK9. Image 
adapted from reference 110. 
 
 
 
24 
 
The role of the LDLR in Lp(a) clearance remains controversial with many studies 
indicating a role [95-103, 113] while other studies reporting no role for this receptor 
[89,104-106, 114]. Certainly, the relative ineffectiveness of statin therapy on Lp(a) levels 
supports a minimal role, if any, for the LDLR in mediating Lp(a) clearance. Statins 
inhibit the rate limiting step in cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reducatase, which is highly regulated by the supply of 
cholesterol [115]. This effectively reduces the production of cholesterol within the cell 
and results in the upregulation of LDLR hepatic levels with a concomitant lowering of 
plasma LDL levels.  
Several reports have shown a role for the LDLR in Lp(a) catabolism using both in 
vitro [95-98, 101] and in vivo methods [103]. Cell culture models using hepatic HepG2 
cells or fibroblasts illustrate that the LDLR can bind to Lp(a) and mediate Lp(a) uptake 
[95, 103]. Lp(a) and LDL can also compete with each other for binding to fibroblasts [98, 
103]. Familial hypercholesterolemia (FH) fibroblast cells with a defective LDLR were 
also shown to bind significantly less Lp(a) compared to wild-type fibroblasts [98, 102]. 
Another study using fibroblasts indicated, in a more indirect manner, that larger isoforms 
of Lp(a) bound to LRP-1 whereas smaller isoforms of Lp(a) bound to the LDLR in these 
cells [101]. These results may suggest that larger isoforms of apo(a) interfere to a greater 
extent with the ability of the apoB-100 component of Lp(a) to bind to the LDLR. The 
most significant finding illustrating the importance of the LDLR was conducted in vivo 
by Hofmann and coworkers using a mouse model [103]. In this study, overexpression of 
the LDLR in mice significantly increased the clearance of injected purified Lp(a) 
compared to wild-type mice [103].  
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 In contrast, several studies have reported that there is no role for the LDLR in 
Lp(a) clearance [89, 104, 114]. For example, Lp(a) clearance was not significantly 
reduced in LDLR
-/- 
mice compared to control mice whereas a significant decrease in LDL 
clearance was observed in the knockout mice [89]. In another study, radiolabeled Lp(a) 
was injected into FH homozygous human subjects with no signifcant difference in Lp(a) 
clearance in the FH patients compared to control subjects [104]. These in vivo models 
suggested that the apo(a) rather than the apoB-100 component of Lp(a) is responsible for 
its clearance from plasma in an LDLR-independent manner.  
 
1.1.4.3 Familial hypercholesterolemia and Lp(a) levels  
FH is an autosomal dominant disorder in which mutations in the LDLR cause 
elevated plasma LDL levels and premature CHD [116]. FH can also arise from mutations 
in the genes encoding the ligand apoB-100 or proprotein convertase subtilisin/kexin type 
9 (PCSK9) [116, 117]. Mutations within apoB-100 may result in the inability of LDL to 
be cleared from the plasma whereas gain-of-function (GOF) mutations of PCSK9 result 
in an increased ability to target the LDLR for degradation (see Section 1.1.4.5.1). 
Autosomal recessive hypercholesterolemia (ARH) is phenotypically similar to FH but is 
generally less severe [118, 119]. ARH is caused by a mutation in the gene encoding the 
putative adaptor protein, ARH, which is important for recruiting the LDLR:LDL complex 
into clathrin-coated pits [118, 119].  
There is contradictory evidence as for the role of the LDLR in Lp(a) catabolism 
from studies looking at endogenous levels of Lp(a) in FH subjects. Individuals that are 
heterozygous or homozygous for a mutation in the LDLR resulted in either an increase 
[99, 100, 113] or had no effect [105, 106] on Lp(a) plasma levels. However, the most 
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recent analysis of 1,960 patients with FH and 957 non-FH relatives revealed that Lp(a) 
plasma levels were significantly higher in FH patients compared to their unaffected 
relatives [99]. Overall, the aforementioned results underscore the contradictory evidence 
that exists for the role of the LDLR in Lp(a) catabolism.  
 
1.1.4.4 Other potential Lp(a) catabolic receptors 
LRP-1 [101] and SR-BI [109] are both expressed in the liver and have been 
shown to potentially regulate Lp(a) clearance. Previous studies found that Lp(a) can bind 
to LRP-1 [101, 108] but this was later disproven in subsequent studies [95, 114]. 
Recently, SR-BI was identified as a receptor for Lp(a) catabolism in vivo [109]. SR-BI 
was previously shown to bind to a variety of lipoproteins including HDL and LDL [120]. 
Yang and coworkers [109] determined that Lp(a) clearance was significantly greater in 
SR-BI transgenic mice and delayed in SR-BI knockout mice compared to control mice. 
However, 65% of the injected Lp(a) was cleared over 24 hours in the SR-BI knockout 
mice suggesting a role for other receptors in the clearance of Lp(a) [109].  
 VLDLR [107], megalin/gp330 receptor [101, 108], and the family of plasminogen 
receptors [53, 95] have all been shown to bind to Lp(a). However, VLDLR and 
megalin/gp330 are not expressed in the liver which is the predominant organ involved in 
plasma Lp(a) catabolism [89, 90]. As such, it is possible that the VLDLR and 
megalin/gp330 receptor may play a minor role in Lp(a) clearance in a non-hepatic setting, 
such as the kidney. Various studies have shown that apo(a) can compete for plasminogen 
for binding to cell surfaces [53, 95]. However, there is no evidence to suggest that 
plasminogen receptors play a role in Lp(a) uptake and degradation in hepatic cells.  
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Taken together, the mechanism of Lp(a) catabolism remains elusive. This may 
reflect the fact that the apo(a) gene is only found in humans and Old World monkeys. 
This complicates the interpretation of data generated for Lp(a) catabolism using 
traditional animal models [121]. Future experiments clearly need to focus on defining the 
mechanism for Lp(a) clearance from human plasma. This could pave the way for the 
development of therapeutic strategies that can be utilized to lower plasma Lp(a) levels.  
 
1.1.4.5 Therapeutic strategies to lower plasma Lp(a) levels  
There is currently no accepted pharmaceutical agent that can specifically reduce 
elevated levels of Lp(a). Many of the treatments that do exist lower both LDL and Lp(a) 
levels. It is important to identify a specific therapeutic agent that can lower elevated 
plasma Lp(a) at either the rate of production, assembly, or catabolism in order to address 
the benefits of Lp(a)-lowering on CHD risk in prospective studies.   
 Lp(a) levels are relatively resistant to traditional lipid-lowering strategies such as 
statin therapy, or diet and exercise [reviewed in ref. 9]. The most effective method of 
lowering Lp(a) is through lipid apheresis procedures [122]. Specific Lp(a)-apheresis for 
18 months in 30 subjects with normal LDL levels and elevated Lp(a) levels resulted in a 
clear regression in CHD and a significant decrease of 73% in Lp(a) levels [123]. 
However, Lp(a)-apheresis is costly, invasive and not a practical long term therapy option. 
Several strategies have or are currently being explored to determine their effectiveness in 
lowering plasma Lp(a) levels; these include statins, niacin, cholesteryl ester transfer 
protein (CETP) inhibitors, antisense oligonucleotide (ASO) approaches, and the use of 
monoclonal antibodies blocking PCSK9.  
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Niacin treatment is perhaps the most popular choice for lowering Lp(a) levels. 
Currently, the European Atherosclerosis Society recommends niacin treatment for 
individuals with Lp(a) levels >50 mg/dL [3]. Niacin can lower Lp(a) levels by 
approximately 20-30% [124, 125] but is also associated with severe side effects including 
flushing and hepatotoxicity [126]. Two clinical trials have recently been terminated as 
niacin treatment did not reduce the overall risk of cardiovascular disease [125, 127]. 
Specifically, Lp(a) levels were reduced in both trials, but this decrease could not be 
correlated with improved outcomes.  
CETP facilitates the transport of cholesteryl esters (CE) and triglycerides between 
lipoproteins and is important for lipoprotein metabolism in the circulation [128]. 
Inhibition of CETP function results in an increase in HDL-cholesterol and a decrease in 
LDL-cholesterol levels [129]. Recently, the CETP inhibitor, anacetrapib, has shown 
success in raising HDL levels as well as lowering plasma Lp(a) levels by approximately 
40% [130]. The mechanism by which anacetrapib can lower Lp(a) is unknown but may 
potentially involve a reduction in the efficiency of Lp(a) assembly due to alterations in 
LDL lipid composition.  
Promising results have also been found with the use of ASO therapy to lower 
Lp(a) levels [131, 132]. ASOs are short, single-stranded, synthetic oligonucleotides that 
are designed to specifically bind to and degrade a target messenger RNA (mRNA) [133]. 
Mipomersen, an ASO targeting apoB, resulted in the reduction in apoB synthesis and 
therefore the production of all apoB containing lipoproteins including VLDL, LDL, and 
Lp(a) [131]. Phase 2 clinical trials with mipomersen for 13 weeks revealed a significant 
reduction in Lp(a) levels [131]. Conversely, an ASO targeting the KIV2 domain of apo(a) 
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resulted in a significant decrease in Lp(a) levels in transgenic mice expressing human 
apo(a)/apoB-100 [132]. The use of ASO targeting either apoB or apo(a) may prove to be 
an attractive method for lowering of Lp(a) levels.   
 
1.1.4.5.1 PCSK9 Based Therapies 
PCSK9 was first discovered in 2003 and is the ninth and most recently identified 
member of the proprotein convertase family. Since its discovery, it has been under 
intense investigation in both basic research and clinical studies as it can drastically affect 
LDL cholesterol levels [134]. PCSK9 is highly expressed in the liver and to a lesser 
extent in the intestine and kidney [135]. The 692 amino acid glycoprotein contains a pro-
domain, followed by a catalytic domain, hinge region, and a C-terminal cysteine-
histidine-rich domain (CHRD) (Fig. 1.5) [136, 137]. The CHRD can be further classified 
into three modules, M1-M3 [138]. Once the signal peptide is cleaved from PCSK9, the 
zymogen proPCSK9 remains in the ER until intramolecular cleavage occurs [139]. The 
proPCSK9 cleaves itself at Gln
152
-Ser
153
 to generate the mature enzyme and prosegment 
[139, 140].  Interestingly, the prosegment remains non-covalently bound to the mature 
PCSK9 which renders it enzymatically inactive since the prosegment occupies the active 
site cleft [136]. The cleaved prosegment domain remains associated with PCSK9 and the 
complex is transported to the Golgi complex and subsequently secreted from the cell.   
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Figure 1.5: Representation of the domains of PCSK9 and its binding to the LDLR. A, 
PCSK9 zymogen contains a prosegment (pro), catalytic domain, hinge region (H), and a 
C-terminal Cys-His-rich domain (CHRD). The zymogen is autocatalytically cleaved 
within the ER at Q152↓S153. The cleaved prosegment (pro) remains attached to the mature 
PCSK9 which renders it catalytically inactive. B, Crystal structure of the ectodomain of 
the LDLR bound to PCSK9. The catalytic domain of PCSK9 (LDLR binding domain in 
PCSK9) interacts with the EGF-A domain of the LDLR (PCSK9 binding site in LDLR). 
A predicted weak hydrophobic interaction between Leu108 of the prosegment domain of 
PCSK9 and Leu626 of the β-propeller domain of the LDLR is also illustrated. The CHRD 
domain can be classified into three modules, M1-M3. Image modified from reference 
137. 
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The main physiological target of PCSK9 in lipoprotein homeostasis is the LDLR. 
In addition to the LDLR, PCSK9 is also an endogenous regulator of other lipoprotein 
receptors including the VLDLR [141], LRP-1 [142], and apolipoprotein E receptor 2 
(ApoER2) [141]. The catalytic domain of PCSK9 can bind to the EGF-A domain of the 
LDLR and target the complex for degradation (Fig. 1.5 and Fig. 1.6) [110, 143]. As 
mentioned above, when the LDLR binds to its ligand LDL, the complex is internalized 
through clathrin-coated vesicles, with the internalized LDL directed to lysosomes and the 
LDLR recycled back to the cell surface [144]. However, in the acidic environment of the 
endosome, the PCSK9:LDLR interaction becomes stronger and, through an as yet 
identified mechanism, the complex is targeted to lysosomes for degradation [145, 146]. 
The M2 module of PCSK9 has been shown to be required for PCSK9 to target the LDLR 
for degradation through the extracellular pathway [138]. Removal of the M2 module 
from PCSK9 still allows for extracellular binding to occur between PCSK9 and the 
LDLR, but the complex is unable to be targeted for lysosomal degradation. This suggests 
that PCSK9 interacts with a putative protein/receptor which allows for targeting of the 
complex for degradation. PCSK9 can also target the LDLR for degradation through an 
intracellular pathway without requiring secretion [147]. In this intracellular pathway, 
PCSK9 can interact with the LDLR in the trans Golgi network (TGN) and the complex is 
shuttled to lysosomes through clathrin-mediated endocytosis [148]. Interestingly, LDL 
acts as a regulator of PCSK9 activity by binding to the N-terminal region of PCSK9 
[149]. PCSK9 cannot function in targeting the LDLR for degradation when LDL is bound 
to PCSK9. [149].  
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Figure 1.6: Representation of the LDLR degradation pathway mediated by PCSK9. At 
low concentrations of PCSK9, or with a LOF PCSK9 mutant, LDLR levels are high, 
which allows for LDL to bind to the LDLR and enter into clathrin-coated vesicles. The 
LDL is released from the LDLR in the low acidic environment of the endosomes and is 
targeted for degradation whereas the LDLR is recycled. Conversely, at high 
concentrations of PCSK9, or with a gain-of-function (GOF) PCSK9 mutant, PCSK9 
binds to the LDLR and targets this complex for degradation in either an extracellular (cell 
surface) or intracellular pathway (trans Golgi network; TGN). This results in low levels 
of hepatic LDLR number and concomitant high plasma LDL levels. PCSK9 monoclonal 
antibodies (mAb) can bind to PCSK9 (extracellular pathway) and prevent its binding to 
the LDLR, thereby increasing hepatic LDLR number. Also, LDL can bind to PCSK9 and 
prevent PCSK9 from targeting the LDLR for degradation. The potential role of PCSK9 
and the LDLR in Lp(a) clearance remains undetermined. Image modified from reference 
137. 
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Natural GOF and loss of function (LOF) mutations of PCSK9 occur within the 
population that result in drastically elevated or lowered plasma LDL levels, respectively. 
The highly active PCSK9 GOF mutation D374Y results in a 10- to 25- fold increased 
binding affinity to the LDLR which leads to decreased hepatic LDLR levels and 
increased circulating LDL levels [136, 137]. Conversely, a patient heterozygous for the 
LOF Q152H mutation (corresponding to the site at which proPCSK9 is autocatalytically 
cleaved in the ER), exhibited up to 80% and 50% decreases in circulating PCSK9 and 
LDL levels respectively [150]. This is in keeping with reports that PCSK9-knockout 
mouse models exhibit an ~80% decrease in LDL levels [151]. On this basis, several 
pharmaceutical companies are developing strategies to decrease the ability of PCSK9 to 
bind to and target the LDLR for degradation.  
Several preclinical and clinical trials are underway to test various approaches to 
inhibit PCSK9 [reviewed in ref. 137]. The most promising approach has been with the 
use of monoclonal antibodies against PCSK9 which block PCSK9 from binding to the 
LDLR [152-156]. Recent clinical trials with a PCSK9 monoclonal antibody resulted in 
decreases of approximately 30% and 70% for Lp(a) and LDL levels respectively [152-
156]. The mechanism by which PCSK9 can regulate Lp(a) catabolism with respect to the 
involvement of the LDLR or other potential Lp(a) receptors that can be targeted by 
PCSK9 is unknown. The decrease of only ~30% for Lp(a) compared to the 70% decrease 
observed for LDL may suggest that Lp(a) may have more than one receptor responsible 
for its clearance, and that the LDLR is not the preferred route for catabolism of Lp(a).  
Targeting PCSK9 may present a useful method to lower elevated plasma Lp(a) 
levels. However, the mechanism of how PCSK9 can effect Lp(a) catabolism is unknown. 
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Identifiying the receptor(s) responsible for the PCSK9-mediated ability to lower Lp(a) 
levels is essential in advancing the therapeutic options to lower Lp(a) catabolism. 
 
1.2 PLASMINOGEN: STRUCTURE, FUNCTION, AND ACTIVATION 
Plasminogen is the zymogen form of the serine protease plasmin and is 
predominantly synthesised and secreted from the liver [157]. Plasminogen is composed 
of a tail domain, followed by five kringle domains (KI-KV) and a serine protease domain 
(Fig. 1.2). The kringle domains are important for mediating the interaction of 
plasminogen with substrates such as fibrin, cell surfaces, and plasminogen activators. 
Generally, these binding interactions are dependent on the lysine binding properties of 
plasminogen [reviewed in ref. 157].  
Native, circulating plasminogen is 791 amino acids with an N-terminal glutamic 
acid (Glu-plasminogen). The zymogen Glu-plasminogen can be activated to form Glu-
plasmin through proteolytic cleavage by plasminogen activators at Arg
561
-Val
562
 [47]. 
Following cleavage, the N-terminal heavy chain remains covalently linked to the 
carboxy-terminal light chain of plasminogen via two disulfide bonds. Cleavage of Arg
561
-
Val
562
 results in the catalytically active serine protease with the active site, His
603
, Asp
646
, 
Ser
741
, in the light chain of plasmin [158] (Fig. 1.7). Plasmin plays a key role in many 
physiological processes including fibrinolysis, cell migration and proliferation, 
angiogenesis, inflammation, wound healing, and tumor cell invasion and metastasis [157-
164].  
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Figure 1.7: Schematic representation of plasminogen activation and Glu- to Lys-
plasminogen conversion. Glu
1
-plasminogen is the native circulating form of 
plasminogen and is in a closed conformation. The closed conformation does not allow for 
rapid activation by plasminogen activators (PA) tissue-type plasminogen activator (tPA) 
or urokinase-type plasminogen activator (uPA). Once bound to fibrin or cell surfaces, 
Glu
1
-plasminogen adopts a more open, extended conformation which allows it to be more 
readily activated through cleavage at Arg
561
-Val
562
 by PA to form Glu-plasmin. Plasmin 
can cleave Glu
1
-plasminogen at Lys
77
-Lys
78
, releasing the N-terminal peptide fragment to 
form Lys
78
-plasminogen (contains an N-terminal Lys). Lys
78
-plasminogen is in a more 
extended, open conformation which allows for accelerated activation by PA to form 
Lys
78
-plasmin. Conversion of Glu
1
- to Lys
78
-plasminogen greatly accelerates the overall 
rate of plasminogen activation on the cell or fibrin surfaces or in solution. The active site 
(His
603
, Asp
646
, Ser
741
) of Glu- or Lys-plasmin is necessary for its catalytic activity. 
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The two main plasminogen activators are urokinase-type plasminogen activator 
(uPA) and tissue-type plasminogen activator (tPA). tPA is predominantly expressed in 
ECs and SMCs [165] whereas uPA is predominantly expressed in the kidney, lung, and 
tumor cell lines and does not bind to fibrin [166, 167]. The role of tPA and uPA varies 
within the vasculature, and is primarily dictated by the cells that express these activators. 
As such, tPA plays a key role in fibrinolysis or EC/SMC migration. Conversely, uPA 
plays a minor role in fibrinolysis and a more primary role in ECM degradation in the 
process of tumor cell invasion and metastasis [46-53].  
 
1.2.1 Positive feedback mechanisms in the process of plasminogen activation 
The rate of plasminogen activation can be greatly accelerated through a variety of 
positive feedback mechanisms. The circulating form of plasminogen, Glu-plasminogen, 
adopts a closed, spiral conformation that limits its accessibility to be activated by 
plasminogen activators [168, 169]. In order for accelerated plasminogen activation to 
occur, Glu-plasminogen must bind to the cell or fibrin surfaces. Once bound to these cell 
surfaces, Glu-plasminogen adopts a more open conformation and is therefore more 
accessible to plasminogen activators [168, 169]. As a result, an initial, small amount of 
Glu-plasminogen can be activated to form Glu-plasmin. Glu-plasmin remains bound to 
the cell and fibrin surfaces in order to prevent rapid inhibition through its natural inhibitor 
α2-antiplasmin [170]. The initial production of Glu-plasmin formed can then directly 
contribute to the positive feedback mechanism of plasminogen activation on these 
surfaces.   
Plasmin can proteolytically cleave Glu-plasminogen at the carboxyl side of Lys
62
, 
Arg
68
, or Lys
77
 to form a product termed “Lys-plasminogen” [170-172]. The most 
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common site of cleavage by plasmin is at Lys
77
-Lys
78
 resulting in an N-terminal Lys 
residue. Lys-plasminogen adopts a more extended/opened conformation that significantly 
lowers its half-life in plasma [173]. However, the benefit of converting Glu- to Lys-
plasminogen is that the more open conformation allows for greater accessibility to 
plasminogen activators in order to accelerate the rate of plasmin formation [174, 175]. In 
solution, the rate of tPA-mediated plasminogen activation increases 11-fold for Lys-
plasminogen compared to Glu-plasminogen, illustrating the importance of the open 
conformation in accelerating plasminogen activation [174-176].  
Cell surface receptors (see Section 1.2.2) play a crucial role in mediating 
plasminogen activation and the positive feedback mechanisms assocaiated with plasmin 
formation. Binding of Glu-plasminogen to cell surface receptors allows for a more open 
conformation that promotes cleavage by plasmin to form Lys-plasminogen [177]. Indeed, 
it has been reported that conversion of Glu- to Lys-plasminogen is necessary for optimal 
stimulation of plasminogen activation on HUVECs and monocytoid cells [178, 179]. 
Gong and coworkers illustrated the importance of Glu- to Lys-plasminogen conversion 
on HUVECs [178]. In this study, a mutant form of plasminogen was used, [D646E] Glu-
plasminogen, that does not contain plasmin activity but can still be cleaved by 
plasminogen activators [178]. This mutant was far less effective in the enhancement of 
plasminogen activation on HUVEC surfaces compared to wild-type plasminogen [178]. 
This underscores the importance of plasmin activity in cleaving Glu- to Lys-plasminogen 
for the enhancement of plasminogen activation.  
Furthermore, the initial production of Glu-plasmin can further contribute to the 
positive feedback mechanism of plasminogen activation through cleavage of both tPA 
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and uPA. Plasmin cleaves single-chain tPA (sc-tPA) at Arg
275
-Ile
276
 resulting in a two-
chain form with slightly better activity than sc-tPA [180]. Conversely, uPA is secreted as 
single-chain uPA (sc-uPA) with minimal activity until it is cleaved by plasmin at Lys
158
-
Ile
159
 resulting in a two-chained form (tc-uPA) [181]. Converting sc-uPA to the tc-uPA 
form lowers the KM for plasminogen from 20-50 µM to approximately 0.2 µM [182].  
Overall, the positive feedback mechanism of plasminogen activation is crucial for 
the enhanced production of plasmin. If in fact apo(a)/Lp(a) can inhibit pericellular 
plasminogen activation it would be imperative to determine if it is through inhibition of 
the positive feedback mechanism involving Glu- to Lys-plasminogen conversion.  
 
1.2.2 Plasminogen receptors  
Plasminogen receptors play a pivotal role in localizing plasmin generation on the 
cell surfaces. These plasminogen binding proteins play an essential role in both 
physiological and pathological processes as discussed above (see Section 1.2). 
Plasminogen receptors are broadly distributed on many cell types including monocytes 
[183], macrophages [184], ECs [185], fibroblasts [186], platelets [187], and carcinoma 
cells [188]. Plasminogen binding occurs with low affinity to these cellular receptors (KD 
~ 1 µM) but with high capacity, ranging from ~10
4
 sites on platelets [189] to >10
7
 sites 
on ECs [190].  
Many cell-surface plasminogen receptors contain a carboxyl-terminal lysine or an 
exposed lysine residue that can mediate their interaction with plasminogen through LBS 
within plasminogen kringles [reviewed in ref. 157]. The LBS present in KI, KIV, and KV 
have all been implicated in the ability of plasminogen to bind to fibrin [191], whereas 
interaction with ECs is primarily through the LBS present in KIV and KV of 
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plasminogen [192]. As such, plasminogen binding to cells can be blocked by the addition 
of the lysine analogue ε-ACA [189]. Furthermore, treatment of monocytoid cells with 
carboxypeptidase B (CpB), which removes carboxyl-terminal Arg or Lys residues from 
cell surfaces, resulted in a decrease in plasminogen binding and plasminogen activation 
by 60% and 95% respectively [193]. Plasminogen receptors are also important due to 
their ability to protect plasmin from its natural inhibitor α2-antiplasmin. Plasmin 
generated in solution is rapidly inhibited by α2-antiplasmin, whereas cell surface-bound 
plasmin is protected from its inhibitor.  
Plasminogen receptors identified to date can be categorized into three subtypes: i) 
those that contain an exposed carboxyl-terminal lysine; ii) those that undergo post-
translational cleavage to expose a carboxyl-terminal lysine; or iii) those that do not 
contain a carboxyl-terminal lysine. The majority of plasminogen receptors identified do 
contain a carboxyl-terminal lysine residue [157]. Some of the more well-known 
plasminogen receptors which contain a carboxyl-terminal lysine include enolase-1 
(present on monocytoid cells), S100A10 (present on ECs), TATA-binding protein-
interacting protein (present on monocytoid cells) and Plg-RKT (present on 
catecholaminergic cells) [157, 194]. An example of a receptor of the second subtype is 
annexin II, which is present on ECs [157]. Annexin II undergoes limited proteolysis on 
the cell surface that results in the exposure of a carboxyl-terminal lysine [195]. The 
modified annexin II can bind to plasminogen but is unable to protect plasmin from α2-
antiplasmin inhibition [195]. However, binding of annexin II with S100A10 to form a 
heteroterameric complex result in an increased ability of this complex to enhance 
plasminogen activation as S100A10 contains a carboxyl-terminal lysine [157]. The 
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annexin II S100A10 heterotetramer can also protect both plasmin and tPA from their 
natural inhibitors α2-antiplasmin and plasminogen activator inhibitor (PAI1) respectively 
[196]. Plasminogen receptors in the third subtype do not contain a carboxyl-terminal 
lysine. These include αMβ2 (present on phorbol 12-myristate 13-acetate (PMA)-
stimulated neutrophils) and glycoprotein IIb/IIIa (present on platelets) [157].  
Another important receptor for the production of plasmin is the glycosyl 
phosphatidylinositol (GPI)-anchored uPA receptor (uPAR). The primary ligand of uPAR 
is uPA, and this receptor plays a key regulatory role in mediating plasminogen activation 
and ECM degradation (Fig. 1.8) [197]. Binding of the zymogen form of uPA (sc-uPA) to 
uPAR promotes its cleavage by plasmin to form tc-uPA [198]. Conversion of sc-uPA to 
tc-uPA results in a more catalytically active enzyme that can accelerate plasminogen 
activation to a greater extent. Plasmin can also activate MMPs that can then degrade 
ECM components [199]. Activated tc-uPA can also cleave uPAR resulting in a soluble 
form of the receptor and a membrane-associated fragment [200]. The membrane-
associated fragment cannot bind to uPA, thereby inactivating the function of uPAR in 
uPA-mediated plasminogen activation [200]. uPAR can also interact with the ECM 
protein vitronectin which is a ligand for integrins such as αVβ3 [201, 202]. uPAR does not 
contain a transmembrane domain and therefore interacts with integrins, such as αVβ3, to 
transmit intracellular signals (reviewed in ref. 203). Interestingly, apo(a)/Lp(a) has been 
shown to stimulate cell growth and migration in ECs through the αVβ3 integrin [46] (see 
Section 1.1.1.2).    
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Figure 1.8: The role of the uPAR in the plasminogen activation system. The uPAR 
functions by binding to pro-uPA or active uPA to accelerate plasminogen activation. The 
inactive pro-uPA binds to uPAR followed by plasmin cleavage of pro-uPA to its active 
form. Active uPA then has increased catalytic activity to cleave the zymogen 
plasminogen to form plasmin. tPA can also cleave plasminogen to its active form 
plasmin. Binding of both uPA to uPAR as well as plasminogen to its cognate receptors 
greatly accelerates the rate of plasmin formation. The plasmin generated can then activate 
pro-matrix metalloproteinases (pro-MMPs) to their active form. Active MMPs and 
plasmin can degrade the ECM to promote cell proliferation and the release of growth 
factors sequestered from the ECM. uPA can also cleave uPAR at the D1-D2 domain and 
renders the membrane bound uPAR unable to bind to uPA thereby inactivating its 
function. uPAR can also interact with vitronectin, a component of the ECM, which can in 
turn interact with integrins. Binding of uPAR/uPA to integrins, through vitronectin, 
allows for intracellular signal transduction pathways to be activated. Plasmin can be 
inhibited by its natural inhibitor α2-antiplasmin whereas plasminogen activator inhibitor 
(PAI1 or PAI2) can inactivate uPA. The role of Lp(a)/apo(a) in potentially inhibiting 
pericellular plasminogen activation is unknown. Image modified from reference 203. 
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1.2.3 The role of Lp(a)/apo(a) in plasminogen activation  
The apo(a) component of Lp(a) has been previously shown to stimulate SMC 
migration and proliferation through inhibition of plasminogen activation [50, 51]; this, in 
turn, results in decreased activity of TGF-β [51]. This process was shown to be dependent 
on the ability of the KIV9 domain of apo(a) to mediate inhibition of  plasminogen 
activation [51]. Apo(a)/Lp(a) can also attenuate fibrinolysis through inhibition of tPA-
mediated plasminogen activation [55]. In the latter study, critical roles for the strong LBS 
in KIV10 and the amino terminal of apo(a) were identified as important in apo(a)-
mediated inhibition of plasminogen activation on fibrin [55]. Inhibition of plasminogen 
activation on the fibrin surface occurred because of reduced turnover number of the 
quaternary complex (cofactor, tPA, plasminogen, and apo(a)) compared to the ternary 
complex (cofactor, tPA, and plasminogen) [55]. Apo(a) has been shown to inhibit Glu- to 
Lys-plasminogen conversion, which contributes to the inhibition of fibrinolysis [56]. In 
the latter study, critical domains in KIV5-9 as well as KV were found to be required for 
maximal inhibition of the Glu- to Lys-plasminogen conversion [56]. As previously noted, 
conversion of Glu- to Lys-plasminogen is a critical positive feedback mechanism which 
greatly accelerates the production of plasmin on both fibrin and cell surfaces. 
The role of apo(a)/Lp(a) in inhibition of pericellular plasminogen on vascular cell 
surfaces has not been fully explored. Lp(a) and apo(a) can compete with plasminogen for 
binding to  EC and monocyte surfaces [54, 204]. Lp(a) was reported to inhibit the 
generation of plasmin on ECs, although the data were not shown and the role of apo(a) in 
this inhibition was not studied [54]. Further experimentation needs to be conducted to 
identify the direct role, if any, that apo(a)/Lp(a) has on the process of pericellular 
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plasminogen activation. The potential ability of Lp(a)/apo(a) to inhibit pericellular 
plasminogen activation may effect the dissolution of mural fibrin clots as well as cell 
migration and proliferation, angiogenesis, wound healing, and tumor cell invasion and 
metastasis. 
 
1.3 RATIONALE AND OBJECTIVES  
Elevated levels of Lp(a) are an independent risk factor for CHD. Determining the 
mechanism of how Lp(a) functions is imperative for developing strategies for the 
treatment of individuals who have elevated plasma levels. Identification of the receptor(s) 
responsible for the binding of Lp(a) to cells is key to understanding the route of Lp(a) 
catabolism, as well as the basis of its pathogenic mechanisms of action.  
Many studies have shown that apo(a)/Lp(a) can interfere with the process of 
fibrinolysis in part through attenuation of the positive feedback mechanism of Glu-
plasminogen to Lys-plasminogen conversion. However, the ability of apo(a)/Lp(a) to 
inhibit pericellular plasminogen activation and Glu- to Lys-plasminogen conversion on 
vascular cells is unclear at present.  
Determination of the receptor(s) responsible for Lp(a) catabolism may provide 
new therapeutic strategies to lower plasma Lp(a) levels in high risk patients. Studies 
using anti-PCSK9 monoclonal antibody have shown promise for reducing plasma Lp(a) 
levels. However, the mechanism by which PCSK9 can regulate Lp(a) levels is unknown, 
which may limit the utility of this approach.  
Our hypothesises is that apo(a)/Lp(a) can inhibit pericellular plasminogen 
activation through attenuation of Glu- to Lys-plasminogen conversion on vascular cells 
and that the ability of apo(a)/Lp(a) to inhibit this process will be dependent on the 
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competition of the apo(a) component of Lp(a) for binding to known plasminogen 
receptors. Moreover, we hypothesize that Lp(a) can be bound and internalized by the 
LDLR, and that this forms the basis by which inhibition of PCSK9 lowers plasma Lp(a) 
levels. 
To address these hypotheses, the research objectives of this dissertation are: 
1) To identify the role of apo(a)/Lp(a) in the inhibition of pericellular 
plasminogen activation on vascular cells; 
2) To elucidate the mechanism by which apo(a)/Lp(a) inhibits pericellular 
plasminogen activation on vascular cells; 
3) To identify candidate vascular receptor(s) that can bind to apo(a); 
4) To identify the mechanism by which PCSK9 can lower Lp(a) levels in hepatic 
cells.    
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2.1 SUMMARY 
  
Apolipoprotein(a) [apo(a)], the distinguishing protein component of 
lipoprotein(a), exhibits sequence similarity to plasminogen and can inhibit binding of 
plasminogen to cell surfaces. Plasmin generated on the surface of vascular cells plays a 
role in cell migration and proliferation, two of the fibroproliferative inflammatory events 
that underlie atherosclerosis. The ability of apo(a) to inhibit pericellular plasminogen 
activation on vascular cells was therefore evaluated. Two isoforms of apo(a), 12K and 
17K, were found to significantly decrease tPA-mediated plasminogen activation on 
HUVECs and THP-1 monocytes and macrophages. Lp(a) purified from human plasma 
decreased plasminogen activation on THP-1 monocytes and HUVECs but not on THP-1 
macrophages. Removal of kringle V or the strong lysine binding site in kringle IV10 
completely abolished the inhibitory effect of apo(a). Treatment with carboxypeptidase B 
(CpB) to assess the roles of carboxyl-terminal lysines in cellular receptors lead in most 
cases to decreases in plasminogen activation as well as plasminogen and apo(a) binding; 
inhibition of plasminogen activation by apo(a) was unaffected, however. Our findings 
directly demonstrate that apo(a) inhibits pericellular plasminogen activation in all three 
cell types, although binding of apo(a) to cell-surface receptors containing carboxyl-
terminal lysines does not appear to play a major role in the inhibition mechanism. 
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2.2 BACKGROUND 
Lipoprotein(a) [Lp(a)] was first discovered in 1963 by Kåre Berg [1] and has 
since been under intense investigation in both basic research and clinical studies [2]. 
Lp(a) has a complex structure consisting of an LDL moiety, which contains apoB-100, 
and the unique glycoprotein apolipoprotein(a) [apo(a)] [3]. The levels of Lp(a) vary over 
1000 fold within the human population ranging from less than 1 to greater than 100 
mg/dL [4]. Lp(a) possesses both proatherogenic and prothrombotic properties due to the 
LDL-like moiety and apo(a) component of the lipoprotein respectively [5, 6]. Elevated 
plasma concentrations of Lp(a) have been identified as an independent risk factor for 
cardiovascular diseases such as coronary heart disease, ischemic stroke, and peripheral 
arterial disease [7-11].
 
Lp(a) has also been associated with purely thrombotic events, such 
as venous thromboembolism [12]. The molecular cloning of a cDNA encoding apo(a) 
revealed that it contains remarkable homology to the fibrinolytic zymogen plasminogen 
[13].
 
 
Apo(a) contains repeated copies of a sequence similar to that of plasminogen 
kringle IV (KIV) followed by sequences similar to the kringle V (KV) and protease 
domain of plasminogen [13]. The kringle IV-like domain in apo(a) can be further 
classified into ten subtypes (KIV1 to KIV10), according to differences in amino acid 
sequence. The number of KIV2 repeats determines the isoform size heterogeneity of 
apo(a) [14, 15] with the number of repeats ranging from 3 to >30 [16]. The protease 
domain in apo(a), unlike that of plasminogen, does not exhibit plasmin-like activity and 
is not proteolytically active [17]. Both apo(a) and plasminogen contain lysine binding 
sites (LBSs) which mediate their respective interactions with various cell surface 
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receptors or the fibrin surface. Apo(a) KIV types 5 to 8 each contain a weak LBS, with 
KIV types 7 and 8 forming a noncovalent association with apoB-100 [18-20]. This 
precedes covalent formation of the Lp(a) particle by facilitating disulfide bond formation 
between a free cysteine in KIV9 of apo(a) and the C-terminus of apoB-100 [21, 22]. 
Apo(a) KIV10 contains a strong LBS that resembles the LBS present in plasminogen 
kringle 4 [23].
 
Apo(a) may therefore potentially interfere with plasminogen binding to or 
activation on vascular cells.
 
Plasminogen is the zymogen form of the serine protease plasmin. The active 
enzyme plays a key role in the processes of fibrinolysis, cell migration and proliferation, 
angiogenesis, and inflammation [24-29].
 
Plasminogen activation is mediated through 
proteolytic cleavage of Arg
561
-Val
562 
of plasminogen by tissue-type plasminogen 
activator (tPA) or urokinase-type plasminogen activator (uPA). This process occurs more 
readily on the cell surface and following conversion of native Glu-plasminogen to Lys-
plasminogen [30-32]. Apo(a) has been shown to inhibit plasminogen activation on the 
fibrin surface through KV and the strong LBS in KIV type 10 [33]. Moreover, apo(a) 
directly inhibits Glu- to Lys-plasminogen conversion on the fibrin surface with critical 
roles identified for kringle IV types 5-9 and KV [34]. An apo(a)-mediated decrease in 
plasmin generation, dependent on apo(a) KIV9, has also been shown in the context of 
smooth muscle cells (SMCs) which results in the inhibition of activation of transforming 
growth factor β (TGF-β) [35]; this leads to the stimulation of SMC migration and 
proliferation [35-37]. 
The strong LBS present in plasminogen allows for its binding and subsequent 
activation to occur on various receptors containing carboxyl-terminal lysines including 
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annexin A2 S100A10 heterotetramer, enolase-1, and Plg-RKT [38].
  
For example, 
treatment of monocytoid cells with carboxypeptidase B (CpB), which removes carboxyl 
terminal lysines, leads to a decrease of 64% for plasminogen binding and greater than 
95% for plasminogen activation [39]. On catecholaminergic cells, binding of 
plasminogen decreased following CpB treatment by approximately 70% whereas a 
decrease of 90% was observed for plasminogen activation [40]. In another study. binding 
of plasminogen to human umbilical vein endothelial cells (HUVECs) was also inhibited 
by ε-aminocaproic acid (ε-ACA), a lysine analogue, by 70-80% [29]. 
CpB and active thrombin-activatable fibrinolysis inhibitor (TAFIa) have also been 
shown to reduce plasminogen activation by 80% on the annexin A2 S100A10 
heterotetramer in vitro [41]. In a rat primary hepatocyte model, TAFI knockdown 
increased the amount of plasmin formed on the cells and promoted proliferation, 
suggesting the ability of TAFIa to decrease plasminogen binding to hepatocytes [42]. 
Previous studies have suggested that apo(a) may inhibit pericellular plasminogen 
activation based on the observation that apo(a) decreases plasminogen binding to 
endothelial cells and monocytes [43]. Moreover, Lp(a) was reported to inhibit the 
generation of plasmin activity on endothelial cell surface and not in the fluid phase [44]. 
The effect of apo(a) on plasminogen activation on vascular cells has not otherwise been 
explored. Most notably, the role of CpB with respect to the effect of apo(a) and 
plasminogen binding and activation has not been shown for relevant vascular and blood 
cells such as endothelial cells, monocytes and macrophages.  
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2.3 METHODS 
 
2.3.1 Construction, expression, and purification of recombinant apo(a)  
 The construction and expression in human embryonic kidney (HEK293) cells of 
the r-apo(a) variants utilized in this study (KIV5-8, 12K, 12ΔV, 17K, 17KΔLBS10, and 
17KΔV) has been previously described [17, 33, 34, 45-4]. Variants were purified from 
conditioned medium, harvested from stably-expressing cell lines, using lysine-Sepharose 
affinity chromatography as previously described [17, 33, 34, 45-48]. Protein 
concentrations were determined spectrophotometrically [17, 33, 34, 45-48] and assessed 
for purity by SDS-PAGE under non-reduced and reduced conditions followed by silver 
staining.  
 
2.3.2 Isolation of Lp(a) 
 Blood was collected from one healthy volunteer homozygous for a 16K apo(a) 
isoform. Blood was collected into BD Vacutainer blood collection tubes containing 
sodium polyanethol sulfonate and acid citrate dextrose. Plasma was obtained through 
centrifugation of whole blood at 3,000 × g for 15 min at 4°C. Phenylmethylsufonyl 
fluoride (PMSF) was added to a final concentration of 0.1 mM and the plasma was 
rotated at 4°C for 15 min. The plasma was adjusted to a density of 1.02 g/mL with solid 
sodium bromide and centrifuged at 45,000 × g for 24 hrs at 6°C. The top fraction was 
removed and the infranatant was adjusted to a density of 1.21 g/mL with solid sodium 
bromide. The sample was centrifuged at 45, 000 g for 24 hrs at 6°C and the top layer was 
isolated and extensively dialyzed against 20 mM Tris-HCl, pH 7.4, containing 150 mM 
NaCl, 0.01% NaN3, and 0.01% EDTA (Buffer A). The sample was then subjected to gel-
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filtration chromatography over Sepharose CL-4B (Sigma-Aldrich) (2.5 cm × 80 cm 
column) using buffer A containing 0.1% (v/v) Tween 20 and 0.1 M proline. Fractions 
were collected and samples with an absorbance over 0.1 at 280 nm were subjected to 
western blot analysis using an anti-apo(a) antibody to determine Lp(a) containing 
fractions. Samples containing Lp(a) were pooled and diluted 3-fold with distilled water 
and loaded onto a DEAE-Sepharose Fast Flow (Pharmacia) ion exchange column (2.5 × 3 
cm column). Lp(a) was eluted with an NaCl concentration gradient (50 to 300 mM NaCl 
in 20 mM Tris-HCl, pH 7.4). Lp(a) containing fractions, as determined by western blot 
analysis, were pooled and dialyzed against HEPES-buffered saline (HBS; 20 mM HEPES 
pH 7.4, 150 mM NaCl). Concentration was determined by bicinchoninic acid assay 
(Pierce) using BSA as a standard. The integrity of the purified Lp(a) was assessed by 
SDS-PAGE under non-reducing and reducing conditions followed by silver staining.  
 
2.3.3 Cell culture 
 HUVECs were obtained from Clonetics and grown in EGM Complete Medium 
(Clonetics). All HUVEC experiments were conducted using cells at passage five. Human 
acute monocytic leukemia (THP-1) cells were grown in RPMI complete growth medium 
1640 (GIBCO) adjusted to contain 4.5 g/L glucose (Sigma-Aldrich), 10 mM HEPES 
(Fisher Scientific), 1.0 mM sodium pyruvate (GIBCO), 0.05 mM 2-mercaptoethanol 
(Sigma-Aldrich) and supplemented with 10% FBS (GIBCO) and 1% antibiotic-
antimycotic (GIBCO). Cells were maintained at a density of 0.3- 1 × 10
6
 cells/ mL and 
subculturing was performed by centrifuging cells at 100 × g for 5 min and resuspending 
in the appropriate volume of fresh medium. PMA (Sigma-Aldrich) was added to THP-1 
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cells at a final concentration of 0.1 μM for 72 hours to differentiate them into 
macrophage-like cells.  
 
2.3.4 Plasminogen activation assay  
 HUVECs were grown to confluency in a 96-well microtiter plate (Corning). THP-
1 cells were seeded at a density of 150 000 – 200 000 cells per well and differentiated for 
72 hours with 0.1 μM PMA. THP-1 monocytes were seeded at a density of 200 000 cells 
per well. Cells were washed three times with HBS containing 0.4% (w/v) BSA (HBS-
BSA) prior to adding reaction mixture. Reaction mixtures contained: 60 nM plasma 
derived plasminogen (purified as per (49)), 15 nM tPA (Alteplase; Kingston General 
Hospital Pharmacy), H-D-Val-Leu-Lys-7-amido-4-methylcoumarin (Bachem), and 
various concentrations of apo(a) (0, 100, 400, or 800 nM) in HBS-BSA. RPMI complete 
growth medium minus FBS and antibiotic and supplemented with 0.4% (w/v) BSA 
(RPMI-0.4%BSA) was used instead of HBS-BSA for THP-1 macrophages. Control 
experiments were conducted in the absence of tPA. Plasmin formation was monitored 
over 2 hours at 37°C at an excitation wavelength of 370 nm and an emission wavelength 
of 470 nm and emission cutoff filter of 455 nm using a plate reading fluorescence 
spectrometer (SpectraMax M5
e
, Molecular Devices). The rate of plasminogen activation 
was taken as the initial slope of the plot of RFU against min
2
 from 10 to 40 mins. Rates 
obtained for each individual experiment performed in triplicate were normalized to the 
rate of plasminogen activation in the absence of apo(a). Plasminogen activation in the 
absence of cells was performed with the same reaction mixture described above. 
Plasminogen activation with Lp(a) was conducted as above with minor changes; 25 nM 
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of plasma derived plasminogen, instead of 60 nM, was utilized with 75 nM of Lp(a) or 
apo(a).  
 
2.3.5 Cell binding assay 
 Assays utilized purified r-apo(a) fluorescently labeled using Alexa Fluor 488 
protein labeling kit (Invitrogen) or fluorescein isothiocyanate-labeled human 
plasminogen (Molecular Innovations). Briefly, cells were washed three times with HBS-
BSA and fluorescently labeled plasminogen or r-apo(a), at a concentration of 400 nM, 
was incubated with cells for one hour at 37°C. Following incubation, cells were washed 
twice with HBS-BSA and the fluorescence was measured at an excitation wavelength of 
494 nm and emission wavelength of 519 nm and cutoff of 515 nm using a plate reading 
fluorescence spectrometer. For THP-1 macrophages, the buffer used was RPMI-BSA 
instead of HBS-BSA. Experiments in which two to three acid wash steps (0.2 M acetic 
acid pH 2.5, 0.5 M NaCl) were included prior to measuring the fluorescence showed that 
at least 80% of the labeled proteins were surface-bound (as opposed to internalized; 
Suppl. Fig. 2.1). Binding of apo(a) and plasminogen to the cells appeared to be specific 
and reversible (Suppl. Fig. 2.2). 
 
2.3.6 Carboxypeptidase treatment  
 CpB (Calbiochem) treatment of HUVECs and THP-1 monocytes was performed 
in HBS-BSA and for THP-1 macrophages in RPMI-BSA. Cells were washed three times 
and incubated with CpB for one hour at 37°C. Cells were then washed three times 
followed by assay of plasminogen activation or apo(a)/plasminogen binding as described 
above. The activity of CpB was measured using anisylazoformylarginine (Calbiochem).  
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2.3.7 Statistical methods 
 Comparisons between data sets were performed using one-way ANOVA with 
SPSS version 22 software. Statistical significance was presumed at p<0.05.   
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2.4 RESULTS 
 
2.4.1 Apo(a) directly inhibits plasminogen activation on THP-1 monocytes, THP-1 
macrophages, and HUVECs  
 We examined two different isoforms of apo(a) (12K and 17K) and both were 
found to inhibit pericellular plasminogen activation in THP-1 monocytes (Fig. 2.1A, B). 
Both isoforms exhibit a similar concentration-dependent effect on inhibition. At 800 nM, 
12K and 17K inhibited plasminogen activation by 57% and 46% respectively. At 800 
nM, 12K was not significantly more effective at inhibiting activation compared to 17K. 
Removal of kringle V in both 12K and 17K not only abolished the inhibitory effect of 
apo(a) but, surprisingly, caused an increase in plasminogen activation (up to 3.6- and 2.4-
fold, respectively; Fig. 2.1A, B). Similarly, inactivation of the strong LBS in apo(a) 
(17KΔLBS10 variant) led to a maximal 2.1 fold increase in plasminogen activation (Fig. 
2.1A). The weak LBSs of apo(a), present in the KIV5-8 variant, do not exhibit a 
significant inhibitory effect at any of the tested concentrations (Fig. 2.1B). These results 
indicate that apo(a) can directly inhibit pericellular plasminogen activation in THP-1 
monocytes and imply roles for kringle V and the strong LBS in KIV type 10 in mediating 
this effect. 
 Comparing plasminogen activation in the presence or absence of THP-1 
monocytes revealed a 74% decrease in activation in the absence of cells, and this rate was 
not affected by 17K, 12K or KIV5-8 (Fig. 2.1A, B). However, 17KΔLBS10, 17KΔV, and 
12KΔV shows a significant increase in plasminogen activation with increasing 
concentration similar to that in the presence of cells, suggesting that the cell-independent 
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stimulation of plasminogen activation by these variants largely accounts for the increase 
in plasminogen activation occurring in the presence of cells. 
Treatment of THP-1 cells for 72 hours with a phorbol ester results in the 
differentiation of these cells into macrophage-like cells [50]. Apo(a) inhibits plasminogen 
activation on THP-1 macrophages in a dose-dependent manner, with a maximal 
inhibition of 57% and 65% for 12K and 17K, respectively, observed at 800 nM (Fig. 
2.1C, D). At 800 nM, 12K and 17K were not significantly different in its ability to inhibit 
activation. Both the strong LBS in KIV type 10 of 17K (17KΔLBS10) (Fig. 2.1C) and the 
kringle V domain (12KΔV) (Fig. 2.1D) are required for the inhibitory effect of apo(a); as 
with the THP-1 monocytes, both of these variants resulted in increased, rather than 
decreased, plasminogen activation. For the 17KΔLBS10 and 12KΔV variant, this increase 
again can be ascribed to stimulation of cell-independent plasminogen activation (Fig. 
2.1C, D). In the absence of THP-1 macrophages, the rate of plasminogen activation was 
significantly lower (71%) and was unaffected by the presence of 12K and 17K, as was 
the case for THP-1 monocytes.  
Similar experiments were also performed with HUVECs, and with similar results. 
Apo(a) directly inhibits pericellular plasminogen activation on the surface of HUVECs. A 
maximal inhibitor effect of 48%, for 12K, and 58%, for 17K was observed at a 
concentration of 800 nM (Fig. 2.1E, F). At 800 nM, 12K was not significantly more 
effective at inhibiting activation compared to 17K. As with THP-1 monocytes and 
macrophages, loss of the strong LBS in KIV10 or the loss of KV resulted in a cell-
independent increase in plasminogen activation (Fig. 2.1E, F). 
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Taken together, the effect of apo(a) on cell-dependent plasminogen activation is 
remarkably similar for all three cell types tested; moreover, the effect of loss or mutation 
of specific domains of apo(a) is consistent in all three cell types. These results indicate a 
potential common mechanism through which apo(a) inhibits pericellular plasminogen 
activation in each cell type.  
To demonstrate that activation of plasminogen observed was dependent on the 
added tPA and plasminogen and not from the cells themselves or contamination of the r-
apo(a), experiments were conducted in the absence of tPA or plasminogen. Omission of 
either of these components virtually eliminated detectable plasminogen activation in the 
presence of all three cell types, either in the presence or absence of various r-apo(a) 
variants (Fig. 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Effect of apo(a) on pericellular plasminogen activation. THP-1 monocytes 
(A, B), THP-1 macrophages (C, D), or HUVECs (E, F) were incubated with various 
concentrations of r-apo(a) (from 100 nM to 800 nM) as well as plasma-derived 
plasminogen (60 nM), tPA (15nM), and H-D-Val-Leu-Lys-AMC; control reactions 
lacked apo(a) or cells. Plasmin generation was monitored over 2 hours at 37°C and the 
slope of RFU from 10-40 min vs min
2 
was determined. The data represent the means ± 
standard deviations from 3 - 16 independent experiments performed in triplicate for cells 
and 3 - 6 independent experiments for no cells. Asterisks: p<0.05 versus absence of 
apo(a) on cells; daggers: p<0.05 versus absence of cells.   
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Figure 2.2: Plasminogen activation in the absence of tPA on THP-1 monocytes, THP-1 
macrophages, and HUVECs. Plasminogen activation experiments were conducted as 
described in the legend to Fig. 2.1, but in the absence of plasminogen and tPA A: Effect 
of plasminogen activation in the absence of plasminogen and tPA for plasminogen alone, 
12K, 12KΔV, 17K, 17KΔLBS10, 17KΔV, and KIV5-8 at 400 nM each on THP-1 
monocytes. B: Effect of plasminogen activation in the absence of tPA for plasminogen 
alone, 17K, 17KΔLBS10, and 17KΔV at 400 nM each on THP-1 macrophages and 
HUVECs. Data represent the means ± standard deviations from 3-7 independent 
experiments performed in triplicate. In all cases, the relative plasminogen activation was 
significantly different (p<0.05) from control (in the presence of plasminogen and tPA 
combined). 
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2.4.2 Lp(a) inhibits plasminogen activation on THP-1 monocytes and HUVECs but 
not on THP-1 macrophages  
 We examined the ability of Lp(a), purified from human plasma, to inhibit 
pericellular plasminogen activation. Experiments were conducted using 25 nM 
plasminogen and 75 nM of Lp(a) or apo(a). Lp(a) and 17K significantly inhibited 
plasminogen activation by 15% and 35% on THP-1 monocytes respectively (Fig. 2.3A). 
However, Lp(a) did not inhibit plasminogen activation on THP-1 macrophages whereas a 
decrease of 24% was observed with 17K (Fig. 2.3B). Conversely, both Lp(a) and 17K 
could inhibit plasminogen activation to the same extent, 30% and 28% respectively, on 
HUVECs (Fig 2.3C). As observed above, plasminogen activation was largely abolished 
in the absence of tPA or cells, and was not altered with the addition of Lp(a) or 17K (Fig. 
2.3) 
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Figure 2.3: Effect of Lp(a) on plasminogen activation on THP-1 monocytes, THP-1 
macrophages, and HUVECs. Plasminogen activation experiments were performed as 
described in the legend to Fig. 2.1 with slight modifications: 25 nM of plasminogen and 
75 nM of Lp(a)/ apo(a) was utilized. A: Effect of Lp(a) on plasminogen activation in the 
presence or absence of THP-1 monocytes and tPA. B: Effect of Lp(a) on plasminogen 
activation in the presence or absence of THP-1 macrophages and tPA. C: Effect of Lp(a) 
on plasminogen activation in the presence or absence of HUVECs and tPA. The data 
represent the means ± standard deviations from 3 - 6 independent experiments performed 
in duplicate. Asterisks: p<0.05 versus plasminogen alone in the presence of cells and 
tPA; daggers: p<0.05 versus Lp(a) in the presence of cells and tPA. 
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2.4.3 Role of carboxyl terminal lysines in cell-dependent plasminogen activation and 
its inhibition by apo(a)  
 It has been previously reported that CpB treatment of U937 monocytoid cells 
reduced plasminogen binding by 64% and cell-enhanced plasminogen activation by 95% 
[39]. These results have been interpreted to mean that plasminogen binding to these 
residues on cell-surface receptors is required for the acceleration of plasminogen 
activation by cells. Treatment of THP-1 monocytes with various concentrations of CpB 
ranging from 0.1 to 100 U/mL results in a significant decrease in plasminogen activation 
(by a modest 16%) at 100 U/ mL (Fig 2.4A, B). Addition of 17K, at 400 nM, at any 
concentration of CpB results in a decrease in plasminogen activation at all concentrations 
of CpB; CpB no longer has any significant effect at any concentration in the presence of 
17K (Fig. 2.4A). Similar results were observed for THP-1 macrophages (Fig. 2.4C), 
except that CpB treatment had a greater effect of plasminogen activation, with significant 
decreases occurring at 50 and 100 U/mL both in the presence and absence of 17K (Fig. 
2.4C). Receptors with carboxyl terminal lysines also influence plasminogen activation on 
HUVECs as a decrease of 24% is observed following treatment with 100 U/mL CpB; a 
decrease in plasminogen activation owing to CpB was also observed in the presence of 
17K although statistical significance was not reached (Fig. 2.4E).  
 
2.4.4 Role of carboxyl terminal lysines in plasminogen and apo(a) binding by cells 
  To attempt to rationalize the effect of CpB on the plasminogen activation on the 
surface of cells, and its inhibition by apo(a), we examined the ability of plasminogen and 
apo(a) to bind  to THP-1 monocytes, macrophages, and HUVECs, after CpB treatment or 
in the presence of the lysine analogue ε-ACA. Plasminogen and apo(a) binding (using 
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400 nM) decreased by 18% and 51% respectively following CpB treatment (100 U/mL) 
on THP-1 monocytes (Fig. 2.4B). Binding of plasminogen and apo(a) decreased by 84% 
and 79% respectively with the addition of 200 mM ε-ACA (Fig. 2.4B). Similarly, in 
THP-1 macrophages, the addition of ε-ACA reduced plasminogen and apo(a) binding by 
91% and 73% respectively (Fig. 2.4D). However, a more modest decrease in 
plasminogen and apo(a) is observed following CpB treatment at 100 U/mL (9% and 13% 
respectively) (Fig. 2.4D). Plasminogen binding to HUVECs also decreases following 
CpB (100 U/mL) treatment and the addition of ε-ACA by 29% and 75% respectively 
(Fig. 2.4F). Surprisingly, however, apo(a) binding actually increases by 25% and 3% 
following CpB (100 U/mL) treatment and the addition of ε-ACA respectively (Fig. 2.4F). 
These results indicate that apo(a) binding is partially mediated through receptors with 
carboxyl terminal lysines on THP-1 macrophages and monocytes but not on HUVECs. 
However, since CpB treatment had little or no effect on the ability of apo(a) to inhibit 
plasminogen activation, these lysine-dependent binding events play a minor role, if any, 
in inhibition of plasminogen activation by apo(a). 
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Figure 2.4: Effect of removal of carboxyl terminal lysines using CpB on plasminogen 
activation and plasminogen and apo(a) binding. A, C, E: Effect of CpB treatment in 
plasminogen activation on THP-1 monocytes (A), THP-1 macrophages (C), or HUVECs 
(E) in the presence or absence of r-apo(a). Cells were washed three times followed by 
incubation with CpB, at various concentrations, for one hour at 37°C. Cells were then 
washed three times following which plasminogen activation was measured as described 
in the legend to Fig 2.1. Asterisks: p<0.05 versus absence of CpB for plasminogen 
activation in absence of apo(a); daggers: p<0.05 versus absence of CpB for plasminogen 
activation in presence of apo(a). B, D, F: Effect on plasminogen and apo(a) binding 
following CpB treatment of THP-1 monocytes (B), THP-1 macrophages (D), or 
HUVECs (F). Cells treated with CpB were washed three times and incubated with 
fluorescently labeled plasminogen or 17K at 400 nM, in the presence or absence of 200 
mM ε-ACA for one hour at 37°C. Cells were washed two times and the amount of bound 
fluorescent proteins was measured using a plate-reading fluorimeter. The data represent 
the means ± standard deviations from 4 - 11 independent experiments performed in 
triplicate for plasminogen activation and 3-7 independent experiments for binding 
experiments. Asterisks: p<0.05 versus absence of CpB (or ε-ACA) for plasminogen; 
daggers: p<0.05 versus absence of CpB (or ε-ACA) for apo(a).  
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2.5 DISCUSSION 
  
 It is generally accepted that apo(a) can inhibit pericellular plasminogen activation 
on vascular and blood cells, although the mechanism is not understood. As well, the 
domains in apo(a) which may potentially mediate this inhibitory effect and the relative 
role of apo(a) in various cell types is unknown. The present study contributes to the 
understanding of the role of apo(a) in inhibiting pericellular plasminogen activation on 
vascular and blood cells, specific domains in apo(a) which mediate this inhibitory effect, 
as well as the role of carboxyl terminal lysines in plasminogen activation and 
plasminogen and apo(a) binding.  
 In this study, we have provided direct evidence that (i) apo(a) inhibits pericellular 
plasminogen activation on HUVECs, THP-1 monocytes, and THP-1 macrophages; (ii) 
the kringle V domain and strong LBS in kringle IV type 10 play a crucial role in 
inhibiting activation whereas kringle 5-8 does not; (iii) Lp(a), at ~7 mg/ dL or 75 nM, can 
inhibit plasminogen activation on THP-1 monocytes and HUVECs but not on THP-1 
macrophages (iv) plasminogen binding to the cells and cell-dependent plasminogen 
activation are dependent to a partial extent on receptors containing carboxyl-terminal 
lysines on all cell types; (v) apo(a) binding to THP-1 monocytes and macrophages is 
partially dependent of these receptors, but apo(a) binding to HUVECs is independent of 
these receptors and of lysine binding in general; and (vi) the binding by apo(a) to 
carboxyl-terminal lysine-containing sites does not appear to account for its ability to 
inhibit plasminogen activation.  
A previous study has shown that Lp(a)/apo(a) can compete with plasminogen for 
binding on the endothelial cell surface and hence inhibit plasminogen activation [44].
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Binding of plasminogen to the cell surface initiates pericellular plasminogen activation 
through interaction with its respective plasminogen activators: tPA and uPA. Both tPA 
and uPA have been shown to be expressed in a variety of cell types, including endothelial 
cells for tPA [51] and lung, kidney, and several tumor cell lines for uPA [52, 53].
 
It has 
been shown that tPA can directly bind to various cell types other than endothelial cells, 
such as platelets, monocytes, and monocytoid cells [30, 39, 54, 55]. Lp(a) was reported to 
inhibit plasminogen activation on the surface of resting platelets by inhibiting 
plasminogen and tPA binding [56]. Therefore, the effects of apo(a) and Lp(a) on tPA-
mediated pericellular plasminogen activation on vascular cells were evaluated. 
Plasminogen receptors are a heterogeneous and ubiquitously present group of cell 
surface proteins [38]. Plasminogen receptors have been shown to contain carboxyl-
terminal lysine residues that bind plasminogen [38]. Removal of these carboxyl-terminal 
lysines destroys the ability of this subset of receptors to bind to plasminogen and support 
its activation [38]. However, not all plasminogen receptors contain a carboxyl-terminal 
lysine, with examples of this type being actin, amphoterin, αVβ3, αMβ2, and αIIbβ3 [57]. 
Binding of plasminogen to these receptors presumably converts plasminogen from its 
native closed conformation into a more open and highly activatable form [38]. The initial 
plasmin generated on the cell surface begins to catalyze the positive feedback mechanism 
of converting Glu- to Lys-plasminogen, the latter of which is itself more readily 
activatable [32]. Furthermore, the plasmin generated on the surface of the cells is 
protected from its natural inhibitor α2-antiplasmin [31]. In the context of fibrin, carboxyl 
terminal lysines have been shown to play a crucial role in regulating plasminogen 
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activation [25, 58]. Hence, the role of carboxyl-terminal lysines on the cell surface was 
also of interest in this study.
 
 
 Our studies, for the first time, have directly demonstrated that apo(a) is capable of 
inhibiting pericellular plasminogen activation. We showed this to be the case with two 
different recombinant apo(a) species, 12K and 17K, representing physiologically-relevant 
apo(a) isoforms. Interestingly, the 12K and 17K were similar in their ability to inhibit 
pericellular plasminogen activation. This suggests that the number of KIV type 2 repeats 
do not dictate the level of inhibition which is in agreement with the findings of Hancock 
and co-workers in the context of fibrin [33]. On the other hand, studies using a wider 
array of apo(a) sizes in the context of an intact Lp(a) particle have reported an inverse 
relationship between isoform size and the ability of Lp(a) to inhibit fibrinolysis and 
interfere with plasminogen binding to fibrin [59, 60], while larger Lp(a) isoforms were 
found to bind with less affinity to THP-1 monocytes [61]. Therefore, additional studies 
are required to assess the possibility that inhibition of pericellular plasminogen activation 
by apo(a)/Lp(a) is also isoform-size dependent. 
 The concentration of circulating plasminogen in plasma is 2.2 μM [62] whereas 
the concentration of Lp(a) varies from 1 to greater than 100 mg/dL, which is 
approximately equal to 0.01 to 1 μM [4]. The molar concentration of plasminogen 
circulating in the blood is generally greater than that of apo(a); however apo(a) has been 
shown to accumulate within atherosclerotic lesions and carotid plaques, likely due to its 
ability to interact with a wide variety of extracellular matrix elements [63-65].
 
Importantly, we showed that the ability of apo(a) and Lp(a) to inhibit pericellular 
plasminogen activation was strictly dependent on the presence of cells (Figs. 2.1, 2.3). 
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This likely reflects the ability of apo(a) to influence binding of plasminogen and/or tPA 
to the cells, although in our own binding studies we were not able to conclusively 
determine the extent to which apo(a) and plasminogen compete for binding to the cells 
(Suppl. Fig. 2.3). 
 Previous studies have identified specific domains of apo(a) that mediate its 
inhibitory effect on plasminogen activation as well as Glu-plasminogen to Lys-
plasminogen conversion on the fibrin surface [33, 34]. Ablation of the strong LBS in 
kringle IV type 10 was shown to substantially reduce the inhibitory effect of apo(a) 
whereas removal of kringle V abolished the effect in plasminogen activation on fibrin 
[33]. Critical roles for kringle IV types 5-9 and kringle V were identified in inhibiting 
Glu- to Lys-plasminogen conversion on fibrin [34]. Interestingly, apo(a) from baboons 
and rhesus monkeys do not contain kringle V and are not prone to atherosclerosis [66, 
67]. In the case of baboons, the absence of KV renders the Lp(a) particle incapable of 
binding to lysine despite the presence of an intact strong LBS in KIV10 [66]. On the other 
hand, in our previous studies of SMCs, we found that KIV9, but not the strong LBS in 
KIV10, mediated a decrease in TGF-β activation in a mechanism that was dependent on 
the presence of plasminogen (and thus, presumably, an effect on plasminogen activation) 
[35]. Therefore, there may be cell-type differences in the mechanisms through which 
apo(a)/Lp(a) interferes with plasminogen activation. This may in turn reflect different 
cohorts of plasminogen – or apo(a) – receptors on difference cell types.  
We show here that the strong LBS in kringle IV type 10 as well as kringle V are 
essential for the inhibitory effects of apo(a) on pericellular plasminogen activation on 
THP-1 monocytes, THP-1 macrophages, and HUVECs. In fact, removal of theses 
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domains had the unexpected effect of enhancing plasminogen activation on the vascular 
cells tested. We suspect that these effects are related to the ability of apo(a) to bind to 
plasminogen in solution [46]. Indeed, from experiments conducted in the presence and 
absence of cells, it appears this enhancing effect of 17KΔLBS10, 17KΔV and 12KΔV is 
unaffected by the presence or absence of cells. However, 12K and 17K r-apo(a) do not 
enhance plasminogen activation in the absence of cells. Accordingly, we must 
hypothesize that 17KΔLBS10 and 12KΔV bind plasminogen in such a way that promotes 
its solution-phase activation, while intact 12K or 17K do not. 
The ability of Lp(a) to inhibiting plasminogen activation was also evaluated (Fig. 
2.3). Lp(a) was found to inhibit plasminogen activation, to the same extent as 17K, on 
HUVECs and to a much lesser extent on THP-1 monocytes. Plasminogen activation was 
not inhibited with the low concentration of Lp(a) utilized, ~7 mg/ dL, on THP-1 
macrophages. We were restricted to a relatively low concentration of Lp(a) by the 
concentration of the preparation. The concentration utilized is less than the cardiovascular 
risk factor of Lp(a) levels >50 mg/ dL and could account for the lack of effect on THP-1 
macrophages, possibly due to more rapid uptake of Lp(a) by these cells for example by 
the apo(a)/Lp(a) receptor identified by Keesler and coworkers [48].  
The importance of carboxyl terminal lysine receptors was determined in vascular 
and blood cells. Overall, CpB treatment had modest but significant decreasing effects on 
plasminogen activation and on plasminogen and apo(a) binding (Fig. 2.4), with CpB 
treatment never decreasing binding or activation to below 50% of control. The exception 
to this was in HUVECs, where apo(a) bound in a manner completely independent of 
carboxyl-terminal lysines (Fig. 2.4F). Addition of the lysine analogue ε-ACA had a more 
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profound effect on plasminogen or apo(a) binding, which may suggest that some binding 
sites may have represented internal, as compared to carboxyl-terminal, lysine residues. 
Because of its profound effects on plasminogen conformation, we were unable to assess 
the effects of ε-ACA on plasminogen activation. Nonetheless, the available data suggest 
that the inhibition of plasminogen activation by apo(a) is not dependent on carboxyl-
terminal lysines, since CpB treatment of the cells had only a small effect, if any, on the 
extent of the inhibition. If carboxyl-lysines played a role (such as mediating the binding 
of apo(a), plasminogen, or tPA required for the inhibition) inhibition by apo(a) would 
have been eliminated, when in fact it was only minimally impacted (Fig. 2.4A, C, E). 
Indeed, in HUVECs, where apo(a) is able to inhibit plasminogen activation over 50%, 
apo(a) binding is completely independent of carboxyl-terminal lysines (Fig. 2.4). It is 
reasonable to hypothesize, then, that if lysines do play a role, they would be internal 
lysines in cell-surface receptors.  
Apo(a) has been shown in this current study to play a crucial role in regulating 
plasminogen activation on vascular cells attributable to kringle V and the strong LBS site 
in kringle IV type 10. What remains to be determined are the identities of the receptors 
that presumably mediate these effects. Moreover, it must be evaluated if the inhibition of 
plasminogen activation by apo(a) results from competition between these proteins for 
binding sites on cells and/or is a consequence of the ability of apo(a) to inhibit 
plasminogen activation via interference with the positive feedback mechanism of Glu- to 
Lys-plasminogen conversion.  
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2.7 SUPPORTING INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.1: Effect of acid washing on the binding of 17K apo(a) or 
plasminogen to THP-1 monocytes. (A), THP-1 macrophages (B), or HUVECs (C). After 
incubating fluorescently-labeled apo(a) or plasminogen (400 nM) with the cells, we 
conducted a series of acid washes in order to assess whether we are detecting bound or 
internalized plasminogen or apo(a). The acid wash (two or three washes with 0.2 M 
acetic acid pH 2.5, 0.5 M NaCl) will remove any surface bound plasminogen or apo(a). 
Upon acid wash of the three cell types, a substantial decrease in the amount of bound 
plasminogen/apo(a) was detected indicating that the majority is surface bound and not 
internalized. The minimal amount detected following acid wash could either be residual 
bound plasminogen/ apo(a) (i.e. non-specific binding) or a small amount that was 
internalized. The results shown are the mean ± s.e.m. of 3 – 6 independent experiments. 
Asterisks: p < 0.05 versus absence of acid wash. 
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Supplementary Figure 2.2: Apo(a) competition binding experiments. Binding of 
Alexa-labeled 17K apo(a) (400 nM) to THP-1 monocytes (A), THP-1 macrophages (B), 
or HUVECs (C) was conducted in the absence or presence of unlabeled 17K apo(a) (400 
to 1600 nM; i.e. up to a 4-fold molar excess). Based on our experiments with ε-ACA, we 
believe that at least 80% of the apo(a) binding is specific in THP-1 monocytes and 
macrophages (see Fig. 2.4B, D). As ε-ACA did not inhibit apo(a) binding to HUVECs 
(nor did CpB), we were not able to make the same estimation, although an acid-wash step 
similarly eliminated at least 80% of the binding (see above). We thus attempted to “self-
compete” the binding to HUVECs of Alexa-labeled apo(a) with unlabeled apo(a). The 
results show a decrease in labeled apo(a) binding in THP-1 monocytes or macrophages, 
although the extent of the decrease was small at the relatively small molar excesses that 
we attempted. The results shown are the mean ± s.e.m. of 3 – 6 independent experiments. 
Asterisks: p < 0.05 versus absence of unlabeled apo(a).  
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Supplementary Figure 2.3: Plasminogen competition binding experiments. Effect of 
unlabeled plasminogen on the binding of Alexa-labeled 17K apo(a) to THP-1 monocytes 
(A), THP-1 macrophages (B), or HUVECs (C). Effect of unlabeled 17K apo(a) on the 
binding of Alexa-labeled plasminogen to THP-1 monocytes (D), THP-1 macrophages 
(E), or HUVECs (F). Binding experiments were conducted with 400 nM Alexa-labeled 
17K apo(a) or plasminogen in the absence or presence of unlabeled plasminogen or 17K 
apo(a). Assessment of the effect of plasminogen on apo(a) binding is perilous because of 
the ability of apo(a) and plasminogen to  bind [Sangrar, W., B. R. Gabel, M. B. Boffa, J. 
B. Walker, M. A. Hancock, S. M. Marcovina, A. J. Horrevoets., M. E. Nesheim, and M. 
L. Koschinsky. 1997. The solution phase interaction between apolipoprotein(a) and 
plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen 
surface. Biochemistry. 36: 10353-10363] such that addition of an unlabeled excess of one 
may not decrease the binding of the other. In any event, whether the competitor genuinely 
competes for a binding site or merely prevents binding to the cell surface through a 
solution-phase interaction cannot be distinguished. Lack of competition may indicate 
binding to different binding sites. The data show that unlabeled plasminogen does not 
compete for binding of labeled apo(a), while unlabeled apo(a) does compete for binding 
of labeled plasminogen. It is possible that the putative apo(a)/plasminogen complex binds 
to apo(a) binding sites but not to plasminogen binding sites, or that apo(a) binds to sites 
that either do or do not binding to plasminogen. The results shown are the mean ± s.e.m. 
of 3 – 6 independent experiments. Asterisks: p<0.05 versus absence of unlabeled 
competitor. 
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3.1 SUMMARY 
Lipoprotein(a) [Lp(a)] is an enigmatic lipoprotein which has been identified as an 
independent, causal risk factor for coronary heart disease. Lp(a) consists of a low-density 
lipoprotein (LDL) moiety covalently linked to the unique glycoprotein apolipoprotein(a) 
[apo(a)]. Apo(a) is homologous to the fibrinolytic zymogen plasminogen and thus may 
interfere with plasminogen activation. Conversion by native Glu-plasminogen by plasmin 
to the more readily activatable Lys-plasminogen greatly accelerates plasminogen 
activation and is necessary for optimal stimulation of plasminogen activation on 
endothelial cells. Lp(a)/apo(a) has been previously shown to inhibit pericellular 
plasminogen activation on vascular cells, but the mechanism underling these observations 
is unknown. We therefore explored whether apo(a) can inhibit pericellular Glu- to Lys-
plasminogen conversion on cell surfaces. A physiologically relevant recombinant version 
of apo(a) (17K) significantly inhibits plasmin-mediated Glu- to Lys-plasminogen 
conversion on human umbilical vein endothelial cells (HUVECs) and smooth muscle 
cells (SMCs). All isoforms of apo(a) that were analyzed, ranging in size from 3 to 21 
kringle IV type 2 repeats, were able to inhibit conversion to a similar extent. Removal of 
the kringle V and protease domain of apo(a) strongly reduces the ability of apo(a) to 
inhibit conversion on HUVECs and SMCs. Removing the strong lysine binding site in 
KIV10 of apo(a) abolishes its ability to inhibit conversion on HUVECs and, to a lesser 
extent, on SMCs. These results indicate a novel mechanism in which apo(a) inhibits the 
positive feedback mechanism that accelerates plasmin formation on vascular cells. 
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3.2 BACKGROUND 
Plasma lipoprotein(a) [Lp(a)] levels vary dramatically within the human 
population, ranging between individuals from undetectable to greater than 100 mg/dL [1, 
2]. Elevated levels of Lp(a) – greater than 30-50 mg/dL – have been established as a 
causal, independent risk factor for atherothrombotic disorders including coronary heart 
disease (CHD) [3-5]. Lp(a) is similar in lipid composition to low-density lipoprotein 
(LDL) and contains apolipoproteinB-100 (apoB-100) [6]. However, Lp(a) constitutes a 
distinct lipoprotein class in that it also contains the unique glycoprotein apolipoprotein(a) 
[apo(a)] [7]. Apo(a) is evolutionarily related to the fibrinolytic proenzyme plasminogen 
[8]: apo(a) consists of multiple copies of a plasminogen kringle IV (KIV)-like domain 
followed by a plasminogen kringle V (KV)-like domain and an inactive protease domain 
[9]. Unlike plasminogen, apo(a) consists of multiple copies of KIV that are classified as 
10 distinct subtypes based on amino acid sequence (KIV1 to KIV10) [8]. Apo(a) isoform 
size is genetically determined based on variation in allele size of LPA (the gene encoding 
apo(a)) which results in varying numbers of identically repeating copies of KIV2 [10-12]. 
The number of identically repeated copies of KIV2 can vary from 3 to >40 which gives 
rise to the isoform size heterogeneity of Lp(a) observed in the human population [12]. 
Lp(a)/apo(a) has been previously reported to inhibit both in vitro and in vivo 
fibrin clot lysis [13-15] and plasminogen activation on fibrin or degraded fibrin [16]. This 
is partially attributable to the ability of apo(a) to inhibit the positive feedback mechanism 
of Glu-plasminogen to Lys-plasminogen conversion [17]. Recently, it has been shown 
that Lp(a)/apo(a) can inhibit pericellular plasminogen activation on human umbilical vein 
endothelial cells (HUVECs), human acute monocytic leukemia (THP-1) cells, and THP-1 
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cells differentiated into macrophages [18]. Plasmin generation is crucial for fibrinolysis, 
angiogenesis, cell migration and proliferation, wound healing, and tumor cell invasion 
and metastasis [19-24].  
Binding of native Glu-plasminogen to fibrin or cell surfaces greatly accelerates 
plasminogen activation [25-26]. Glu-plasminogen exhibits a tight, spiral structure [27] 
and is thought to adopt a more open conformation that is more readily activated when 
bound to fibrin or cell surfaces [28]. Glu-plasminogen can also be converted by plasmin 
cleavage at Lys
77
 to form Lys-plasminogen which can be more readily activated by 
plasminogen activators as it is in a more open, extended conformation compared to the 
native circulating Glu-plasminogen [25, 27]. Lys-plasminogen can also bind with a 
higher affinity to substrates such as fibrin which further accelerates plasmin formation 
[29-31]. Conversion of Glu- to Lys-plasminogen is also necessary for optimal activation 
of plasminogen on HUVECs and monocytoid cells [26, 32]; stimulation of Glu- to Lys-
plasminogen conversion is the main mechanism by which cell surfaces accelerate 
plasminogen activation. Once Lys-plasminogen is formed, it is more readily converted to 
plasmin in solution by tPA or uPA [26, 32, 33].  
In the present study, we evaluated the mechanism by which apo(a) can inhibit 
pericellular plasminogen activation on HUVECs and smooth muscle cells (SMCs), 
focusing specifically on the effect of apo(a) on plasmin-mediated Glu- to Lys-
plasminogen conversion on these cell surfaces. 
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3.3 METHODS 
 
3.3.1 Cell culture 
Human umbilical vein endothelial cells (HUVECs) were obtained from Clonetics 
and maintained in EBM-2 media supplemented with the EGM-2 bulletkit (Lonza). 
Smooth muscle cells (SMCs) were obtained from Clonetics and maintained in smooth 
muscle basal medium (SmBM) medium (Lonza) supplemented with the SmGM-2 bullet 
kit (Lonza). Human embryonic kidney cells (HEK293) cells were maintained in MEM 
(GIBCO) containing 5% fetal bovine serum (FBS; GIBCO) and 1% antibiotic-
antimycotic (GIBCO). Baby hamster kidney (BHK-21) cells were maintained in DMEM 
(GIBCO) containing 5% newborn calf serum (NCS; Sigma) and 1% antibiotic-
antimycotic (GIBCO). All cells were maintained in a humidified incubator at 37°C and 
95% air/5% CO2 atmosphere. All experiments were conducted at passage five for both 
HUVECS and SMCs. 
 
3.3.2 Construction, expression, and purification of recombinant apo(a) 
The recombinant apo(a) (r-apo(a)) variants used in this study are shown 
schematically in Fig. 3.1. The construction and expression of the r-apo(a) variants have 
been previously described [9, 16, 34-36]. Briefly, the expression plasmids used to express 
the r-apo(a) variants were constructed in the pRK5 vector containing a cytomegalovirus 
promoter and SV40 transcription termination signal. Expression plasmids encoding the 
recombinant apo(a) (r-apo(a)) variants 12K, 12KΔV, 14K, 17K, 17KΔLBS10, 17KΔP, 
17KΔV, 23K, and 30K were transfected into HEK293 and stably-expressing cell lines 
derived. Recombinant proteins were purified from cell-conditioned medium using lysine-
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Sepharose affinity chromatography. Protein concentrations were determined using 
absorbance measurements taken at 280 nm and extinction coefficients corresponding to 
each respective variant as previously described [9, 16, 34-36]. Purity of the proteins was 
confirmed by SDS-PAGE under non-reduced and reduced conditions followed by silver 
staining. 
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Figure 3.1: Recombinant-apo(a) constructs utilized in study. The domain structure of 
the full-length r-apo(a) constructs is presented, where KIV and KV denote kringle 
homologous to plasminogen kringles 4 and 5, respectively, and P represents the 
plasminogen-like protease domain. The bar indicates the location of the free-cysteine by 
which apo(a) is covalently bound to apoB-100 in the Lp(a) particle. Mutations and 
deletions of specific domains are schematized, with the circle representing an Asp.→ Ala 
mutation at position 57 of KIV10 that abolishes the strong LBS in this kringle. 
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3.3.3 Construction, expression, purification, and labeling of recombinant 
plasminogen 
The construction and expression of plasminogen has been previously described 
[16, 36]. Briefly, full length plasminogen cDNA was inserted into the multiple-cloning 
site of the pNUT expression vector, followed by site-directed mutagenesis to achieve a 
recombinant variant of plasminogen containing a serine to cysteine mutation (S741C) in 
the active site. The plasmid was then transfected into BHK-21 cells to produce a stably-
expressing cell line. Recombinant plasminogen in cell-conditioned medium was purified 
using affinity chromatography over lysine-Sepharose. Purified plasminogen was 
fluorescently labeled using the cysteine-specific fluorescent probe, 5-
iodoacetamidofluorescein (5’-IAF). Protein concentrations were determined using 
absorbance measurements taken at 280 nm (extinction coefficient of 1.6 M
-1 
cm
-
1) and 
corrected for the contribution of fluorescein (A280 = 0.19×A495). Purity of the protein was 
confirmed by SDS-PAGE under non-reduced and reduced conditions followed by silver 
staining. 
 
3.3.4 Measurement of Plasmin-Mediated Conversion of Glu-Plasminogen to Lys-
Plasminogen 
Passage five HUVECs and SMCs were grown to confluence in a 24-well cell 
culture plate and washed two times with Hanks buffered salt solution (HBSS; 0.137 M 
NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM 
MgSO4, 4.2 mM NaHCO3, 1 g/L glucose, pH 7.4) containing 0.1% (w/v) BSA (HBSS-
BSA). The cells were treated with 200 μL of a solution containing 50 nM fluorescently 
labelled recombinant-Glu-plasminogen, 5 nM Lys-plasmin (Haematologic Technologies 
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Inc.), and various concentrations of r-apo(a) (ranging from 0 to 400 nM) in HBSS-BSA. 
Reactions were terminated by rapidly washing the cells once with HBSS-BSA then 
adding 100 μL of reducing sample buffer (31.2 mM Tris, pH 7.2, 2% SDS, 10% sucrose, 
0.002% bromophenol blue, 15 mM dithiothreitol, 10mM EDTA, 10 mM benzamidine, 2 
mM phenylmethylsulfonyl fluoride, 10 μg/ml soybean trypsin inhibitor (Sigma), 0.02% 
NaN3, 5 units/ml Trasylol, 50 mM ε-aminocaproic acid (ε-ACA)). This technique has 
been previously shown to capture greater than 90% of the cell-associated plasminogen 
with minimal contamination by unbound plasminogen [26]. Samples were subjected to 
7% SDS-PAGE under reducing conditions. The resulting gels were exposed under a cy2 
lens using the FluoroChem Q system (AlphaInnotech) to visualize Glu- and Lys-
plasminogen utilizing the fluorescent tag on plasminogen. Band intensities were 
determined using Alpha View software (AlphaInnotech). Percent conversion values were 
calculated by dividing the Lys-plasminogen band intensity with the sum of the Glu- and 
Lys-plasminogen band intensities. Experiments were performed in the absence of cells in 
a 1.5 mL amber tube (Eppendorf) at 37°C, with the same concentrations of plasminogen, 
plasmin, and r-apo(a) as above. At specific time points, a sample of the solution was 
removed followed by the addition of reducing sample buffer in a 1:1 ratio. The samples 
were then subjected to SDS-PAGE and imaging as above. 
 
3.3.5 Statistical Methods 
 Comparisons between data sets were performed using two-tailed Student t-test 
assuming unequal variance. Statistical significance was presumed at p<0.05.  
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3.4 RESULTS 
Previous work has shown that plasmin-mediated conversion of Glu- to Lys-
plasminogen is necessary for optimal stimulation of plasminogen activation on HUVECs 
[26]. We have previously reported that apo(a) can inhibit plasminogen activation as well 
as the conversion of Glu- to Lys-plasminogen on the fibrin surface [16, 17]. We have also 
reported that apo(a) can inhibit pericellular plasminogen activation on the surface of 
vascular cells [18]. In this study, we determined the effect of apo(a) on pericellular Glu- 
to Lys-plasminogen conversion by plasmin. We utilized a recombinant variant of 
plasminogen that contains a Ser to Cys mutation in the active site such that no plasmin 
activity develops upon cleavage of the variant with plasminogen activators [36]. 
Therefore, no plasmin beyond that added to the reaction is formed which prevents 
positive feedback in the conversion reaction. Moreover, the mutation allows labeling of 
the recombinant plasminogen with a fluorophore containing a sulfhydryl-directed 
functional group, allowing for detection specifically of the Glu-plasminogen substrate 
and its Lys-plasminogen product following electrophoretic separation of the reactions. 
We used a washing technique that specifically captures the cell-associated plasminogen 
forms with minimal contamination from the reactants in the cell medium [26].  
HUVECs and SMCs were treated with 50 nM labeled recombinant plasminogen, 
5 nM plasmin, and various concentrations of r-apo(a) and at specific time points the 
reaction was terminated through the addition of reduced sample buffer directly to the 
cells. Following resolution of Glu- and Lys-plasminogen by SDS-PAGE, the extent of 
conversion was determined by dividing the Lys-plasminogen band intensity with the sum 
of the Glu- and Lys-plasminogen bands intensities. Shown in Fig. 3.2 are representative 
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gels showing the effect of apo(a) on Glu- to Lys-plasminogen conversion on the surface 
of HUVECs (Fig. 3.2A), SMCs (Fig. 3.2B), and in the absence of cells (Fig. 3.2C). 
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Figure 3.2: Inhibition of plasmin-mediated Glu- to Lys-plasminogen conversion by 
apo(a). Reactions contained 50 nM fluorescently labeled Glu-plasminogen (in which the 
active site serine is mutated to a cysteine and fluorescently labeled), 5 nM plasmin, and 
various concentrations of r-apo(a). At specific time points, the cells were washed and 
reactions were terminated by the addition of SDS-PAGE sample buffer. In the absence of 
cells, sample buffer was added in a 1:1 ratio to reaction mixture to terminate reactions at 
specific time points. Samples were subjected to SDS-PAGE and Glu- and Lys-
plasminogen bands were observed and quantified by fluorescence image analysis 
Representative gels are shown for the effect of apo(a) on Glu- to Lys-plasminogen 
conversion on (A) HUVECs, (B) SMCs, and (C) in the absence of cells. Glu- and Lys-
plasminogen (Pg) are the upper and lower bands, respectively, on the gels.  
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We performed both a titration of the physiologically relevant 17K r-apo(a) variant 
as well as a time course of the conversion reaction on HUVECs. Conversion in the 
absence of apo(a) is initially rapid, with the rate slowing considerably after 30 minutes 
(Fig. 3.3A). Addition of 17K r-apo(a) results in a dose-dependent decrease in the extent 
of conversion at all time points, with the maximal effect of 17K r-apo(a) being an almost 
60% decrease in conversion at 400 nM 17K at 20 minutes. 
We next utilized a series of r-apo(a) containing deletions of either specific 
domains or point mutations (Fig. 3.1) in order to assess which sequences of apo(a) 
mediate the ability of 17K to inhibit Glu- to Lys-plasminogen conversion on HUVECs. 
Removal of the protease domain and kringle V domain of 17K resulted in at least a 50% 
decrease in the ability to inhibit conversion on HUVECs (Fig. 3.3B). Removal of the 
strong lysine binding site (LBS) in kringle IV type 10 (17KΔLBS10) abolishes the ability 
of 17K to inhibit Glu- to Lys-plasminogen conversion on HUVECs (Fig. 3.3B). 
In order to determine if the effect of deleting certain domains is isoform-
dependent, we analyzed the inhibitory effect of 12KΔV in comparison to 12K. As with 
17K and 17KΔV, kringle V in 12K is required for maximal inhibition on HUVECs (Fig. 
3.3C), with the loss of this kringle resulting in at least a 50% decrease in the extent of 
inhibition. 
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Figure 3.3: Inhibition by apo(a) of Glu- to Lys-plasminogen conversion on HUVECs. 
HUVECs were grown to confluence in a 24 well plate and conversion experiments were 
conducted as described in the legend to Fig. 3.2. Percent conversion values were 
calculated by dividing the Lys-plasminogen band intensity with the sum of the Glu- and 
Lys-plasminogen band intensities. (A) Titration of 17K r-apo(a) on HUVECs. Data 
shown are the means ± standard error of the mean (SEM) from at least seven independent 
experiments. **: p<0.01 for each concentration of 17K (100, 200, and 400 nM) in 
comparison to plasminogen alone. (B) Examination of a series of domain 
deletions/mutations (see Fig. 3.1), each at 400 nM. Data shown are the means ± SEM 
from at least three independent experiments. **: p<0.01 for 17K in comparison to 
plasminogen alone. #:p<0.05 and ##: p<0.01 for 17KΔP in comparison to plasminogen 
alone. ǂ: p<0.05 and ǂ ǂ:p<0.01 for 17KΔV in comparison to plasminogen alone. (C) 
Comparison of the effects of 12K and 12KΔV. Data show are the means ± SEM from at 
least three independent experiments. *:p<0.05 and **: p<0.01 for 12KΔV in comparison 
to plasminogen alone. ǂ: p<0.05 and ǂ ǂ:p<0.01 for 12KΔV in comparison to 12K. 
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A series of r-apo(a) variants containing different numbers of KIV2 repeats (Fig. 
3.1) was utilized in order to assess whether apo(a) isoform size contributes to the 
inhibitory effect of Glu- to Lys-plasminogen conversion on HUVECs. All isoforms tested 
were able to inhibit Glu- to Lys-plasminogen conversion to a similar extent (Fig. 3.4), 
with no trend with respect to size apparent.  
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Figure 3.4: Effect of r-apo(a) isoform size on Glu- to Lys-plasminogen conversion on 
HUVECs. Conversion experiments were conducted as described in the legend to Fig. 3.2 
in the presence of 400 nM r-apo(a) variants differing in the number of KIV2 repeats (see 
Fig. 3.1). Data shown are the means ± SEM from at least three independent experiments. 
**: p<0.01 for all isoforms tested (12K, 14K, 17K, 23K, and 30K) at each time points 10, 
20, 30, 60 and 100 nM in comparison to plasminogen alone.  
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The ability of apo(a) to inhibit Glu- to Lys-plasminogen conversion on SMCs was 
also evaluated. The same dose-dependent decrease in Glu- to Lys-plasminogen 
conversion is observed on SMCs as was seen on HUVECs following the addition of 17K 
(Fig. 3.5A). Compared to on HUVECs, there is a more rapid initial increase in the rate of 
conversion in the absence of apo(a), and the maximal inhibitory effect of 17K occurs 
sooner and is greater in magnitude. Removal of the strong LBS significantly abrogates 
the inhibitory effect of 17K (Fig. 3.5B), but unlike in HUVECs this variant retains some 
inhibitory effect in SMCs, at least at early time points.  
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Figure 3.5: Inhibition by apo(a) of Glu- to Lys-plasminogen conversion on SMCs. 
Conversion experiments were conducted as described in the legend to Fig. 3.2. (A) 
Titration of 17K r-apo(a) on SMCs Data shown are the means ± SEM from at least four 
independent experiments. **: p<0.01 for each concentration of 17K (100, 200, and 400 
nM) in comparison to plasminogen alone. (B) Comparison of 17K and KIVΔLBS10 (each 
at 400 nM). Data shown are the means ± SEM from at least four independent 
experiments. **: p<0.01 for 17KΔLBS10 in comparison to plasminogen alone. ǂǂ:p<0.01 
for 17KΔLBS10 in comparison to 17K.  
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Previous work has also shown that plasminogen activation and Glu- to Lys-
plasminogen conversion is greatly accelerated on fibrin or cell surfaces compared to in 
solution [17, 18]. In our assays, the percent Glu- to Lys-plasminogen conversion for 
HUVECs or SMCs compared to the reaction in solution was reduced by 73% and 82% 
respectively at the 10 min time point (Fig. 3.6). Interestingly, 17K retains the ability to 
inhibit Glu- to Lys-plasminogen conversion in the absence of cells, with the percentage 
decrease being of a similar magnitude to that observed on cells (Fig. 3.6). 
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Figure 3.6: Comparison of Glu- to Lys-plasminogen conversion in the presence or 
absence of cells. Conversion experiments were conducted as described in the legend to 
Fig. 3.2. Data shown are the means ± SEM from at least three independent experiments. 
*:p<0.05 for comparison of plasminogen alone between HUVECs and SMCs. ǂ: p<0.05 
and ǂǂ:p<0.01 for comparison of plasminogen alone and 17K in the absence of cells.  
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3.5 DISCUSSION 
 It has been previously shown that Lp(a)/apo(a) can inhibit pericellular 
plasminogen activation on HUVECs, THP-1 monocytes, and THP-1 cells differentiated 
into macrophages [18]. However, the mechanism by which Lp(a)/apo(a) can inhibit this 
process is unknown. Lp(a)/apo(a) can inhibit plasminogen activation on the fibrin 
surface, in part, through inhibiting plasmin-mediated Glu- to Lys-plasminogen 
conversion [17]. This mechanism has also been shown to be crucial for the ability of cell 
surfaces to accelerate plasminogen activation [26, 32]. In this scenario, binding of Glu-
plasminogen (closed conformation) to cells increases the rate at which plasmin cleaves 
the protein to form Lys-plasminogen (open conformation), which is then activated at a 
much higher rate by plasminogen activators in solution. Glu-plasminogen is in a closed, 
spiral conformation that limits accessibility of the plasmin cleavage site at Lys
77
 as well 
as the tPA/uPA cleavage site at Arg
562
; conversion to Lys-plasminogen results in an open, 
extended conformation that relieves the latter conformational barrier. Presumably, 
binding of Glu-plasminogen to lysine-containing cell surface receptors similarly results in 
a more open conformation that promotes cleavage by plasmin to form Lys-plasminogen. 
Note that this model contrasts with earlier models that assumed that cell surfaces 
constitute a template to which Glu-plasminogen and plasminogen activators bind to form 
a ternary complex that accelerates plasminogen activation, in a manner analogous to the 
role of fibrin surfaces [26, 32]. 
Therefore, the current study set out to determine if apo(a) inhibits pericellular 
plasminogen activation specifically through inhibition of plasmin-mediated Glu- to Lys-
plasminogen conversion. We found that, indeed, apo(a) can act as a potent inhibitor of 
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Glu- to Lys-plasminogen conversion on two vascular cell types: HUVECs and SMCs. 
The magnitude of the reduction (over 2-fold) is in keeping with our recent report of the 
effect of apo(a) on plasminogen activation on vascular and blood cells [18]. Together 
these findings suggest that inhibition of Glu- to Lys-plasminogen conversion is crucial to 
the overall mechanism of plasminogen activation inhibition by apo(a).  
We found that Glu- to Lys-plasminogen conversion is significantly accelerated in 
the presence of cells compared to that observed in solution. Moreover, in the current 
study, apo(a) was able to inhibit conversion in the absence of cells. These results 
contradict previous findings which demonstrated that apo(a) accelerates Glu- to Lys-
plasminogen conversion in the absence of fibrin [17]. The differences observed could be 
due to the contrast in the ratio of plasminogen:plasmin:apo(a) in the two systems. 
Nonetheless, apo(a) was not able to accelerate pericellular plasminogen activation in the 
absence of cells as was observed in the current study [18].  
In order to gain mechanistic insights, we investigated the importance of specific 
domains of apo(a) which mediate its inhibitory capabilities in Glu- to Lys-plasminogen 
conversion. In the current study, we identified a crucial role for the strong LBS present in 
KIV type 10 in the inhibition of Glu- to Lys-plasminogen conversion. A mutant form of 
apo(a) lacking this LBS was completely unable to inhibit conversion on HUVECs and 
was considerably reduced in its ability to inhibit conversion on SMCs. As well, key roles 
were identified for the protease and KV domains. Removal of these domains resulted in a 
reduced ability of apo(a) to inhibit Glu- to Lys-plasminogen conversion on both cell 
types. The strong LBS and KV domain have been previously shown to be crucial for 
inhibiting plasminogen activation on HUVECs and THP-1 monocytes and macrophages, 
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with removal of either of these elements rendering apo(a) completely incapable of 
inhibition [18]. In addition, we found that apo(a) (at a concentration of 100 nM) inhibits 
plasminogen activation on SMCs and that removal of the KIV10 strong LBS abolished 
this effect (R.R. and M.L.K., unpublished data). It is notable, however, that removal of 
the KIV10 LBS and KV does not always abolish the ability of apo(a) to inhibit Glu- to 
Lys-plasminogen conversion (Figs. 3.3, 3.5) suggesting that other mechanisms may also 
contribute to inhibition of pericellular plasminogen activation. We previously found that 
apo(a) can bind to plasminogen in solution [34, 37] which may inhibit the ability of tPA 
to cleave plasminogen in solution. 
Previous results have shown that the protease domain of apo(a) is crucial for its 
ability to bind to plasminogen in solution, whereas the strong LBS in KIV10 had no effect 
on this interaction [34]. The role of KV in this solution phase interaction is not known. In 
the present study, removal of the strong LBS abolishes the inhibition of Glu- to Lys-
plasminogen conversion on HUVECs and to a less extent on SMCs whereas removal of 
the protease domain only partially decreases inhibition of conversion on HUVECs. These 
results suggest that the predominant mechanism of the ability of apo(a) to inhibit 
conversion is not due to the interaction of apo(a) and plasminogen in solution. 
Furthermore, previous studies have shown that apo(a) can bind to Glu-plasminogen with 
high affinity (KD ~0.3 µM) but to Lys-plasminogen with much lower affinity (KD >50 
µM) [37]. It is likely that apo(a) is inhibiting conversion either (i) through binding to 
Glu-plasminogen on the cell surface and inhibiting its ability to be cleaved by plasmin; or 
(ii) through preventing Glu-plasminogen from binding to the cell surface. Lp(a) has been 
previously shown to compete with plasminogen for binding to various cells [38]. Our 
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own work showed that 17K apo(a) could decrease binding of plasminogen to HUVECs 
and THP-1 cells, although plasminogen could not decrease 17K binding [18]. The role of 
the solution phase interaction between apo(a) and plasminogen on these effects is 
unclear. In light of the limited effect of removal of the protease domain in the current 
work, it is clear that there are complexities in the binding of apo(a) and plasminogen – 
both to each other and to cells – that will require a more detailed analysis with our r-
apo(a) variants.   
 Various apo(a) isoform sizes were also analyzed in order to determine the 
importance of the number of KIV2 domains in inhibiting conversion. Smaller isoforms of 
apo(a) – <22 KIV domains – have been identified as a risk factor for CHD [39]. While 
one study found that smaller isoforms are a risk factor for early atherosclerosis 
irrespective of Lp(a) concentration [40], the extent to which small apo(a) isoforms are a 
truly independent risk factor remains unclear. Lp(a) species containing smaller apo(a) 
isoforms bind more avidly to fibrin [41] and appear to cause hypofibrinolysis [42]. It has 
also been shown that smaller isoforms of Lp(a) bind with higher affinity to the surface of 
THP-1 monocytes [43]. However, the five isoforms analyzed in this study, ranging in size 
from 12 to 30 KIV domains, were able to inhibit conversion to similar extents on 
HUVECs. These results corroborate previous findings that showed no effect of isoform 
size on the ability of apo(a) to inhibit plasminogen activation on vascular cells [18] and 
Glu- to Lys-plasminogen conversion on fibrin surface [17].  
 We have described here a novel mechanism underlying the ability of apo(a) to 
inhibit pericellular plasminogen activation: attenuation of plasmin-mediated Glu- to Lys-
plasminogen conversion on the vascular cell surface. The effect of apo(a) on conversion 
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appears to account for most, if not all, of the inhibitory effect of apo(a) on plasminogen 
activation. Therefore, our data generally support a model where the major effect of cell 
surfaces on plasminogen activation is to promote Glu- to Lys-plasminogen conversion 
[26, 32]. In the context of vascular cells, our findings would reflect the ability of apo(a) 
to influence dissolution of mural fibrin clots as well as cell migration and proliferation, 
angiogenesis, wound healing, and tumor cell invasion and metastasis. 
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4.1 SUMMARY 
 
Lipoprotein(a) (Lp(a)) is an independent risk factor for numerous cardiovascular 
disorders including coronary heart disease. Apolipoprotein(a) (apo(a)), the unique 
glycoprotein component of Lp(a), contains sequences homologous to plasminogen. 
Plasminogen activation is markedly accelerated in the presence of cell surface receptors 
and can be inhibited in this context by apo(a). We evaluated here the role of potential 
receptors in regulating plasminogen activation and the ability of apo(a) to mediate 
inhibition of plasminogen activation on vascular cells as well as plasminogen and apo(a) 
binding to cells. The urokinase-type plasminogen activator receptor (uPAR) modulates 
plasminogen activation as well as plasminogen and apo(a) binding on human umbilical 
vein endothelial cells (HUVECs), human acute monocytic leukemia (THP-1) cells, and 
THP-1 macrophages as determined through uPAR knockdown and overexpression. 
Apo(a) variants lacking either the kringle V or the strong lysine binding site in kringle IV 
type 10 are not able to bind to uPAR to the same extent as wild-type apo(a). Plasminogen 
activation is also modulated, albeit to a lower extent, through the MAC-1 (αMβ2) integrin 
on HUVECs and THP-1 monocytes. Integrin αVβ3 can regulate plasminogen activation 
on THP-1 monocytes and to a lesser extent on HUVECs. The ability of apo(a) to inhibit 
plasminogen activation is abolished after blocking either the αM, β2, or αVβ3 integrins on 
HUVECs and THP-1 monocytes. These results indicate cell type-specific roles for uPAR, 
αMβ2, and αVβ3 in promoting plasminogen activation and in mediating the inhibitory 
effects of apo(a) on this process. 
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4.2 BACKGROUND 
 
Elevated levels of plasma lipoprotein(a) (Lp(a)) have been identified as an 
independent risk factor for cardiovascular disorders such as coronary heart disease 
(CHD), ischemic stroke, and peripheral arterial disease (PAD) [1-5]. The structure of 
Lp(a) is similar to that of LDL, in that it contains apolipoprotein B-100 (apoB-100) as 
well as an identical lipid content [6], but differs from LDL by virtue of the unique 
glycoprotein apolipoprotein(a). Cloning of apo(a) revealed a high degree of sequence 
similarity to that of the plasma zymogen plasminogen [7]. Apo(a) contains repeated 
copies of a sequence similar to that of plasminogen kringle IV (KIV) followed by 
sequences similar to the kringle V (KV) and protease domain of plasminogen. Unlike that 
of plasminogen, the protease domain in apo(a) is catalytically inactive [8]. Apo(a) KIV 
can also be further classified into 10 subtypes (KIV1 to KIV10) based on amino acid 
sequence. Each KIV subtype is present in single copy number except for KIV2 which is 
present in identical repeated copies from 3 to >40 giving rise to the isoform size 
heterogeneity present in apo(a) [9, 10]. Apo(a) is covalently linked to apoB-100 via a 
single disulfide bond whose formation is preceded by interactions between apoB-100 and 
the weak lysine binding sites (LBSs) of apo(a) kringle IV types 6-8 [11, 12].  
The homology between plasminogen and apo(a) has been suggested to underlie 
the pathogenic effects of Lp(a) whereby the apo(a) component interferes with the 
plasminogen activation system [13]. Plasmin, generated through plasminogen activation, 
is a key component not only of fibrinolysis but also of cell migration and proliferation, 
angiogenesis, inflammation, wound healing, and tumor cell invasion and metastasis [14-
20]. Apo(a) and plasminogen both contain LBSs which mediate their respective 
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interactions with fibrin and various cell surface receptors [21]. Plasminogen activation is 
inherently inefficient, and biologically meaningful rates of plasmin formation require a 
cofactor in the form of fibrin or a cellular surface [22, 23]. Apo(a) is able to inhibit 
plasminogen activation within the fibrin clot, leading to impaired fibrinolysis [24]. 
Moreover, Lp(a) and apo(a) have been recently shown to be capable of inhibiting 
pericellular plasminogen activation on monocytes, macrophages, and vascular endothelial 
cells (ECs) [25]. To date, however, the identity of lysine-containing receptors that bind 
apo(a) and mediate its inhibition of plasminogen activation remain obscure. Apo(a) has 
been shown to stimulate cell growth and migration in ECs through integrin αVβ3 and 
Lp(a) can recruit inflammatory cells through MAC-1 (αMβ2) integrin; direct binding of 
apo(a) to the latter integrin has been demonstrated [26, 27].  
The uPA receptor (uPAR) has been shown to be a key regulator in mediating 
plasminogen activation and extracellular matrix (ECM) degradation [28]. The glycosyl 
phosphatidylinositol (GPI)-anchored uPAR can bind to uPA with high affinity (1 nM) as 
well as the ECM protein vitronectin, a ligand of αVβ3 [29, 30]. Activation of pro-uPA to 
its active form is mediated through the binding of pro-uPA to uPAR [28, 31].  
A variety of receptors have been identified on different cell types which can 
mediate both plasminogen activation as well as plasmin binding [14, 32]. Most 
plasminogen receptors are synthesized with a carboxyl terminal lysine or expose a lysine 
on the cell surface which can mimic a carboxyl-terminal lysine. The receptors that bind 
plasminogen are redundant and broadly distributed on various cells with binding sites 
ranging from 10
5
 to 10
7
 per cell [33]. Known receptors for plasminogen on vascular cells 
include annexin A2/p11, actin, αVβ3 integrin, histone H2B, αMβ2 integrin, Plg-RKT, α-
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enolase, αIIbβ3, and the TAT-binding protein-interacting protein [14, 32-40]. 
Collectively, these receptors serve to accelerate plasminogen activation as well as to 
protect plasmin from its natural physiological inhibitor, α2-antiplasmin.  
In the present study, we describe the role of various specific receptors – namely 
uPAR, αMβ2, and αVβ3 – in regulating plasminogen activation as well as plasminogen and 
apo(a) binding.  
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4.3 METHODS 
 
4.3.1 Construction, expression, and purification of recombinant apo(a) 
  The construction and expression of the various r-apo(a) variants have been 
previously described. The pRK5 expression vectors encoding 10K, 12K, 12ΔV, 17K, 
17KΔLBS10 and 17KΔV were stably transfected into human embryonic kidney (HEK) 
293 cells as previously described [8, 41-46]. All r-apo(a) variants were purified from 
conditioned media by lysine-Sepharose affinity chromatography as previously described 
[8, 41-46]. All r-apo(a) protein concentrations were determined spectrophotometrically 
and assessed for purity by SDS-PAGE under non-reduced and reduced conditions 
followed by silver staining.  
 
4.3.2 Cell culture  
Human umbilical vein endothelial cells (HUVECs) and human acute monocytic 
leukemia (THP-1) cells were cultured, and the latter cell line differentiated into 
macrophage-like cells, as described previously [25]. 
 
4.3.3 Plasmid Mutagenesis  
A plasmid containing the cDNA encoding carboxyl-terminally GFP tagged 
human uPAR, in the pCMV-AC-GFP vector, was purchased from Origene (catalog 
number RG201222). The plasmid was mutated to introduce a stop codon immediately 
upstream of the GFP tag via site directed mutagenesis, thereby restoring the natural 
carboxyl-termine Thr reside in uPAR. Site directed mutagenesis of the plasmid was 
conducted using the QuikChange II-E kit (Stratagene) as per the manufacturer’s 
recommendations with the following primers: forward 5’-TCT CCT CTG GAC CTA 
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GCG TAC GCG GCC G-3’ and reverse 5’-CGG CCG CGT ACG CTA GGT CCA GAG 
GAG A-3’. Base pairs AC were mutated to TA as indicated to introduce the stop codon. 
The resultant plasmid was used in overexpression experiments. 
 
4.3.4 Transient transfection 
HUVECs, THP-1 monocytes, and THP-1 macrophages were transfected with 
uPAR siRNA or control siRNA (Santa Cruz Biotechnology) at a concentration of 40-80 
nM with transfection reagent and medium from Santa Cruz Biotechnology following the 
manufacturer’s protocols. Transfection mixture was removed following 5-6 hour 
incubation and replaced with complete medium. Cells were assayed 72 hours following 
transfection. Percent knockdown was determined using qRT-PCR (see below). HUVECs, 
THP-1 monocytes, and THP-1 macrophages were transiently transfected with uPAR 
plasmid using Lipofectamine LTX and Plus Reagent (Invitrogen) as per the 
manufacturer’s protocol. HUVECs were transfected with 0.3 µg/mL of DNA and 
incubated with transfection mixture for 4 hours, after which the cells were incubated in 
fresh medium for 48 hours prior to assay. THP-1 monocytes and macrophages were 
transfected with 0.75 µg/mL of DNA and incubated with transfection mixture for 24 
hours, after which the cells were incubated in fresh medium for 48 hours prior to assay. 
Overexpression of uPAR was verified with western blot analysis.  
 
4.3.5 Plasminogen activation and cell binding assays  
Plasminogen activation experiments were performed as previously described [25], 
and utilized the fluorogenic plasmin substrate H-D-Val-Leu-Lys-7-amido-4-
methylcoumarin (Bachem). The rate of plasminogen activation was taken between 10 and 
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40 min from the slope of relative fluorescent units (RFU) against min
2
. Rates obtained for 
each individual experiment performed in triplicate were normalized to the rate of 
plasminogen activation in the absence of apo(a). For experiments using blocking 
monoclonal antibodies, prior to assay of plasminogen activation, cells were washed three 
times with blocking solution (10 mM Tris-HCl, pH 7.4,, 0.14 mM NaCl, 0.1% (w/v) 
BSA, 1 mM CaCl2, and 1 mM MgCl2) followed by incubation with mouse anti-human 
integrin αVβ3 (Millipore), mouse-anti human CD18 clone IB4 (Labs Inc Biotechnology), 
and/or mouse-anti human CD11b clone 44aacb (Imgenex) for one hour at 37°C. Cells 
were then washed three times with blocking solution followed by plasminogen activation 
assay as described above.  
 Cell binding assays used purified apo(a), fluorescently labeled using Alexa Fluor 
488 protein labeling kit (Invitrogen), or fluorescein isothiocyanate-labeled human 
plasminogen (purchased from Molecular Innovations) as previously described [25]. 
 
4.3.6 qRT-PCR 
Determination of uPAR knockdown efficiency was determined through iScript 
one-step RT-PCR kit with SYBR® green (Biorad). Total RNA was isolated from the 
transfected cells using RNeasy Plus Mini kit (QIAGEN). RT-PCR was executed using 
the following conditions: reverse transcription at 50°C for 30 min followed by heat 
inactivation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec 
and annealing/extension at 59°C for 1 min. The data were analyzed using Bio-Rad CFX 
Manager software version 3.1. The following primers were used: uPAR forward: 5’-GCC 
CAA TCC TGG AGC TTG A-3’; uPAR reverse: 5’-TCC CCT TGC AGC TGT AAC 
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ACT-3’; GAPDH forward: 5’-CTG CTC CTC CTG TTC GAC AGT-3’; GAPDH 
reverse: 5’-CCG TTG ACT CCG ACC TTC AC-3’.  
 
4.3.7 Western Blotting 
Determination of uPAR overexpression was determined through western blot 
analysis. Cells were lysed (50 mM Tris pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, 
150 mM NaCl, 1 mM EDTA) and samples (50 μg total protein per lane) were subjected 
to SDS-PAGE on 12% polyacrylamide gels under non-reducing conditions, after which 
the resolved proteins were transferred to an Immobilon-P transfer membrane (Millipore). 
Blocking of the membrane and incubation with primary and secondary antibodies was 
performed in 5% (w/v) non-fat dry milk in Tris-buffered saline with Tween (TBST; 50 
mM Tris, pH 7.4, 150 mM NaCl, 0.05% Tween 20) and washing was performed with 
TBST. The primary antibody was polyclonal rabbit anti-human uPA Receptor (American 
Diagnostica) and secondary antibody was goat-anti rabbit IgG (Santa Cruz 
Biotechnology). SuperSignal West Femto Maximum Sensitivity Substrate (Pierce 
Biochemical) was used for the detection of bands, which were visualized with a 
FluorChem Q system (Alpha Innotech).  
 
4.3.8 Statistical analysis 
Comparisons were performed using the two-tailed Student's t-test assuming 
unequal variances. 
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4.4 RESULTS 
 
4.4.1 Effect of uPAR knockdown on plasminogen activation on HUVECs, its 
inhibition by apo(a), and plasminogen and apo(a) binding  
Analysis of uPAR mRNA expression indicates that uPAR knockdown was 
approximately 80% effective in HUVECs (Fig. 4.1A). Plasminogen activation decreases 
approximately 20-30% with the addition of 12K r-apo(a) (Fig. 4.1B). Removal of the 
strong LBS in KIV10 (17KΔLBS10) or the kringle V domain (17KΔV) paradoxically 
increases the rate of plasminogen activation. As we have previously described [25], this 
effect is attributable to increased solution-phase (i.e. cell-independent) plasminogen 
activation promoted by these variants that does not occur with wild-type apo(a). The KV 
domain and strong LBS in KIV10 have also been previously shown to be required for 
optimal ability for apo(a) to inhibit plasminogen activation on the fibrin surface [24].  
 Knockdown of uPAR expression using siRNA results in a 22% decrease in 
plasminogen activation on HUVECs (Fig. 4.1B). However, no further significant 
decrease in activation is observed in the presence of apo(a) in the setting of uPAR 
knockdown. By contrast, uPAR knockdown had no effect on the increase in cell-
independent plasminogen activation elicited by 17KΔLBS10 or 17KΔV (Fig. 4.1B). 
 Binding of plasminogen and apo(a) also decreased on HUVECs following uPAR 
knockdown (Fig. 4.1C-E). On the other hand, uPAR knockdown had no effect on 
17KΔLBS10 or 17KΔV binding. Note that comparable binding was observed for wild-
type apo(a) and the variants 17KΔLBS10 and 17KΔV in the absence of uPAR knockdown 
(data not shown), a result in keeping with previous findings which indicated that 17K and 
17KΔLBS10 can bind equally well to HUVECs [47]. Interestingly, the lysine analogue ε-
137 
 
ACA only decreased binding of plasminogen by about 50% (Fig. 4.1D) but appeared to 
increase 17K binding (Fig. 4.1E). Both apo(a) and plasminogen binding became 
insensitive to ε-ACA in the context of uPAR knockdown (Fig. 4.1D, E). 
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Figure 4.1: Effect of uPAR knockdown in HUVECs on plasminogen activation and r-
apo(a) and plasminogen binding. Passage 5 HUVECs were transfected with uPAR 
siRNA for 72 hours followed by plasminogen activation and cell binding analysis. (A) 
Quantitative RT-PCR data showing a decrease in uPAR gene expression following uPAR 
knockdown. (B) The effect of uPAR knockdown on plasminogen activation on HUVECs 
was assessed in the absence of apo(a) or in the presence of the indicated quantities of 12K 
r-apo(a) or the mutants variants 17KΔLBS10 or 17KΔV. (C) Effect of uPAR knockdown 
on the binding of plasminogen and r-apo(a) to HUVECs, expressed as the percent change 
in binding as a result of uPAR knockdown. (D and E) Binding data for plasminogen and 
17K r-apo(a), respectively along with the effects of ε-ACA on the binding with uPAR 
knockdown. Error bars indicate standard error of the mean (SEM) with n≥3 independent 
experiments performed in triplicates. *: p<0.05 **: p<0.01.  
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4.4.2 Effect of overexpression of uPAR in HUVECs on plasminogen activation, its 
inhibition by apo(a), and plasminogen and apo(a) binding  
uPAR was successfully overexpressed in HUVECs as can be observed from the 
western blot against uPAR presented in Fig. 4.2A. Overexpression of uPAR results in a 
31% increase in plasminogen activation (Fig. 4.2B) in the absence of apo(a). As was 
observed in Fig. 4.1B, apo(a) inhibited plasminogen activation. However, in the presence 
of apo(a) there was no increase in plasminogen activation in the context of 
overexpression of uPAR (Fig. 4.2B). These results corroborate our findings with uPAR 
knockdown: in both situations it is apparent that apo(a) regulates plasminogen activation 
via uPAR. Removal of the strong LBS in apo(a) abolishes the inhibitory effect on 
plasminogen activation, and overexpression of uPAR results in no significant change in 
plasminogen activation in the presence of this mutant (Fig. 4.2B). Overexpression of 
uPAR leads to increases in the binding of plasminogen, 12K, 17K and both mutants of 
17K (Fig. 4.2C). Interestingly, the effect of uPAR overexpression on plasminogen 
binding to HUVECs is markedly reduced by the addition of ε-ACA (Fig. 4.2D) but not 
the effect of uPAR overexpression on 17K binding (Fig. 4.2E). 
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Figure 4.2: Effect of uPAR overexpression in plasminogen activation and r-apo(a) and 
plasminogen binding on HUVECs. Passage 5 HUVECs were transfected with uPAR for 
48 hours followed by plasminogen activation and cell binding analysis. (A) Western blot 
showing uPAR overexpression in HUVECs with β-actin as loading control. (B) 
Plasminogen activation was measured in the presence or absence of the indicated 
concentrations of 12K r-apo(a) or the 17KΔLBS10 variant. (C) Effect of uPAR 
overexpression on the binding of plasminogen and r-apo(a) variants to HUVECs, 
expressed as a fold change in binding as a result of uPAR overexpression compared to 
control. (D and E) Binding data for plasminogen and 17K r-apo(a), respectively, along 
with the effects of ε-ACA on the binding with uPAR overexpression. Error bars indicate 
SEM with n≥3 independent experiments performed in triplicates. *: p<0.05 **: p<0.01.  
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4.4.3 Effect of overexpression of uPAR in THP-1 monocytes on plasminogen 
activation, its inhibition by apo(a), and plasminogen and apo(a) binding  
uPAR was successfully overexpressed in THP-1 monocytes as can be observed 
from the western blot against uPAR shown in Fig. 4.3A. Overexpression of uPAR in 
these cells leads to a more than two-fold increase in plasminogen activation (Fig. 4.3B). 
Plasminogen activation is reduced with the addition of increasing concentrations of 12K 
or 17K whereas the inhibitory effect is abolished with the removal of KV or the strong 
LBS (Fig. 4.3B, C). In contrast to the results in HUVECs, an increase in plasminogen 
activation is observed following uPAR overexpression in the presence of apo(a) versus 
control. However, the extent of the increase declines at higher concentrations of 12K, but 
still remains significantly higher with 800 nM 12K. Similarly, increasing concentrations 
of 17K did not blunt the increase in activation observed upon uPAR overexpression 
(compare Figs. 4.3B and 4.3C). Addition of increasing concentrations of 12KΔV or 
17KΔLBS10 attenuated the extent to which uPAR overexpression increased plasminogen 
activation compared to wild-type 12K or 17K (Fig. 4.3B, C).  
 Overexpression of uPAR substantially increases plasminogen, 12K and 17K 
binding in THP-1 monocytes (Fig. 4.3D), whereas only a non-significant increase in 
binding of 17KΔLBS10 and 17KΔV was observed. As with HUVECs, the mutants can 
bind to THP-1 monocytes in a manner comparable to wild-type apo(a) (data not shown). 
Addition of ε-ACA dramatically decreased binding of both plasminogen and 17K to 
THP-1 monocytes (Fig. 4.3E, F), in contrast to what we observed on HUVECs (Fig. 
4.2D, E). 
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Figure 4.3: Effect of uPAR overexpression in plasminogen activation and r-apo(a) and 
plasminogen binding on THP-1 monocytes. THP-1 monocytes were transfected with 
uPAR for 48 hours followed by plasminogen activation and cell binding assay. (A) 
Western blot showing uPAR overexpression in THP-1 monocytes with β-actin as loading 
control. The data are shown for the effect of uPAR overexpression on plasminogen 
activation on THP-1 monocytes in the presence of various concentrations of 12K and 
12KΔV (B) and 17K and 17KΔLBS10 (C). (D) Effect of uPAR overexpression on the 
binding of plasminogen and r-apo(a) variants to THP-1 monocytes, expressed as the fold 
change in binding as a result of uPAR overexpression. (E and F) Binding data for 
plasminogen and 17K r-apo(a), respectively, along with the effects of ε-ACA on the 
binding with uPAR overexpression. Error bars indicate SEM with n≥3 independent 
experiments performed in triplicates. *: p<0.05 **: p<0.01. 
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4.4.4 Effect of overexpression of uPAR in THP-1 macrophages on plasminogen 
activation, its inhibition by apo(a), and plasminogen and apo(a) binding  
An increase in the expression of uPAR is known to occur following 
differentiation of THP-1 monocytes into macrophages [48]. Western blot analysis of 
lysates from control THP-1 macrophages (Fig. 4.4A) indicates a more prominent band 
than was observed in control HUVECs or THP-1 monocytes (Figs. 4.2A and 4.3A). 
Accordingly, plasminogen activation increased by a lesser extent following uPAR 
overexpression (Fig. 4.4B) (1.6-fold versus a 2-fold increase in THP-1 monocytes). As 
was observed in THP-1 monocytes, increasing concentrations of 12K decreased 
plasminogen activation but in THP-1 macrophages had a reduced effect on the extent to 
which plasminogen activation was enhanced by uPAR overexpression (Fig. 4.4B). 
Interestingly, addition of increasing concentrations of 17KΔLBS10 did not increase 
plasminogen activation as was observed in the other cell types (Fig. 4.4B) and higher 
concentrations of 17KΔLBS10 seemed to blunt the effect of uPAR overexpression on 
plasminogen activation. Also in contrast to THP-1 monocytes, binding of 17KΔLBS10 
and 17KΔV was impacted by uPAR overexpression to a similar extent as 17K (Fig. 
4.4C). The effect of ε-ACA on plasminogen and apo(a) binding was similar to that seen 
in THP-1 monocytes (Fig. 4.4D, E).  
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Figure 4.4: Role of uPAR in plasminogen activation and r-apo(a) and plasminogen 
binding on THP-1 macrophages as determined through uPAR overexpression. THP-1 
monocytes were differentiated into macrophage like cells with PMA for 72 hours 
followed by transfection of uPAR for 48 hours. (A) Western blot showing the successful 
overexpression of uPAR in THP-1 macrophages with β-actin as loading control. (B) The 
data are shown for the effect of uPAR overexpression on plasminogen activation on 
THP-1 macrophages in the presence of various concentrations of 12K r-apo(a) or the 
variants 17KΔLBS10. (C) Effect of uPAR overexpression on the binding of plasminogen 
and r-apo(a) variants to THP-1 macrophages, expressed as the fold change in binding as a 
result of uPAR overexpression. (D and E) Binding data for plasminogen and 12K r-
apo(a), respectively, along with the effects of ε-ACA on the binding with uPAR 
overexpression. Error bars indicate SEM with n≥3 independent experiments performed in 
triplicates. *: p<0.05 **: p<0.01. 
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4.4.5 Role of MAC-1 in regulating plasminogen activation on HUVECs and THP-1 
monocytes  
MAC-1 consists of the integrin subunits αM and β2. Both αM and β2 on HUVECs 
were blocked individually with monoclonal antibodies; this resulted in a reduction in 
plasminogen activation by a small but significant extent (Fig. 4.5A). Addition of 12K r-
apo(a) resulted in a decrease in plasminogen activation compared to control, but addition 
of either monoclonal antibody resulted in no further significant decrease in plasminogen 
activation. These data suggest that the effect of 12K is mediated in part through MAC-1. 
Essentially identical results were obtained when the experiments were conducted using 
THP-1 monocytes (Fig. 4.5B).  
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Figure 4.5: Role of αM and β2 in plasminogen activation on HUVECs and THP-1 
monocytes. The αM and β2 receptors were blocked with mouse-anti human CD18 and 
mouse-anti human CD11b, respectively, for 1 hour at 37°C. Plasminogen activation data 
for HUVECs (A) and THP-1 monocytes (B) are shown in the presence or absence of 
different concentrations of r-apo(a). Error bars indicate SEM with n≥3 independent 
experiments performed in triplicates. *: p<0.05 **: p<0.01 
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4.4.6 Role of integrin αVβ3 in regulating plasminogen activation on HUVECs and 
THP-1 monocytes  
Blocking αVβ3 with a monoclonal antibody reduced plasminogen activation by a 
very small but significant extent (10%) in HUVECs (Fig. 4.6A). Addition of the antibody 
in the presence of 17K resulted in no further effect. Using THP-1 monocytes, blocking of 
αVβ3 had a much greater effect on plasminogen activation (Fig. 46B). Apo(a) reduced 
plasminogen activation in a dose-dependent manner on these cells; the inhibitory effect of 
αVβ3 blockade disappeared at the higher concentrations of apo(a). These findings suggest 
a key role for this integrin in stimulating plasminogen activation on THP-1 monocytes 
and in mediating the inhibitory effects of apo(a) on pericellular plasminogen activation 
on these cells.  
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Figure 4.6: Role of αVβ3 in regulating pericellular plasminogen activation in THP-1 
monocytes and HUVECs. Cells were treated with mouse anti-human integrin αVβ3 
monoclonal antibody for one hour at 37°C to block this receptor. Plasminogen activation 
was then measured in HUVECs (A) or THP-1 monocytes (B). Error bars indicate SEM 
with n≥3 independent experiments performed in triplicates. *: p<0.05 **: p<0.01 
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4.5 DISCUSSION 
 Plasminogen receptors play a key role in regulating plasminogen activation 
leading to cell migration and proliferation, angiogenesis, inflammation, wound healing, 
and tumor cell invasion and metastasis [14-20]. To date, various plasminogen receptors 
have been identified on different vascular and blood cells and have been shown to be 
heterogeneous in nature. The roles of these receptors in apo(a)-mediated inhibition of 
plasminogen activation is less well-understood. The αMβ2 and αVβ3 integrins have been 
shown to mediate the effects of Lp(a) and apo(a), respectively, on recruitment of 
inflammatory cells and stimulation of cell growth and migration in ECs [26, 27]. 
Lp(a)/apo(a) has been previously shown to reduce plasminogen binding to monocytes 
and ECs [21, 49-51]. Moreover, binding of apo(a) to unidentified plasminogen receptors 
on hepatoma cells, fibroblasts, and platelets has been documented [52, 53]. It has been 
recently shown that Lp(a)/apo(a) can affect plasminogen activation on vascular cells [25]. 
However, the roles of specific plasminogen receptors in this process have yet to be 
explored. We have shown here that uPAR and the αMβ2 and αVβ3 integrins regulate 
plasminogen activation, and can mediate the ability of apo(a) to inhibit pericellular 
plasminogen activation.  
 We demonstrate that the GPI-anchored uPAR accelerates tPA-mediated 
plasminogen activation on the cell surface of HUVECs (Figs. 4.1 and 4.2), THP-1 
monocytes (Fig. 4.3), and THP-1 macrophages (Fig. 4.4) as determined through either 
uPAR overexpression or knockdown. uPAR has been previously shown to bind to uPA, 
vitronectin, and β3 integrins [54]. However, plasminogen, apo(a), and tPA have not 
previously been shown to bind to uPAR. Studies have indicated that apo(a) can bind to 
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the ECM protein fibronectin but not to vitronectin [55]. uPAR is involved in the 
remodeling of the ECM through regulation of plasminogen activation. This occurs 
through uPA binding to uPAR in close proximity to the cell surface where plasminogen 
binds to its respective receptors, thereby accelerating plasmin formation [54]. Our current 
results indicate that uPAR can directly regulate tPA-mediated plasminogen activation on 
vascular cells since knockdown or overexpression of uPAR altered the rate of 
plasminogen activation (Figs. 4.1-4.4). Furthermore, binding of both plasminogen and 
apo(a) increased following uPAR overexpression in HUVECs, THP-1 monocytes, and 
THP-1 macrophages. The mechanism underlying each of these observations remains to 
be fully elucidated: it is not clear if tPA, plasminogen or apo(a) directly bind uPAR or 
another protein (such as an integrin) to which uPAR may be bound.  
 We have recently directly demonstrated that apo(a) can inhibit plasminogen 
activation on the surface of ECs, monocytes and macrophages [25]. The mechanism by 
which apo(a) may inhibit plasminogen activation on the cell surface has not been fully 
explored to date. Previous studies indicated that apo(a) could decrease the binding of 
plasminogen to the cell surface by competition for binding sites [21, 49-51]. A key role 
for the strong LBS in KIV10 in binding to U937 monocytoid cells has been described 
[56]. Our previous study found only modest, cell-type-specific effects of 
carboxypeptidase B treatment on apo(a) and plasminogen binding as well as on 
plasminogen activation and its inhibition by apo(a) [25]. The current study integrates 
these findings by demonstrating roles in plasminogen activation and its inhibition by 
apo(a) of three receptors that lack carboxyl-terminal lysine residues: uPAR, MAC-1 and 
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αVβ3. It is possible, however, that these receptors contain internal lysines that modulate 
plasminogen activation and plasminogen and apo(a) binding.  
In our previous findings we also identified key roles for apo(a) KV and the strong 
LBS in KIV10, in that mutations in these sequences abolished the inhibitory effect of 
apo(a) and cell-surface plasminogen activation [25]. In HUVECs, uPAR knockdown or 
overexpression results in a decrease or increase, respectively, in plasminogen binding and 
activation as well as apo(a) binding (Figs. 4.1 and 4.2). Inhibition of plasminogen 
activation by apo(a) is dependent on kringle V and the strong LBS in KIV10 (Figs. 4.1 
and 4.2). Previous studies have underscored the importance of both kringle V and the 
KIV10 strong LBS in inhibiting fibrinolysis [24]. While overexpression of uPAR 
increases plasminogen activation on HUVECs, this increase is abolished in the presence 
of apo(a) (Fig. 4.2). These results indicate that apo(a) can inhibit plasminogen activation 
via uPAR on HUVECs with critical roles for kringle V and the strong LBS in KIV10 in 
mediating this effect. It appears that the LBSs are not crucial for apo(a) to bind to uPAR 
on HUVECs since addition of the lysine analogue ε-ACA does not influence the ability 
of uPAR overexpression to increase apo(a) binding (Fig. 4.2). The role of uPAR seems to 
be cell-specific, since the effects of overexpression of uPAR in either THP-1 
macrophages or monocytes are distinct from those documented in HUVECs. This 
suggests that uPAR is potentially interacting with another cell-specific receptor which 
varies the ability of apo(a) to both bind to and to inhibit plasminogen activation via 
uPAR. Both plasminogen and apo(a) binding increase following uPAR overexpression in 
all cell types studied (Figs.. 4.2C, 4.3D, 4.4C). However, the kringle V domain and the 
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strong LBS in KIV10 of apo(a) contribute to uPAR binding in HUVECs and THP-1 
monocytes but not in THP-1 macrophages.  
Interestingly, however, apo(a) does not inhibit plasminogen activation via uPAR 
on either THP-1 monocytes or macrophages (Fig. 4.3B, 4.3C, and 4.4B) as was shown 
using HUVECs. This is demonstrated by the percentage difference in plasminogen 
activation upon uPAR expression being unaffected by the addition of increasing 
concentrations of apo(a). The findings are surprising given the fact that apo(a) binding 
increased with uPAR overexpression in THP-1 monocytes and macrophages. These 
results suggest that the ability of apo(a) to inhibit plasminogen activation, through the 
uPAR, in THP-1 monocytes and macrophages is dependent on uPAR interacting with 
another cell-specific protein (such as an integrin). 
Analysis of the role of the MAC-1 receptor on apo(a)-mediated plasminogen 
activation on HUVECs and THP-1 cells was also performed. The αMβ2 integrin is a 
prominent plasminogen receptor in neutrophils and has been reported to bind to apo(a) in 
monocytes through the β2 integrin component [27]. Based on this report, plasminogen 
activation was analyzed in THP-1 monocytes and HUVECs in order to elucidate the 
contribution of this receptor to plasminogen activation on these cells. Results obtained 
using a monoclonal antibody targeting either the αM or β2 subunits indicate a small but 
significant role for the αMβ2 integrin in regulating plasminogen activation in the two cell 
types studied. However, blocking either αM or β2 did not further decrease plasminogen 
activation in the presence of increasing concentrations of apo(a), indicating that the effect 
of apo(a) on plasminogen activation may, in part, be mediated by the αMβ2 integrin.  
157 
 
Another candidate receptor, αVβ3 integrin, has been previously shown to elicit 
apo(a)/Lp(a) induced focal adhesion kinase (FAK) and mitogen-activated protein kinase 
(MAPK) activation in HUVECs [26]. In this study, apo(a) was shown to signal through 
αVβ3 resulting in downstream FAK and MAPK activation, stimulating EC migration and 
proliferation. We found that blocking the αVβ3 receptor with a monoclonal antibody in 
either THP-1 monocytes or HUVECs leads to a decrease in plasminogen activation with 
no difference in activation following the addition of apo(a). These results indicate that the 
αVβ3 integrin also plays a significant role in regulating plasminogen activation as well as 
enhancing the ability of apo(a) to inhibit plasminogen activation. 
In conclusion, we have shown for the first time, the role of specific receptors in 
binding of apo(a) to vascular cell surfaces and in mediating the inhibitory effects of 
apo(a) on pericellular plasminogen activation. Our results suggest against an exclusive 
role for a particular receptor in mediating these effects, and instead are consistent with a 
model in which there are several contributing receptors in regulating plasminogen 
activation on various cell types. Moreover, there appear to be cell-type-specific 
differences in the roles of particular receptors. Recent, intriguing evidence suggest that 
Lp(a) levels <80 mg/dL is a significant risk factor for different forms of cancer including 
hepatocellular carcinoma, pancreatic cancer, and leukemia with no association of Lp(a) 
levels as a risk factor for lung cancer [57]. It is possible that apo(a) may inhibit 
plasminogen activation on cancerous cells via uPAR and reduce metastasis through 
attenuating cancer cell migration. It is tempting to speculate that Lp(a)/apo(a) may 
potentially play a role in inhibiting cancer progression. Our findings contribute 
significantly to unravelling the molecular basis of the physiological and 
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pathophysiological role of Lp(a)/apo(a) in the vasculature. Future work should explore 
the potential ability of Lp(a)/apo(a) to inhibit cancer metastasis and invasion through 
uPAR and the plasminogen activation system.  
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5.1 SUMMARY 
Elevated levels of Lipoprotein(a) (Lp(a)) have been identified as an independent 
risk factor for coronary heart disease. Plasma Lp(a) levels are reduced by monoclonal 
antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). However, the 
mechanism of Lp(a) catabolism in vivo and the role of PCSK9 in this process are 
unknown. We report that Lp(a) internalization by hepatic HepG2 cells and primary 
human fibroblasts was effectively reduced by PCSK9. Overexpression of the low-density 
lipoprotein (LDL) receptor (LDLR) in HepG2 cells dramatically increased the 
internalization of Lp(a). Internalization of Lp(a) was markedly reduced following 
treatment of HepG2 cells with a function-blocking monoclonal antibody against the 
LDLR or the use of primary human fibroblasts from an individual with familial 
hypercholesterolemia; in both cases, Lp(a) internalization was not affected by PCSK9. 
Optimal Lp(a) internalization in both hepatic and primary human fibroblasts was 
dependent on the LDL rather than the apolipoprotein(a) component of Lp(a). Lp(a) 
internalization was also dependent on clathrin-coated pits and Lp(a) was targeted for 
lysosomal and not proteasomal degradation.  Our data provide strong evidence that the 
LDLR plays a role in Lp(a) catabolism and that this process can be modulated by PCSK9. 
These results provide a direct mechanism underlying the therapeutic potential of PCSK9 
in effectively lowering Lp(a) levels. 
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5.2 BACKGROUND 
Lipoprotein(a) [Lp(a)] has been identified as an independent, causal risk factor for 
cardiovascular disease including coronary heart disease (CHD) [1, 2]. Lp(a) is similar to 
low-density lipoprotein (LDL) in lipid core composition and the presence of 
apolipoprotein B-100 (apoB), but also contains a unique glycoprotein apolipoprotein(a) 
(apo(a)) that has strong structural homology with the fibrinolytic zymogen plasminogen 
[3]. Apo(a) contains multiple copies of plasminogen-like kringle IV (KIV) sequences, 
followed by sequences closely resembling plasminogen kringle V (KV) and an inactive 
protease domain [3, 4]. The KIV domain can be further sub-divided into ten types (KIV1-
10) differing from each other in amino acid sequence. In Lp(a) particles, apo(a) is 
disulfide linked to the apoB component of the LDL-like moiety through a free cysteine 
residue in KIV9 [5]; formation of Lp(a) requires initial non-covalent interactions between 
lysine residues in apoB with weak lysine binding sites present in apo(a) KIV7 and KIV8 
[6]. Additionally, apo(a) contains a strong lysine binding site present in KIV10 which is 
important for its ability to interact with substrates such as fibrin [7].  
Apo(a) can contain from 3 to >40 identically repeated KIV2 domains which gives 
rise to the isoform size heterogeneity reported in the population [8]. A general inverse 
relationship between the size of apo(a) and Lp(a) plasma concentration has been well-
established, with Lp(a) levels varying widely in the population [8]. It has been reported 
that the variation in concentration of Lp(a) is primarily controlled by  the level of 
synthesis rather than catabolism [9, 10] with up to 90% of the variation being genetically 
determined based on variation in LPA, the gene encoding apo(a), including its size 
heterogeneity [11].  
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Many of the details of Lp(a) catabolism remain obscure. Various receptors have 
been suggested to mediate Lp(a) catabolism by the liver which include the LDL receptor 
(LDLR) [12-15], very low-density lipoprotein receptor (VLDLR) [16], low density 
lipoprotein receptor-related protein 1 (LRP-1) [17], megalin/gp330 [18], scavenger 
receptor class B type 1 (SR-B1)
 
[19] and plasminogen receptors [12]. The role of the 
LDLR remains highly controversial, however. Hofmann and coworkers reported that 
Lp(a) clearance was significantly increased in mice overexpressing LDLR [20]. 
Additionally, several other studies both in vitro and in vivo have shown that the LDLR is 
capable of mediating Lp(a) binding and uptake [13-15]. A recent cross-sectional analysis 
of 1,960 patients with familial hypercholesterolemia (FH) revealed that Lp(a) levels were 
significantly higher in patients with a null LDLR allele compared to control subjects [21], 
a finding that is in agreement with an earlier report on this topic [22]. Conversely, Cain 
and colleagues reported that while plasma clearance of Lp(a) in mice occurs primarily 
through the liver and is mediated by apo(a), the catabolism of Lp(a) in Ldlr
-/- 
mice was 
similar to that in wild-type mice [23]. Similar results were observed in metabolism 
studies of Lp(a) in human subjects with FH [24].  
Recent studies have shown that Lp(a) levels in plasma can be reduced up to 30% 
using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitory monoclonal 
antibody [25-29]. In patients treated with a PCSK9 monoclonal antibody, the extent of 
Lp(a) lowering correlated with the extent of LDL lowering, although a more robust effect 
was observed for LDL levels which decreased  up to ~70% [27, 28]. 
PCSK9 is an important regulator of hepatic LDLR number, and consists of a pro-
domain, followed by a catalytic domain, a hinge region, and a carboxyl-terminal 
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cysteine/histidine-rich domain [30-32]. PCSK9 is synthesized as an inactive proenzyme 
that undergoes intramolecular autocatalytic cleavage in the endoplasmic reticulum (ER) 
[31, 32]. The cleaved prosegment remains associated with PCSK9, maintaining PCSK9 
in a catalytically inactive form, and the complex is transported to the Golgi apparatus and 
subsequently secreted. PCSK9 acts as an endogenous regulator of LDLR levels and has 
been implicated in some cases of FH due to the dominant gain-of-function (GOF) 
mutations identified in the population [33].
 
GOF mutations lead to increased affinity of 
PCSK9 for the LDLR which results in a more rapid degradation of the LDLR and thus 
higher plasma LDL [34]. Conversely, loss-of-function mutations in PCSK9 result in 
dramatically lowered plasma LDL [33]. It is not yet known if PCSK9 mutation influence 
Lp(a) concentrations. PCSK9 can target the LDLR for degradation as well as the 
VLDLR, LRP-1, and apolipoprotein E receptor 2 (apoER2; LRP8) [35, 36]. However, 
plasma LDL is predominately cleared through the LDLR [37, 38].
 
 In the current study, using a human hepatocellular carcinoma model system, we 
sought to understand the mechanistic basis of the ability of PCSK9 inhibitory antibodies 
to lower plasma Lp(a) concentrations, in the context of the ongoing controversy about the 
role of the LDLR in Lp(a) catabolism.  
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5.3 METHODS 
 
5.3.1 Cell Culture 
Human embryonic kidney (HEK293) cells were maintained in MEM (GIBCO) 
containing 5% fetal bovine serum (FBS; GIBCO) and 1% antibiotic-antimycotic 
(GIBCO). Human hepatocellular carcinoma (HepG2) cells were obtained from the 
American Type Culture Collection (ATCC) and maintained in MEM supplemented with 
10% FBS (ATCC) and 1% antibiotic-antimycotic (GIBCO). Primary familial 
hypercholesterolemic (FH) fibroblasts were obtained from Coriell Institute (catalogue 
numbers GM01386, GM01355, and GM00701) and maintained in MEM containing 10% 
FBS (ATCC). Experiments with FH fibroblasts were performed between passages 5 and 
20.  
 
5.3.2 Construction, Expression, and Purification of Recombinant Apo(a) 
The construction of expression plasmids encoding the various recombinant apo(a) 
(r-apo(a)) variants utilized in this study (17K, 17KΔLBS10, and 17KΔLBS7,8), their 
transfection HEK293 cells and the purification of r-apo(a) from conditioned medium 
were previously described [6]. Briefly, the conditioned medium was subjected to lysine-
Sepharose affinity chromatography and r-apo(a) was eluted using the lysine analogue ε-
aminocaproic acid (ε-ACA). Following concentration and buffer exchange, protein 
concentrations were determined spectrophotometrically. The purity of r-apo(a) was 
assessed using SDS-PAGE followed by silver staining.   
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5.3.3 Construction, Expression, and Purification of Recombinant PCSK9 
PCSK9 and PCSK9 D374Y expression plasmids in pIRES2-EGFP (Clontech) 
were previously-described [31, 32]. The PCSK9 cDNAs were excised from pIRES2-
EGFP using AfeI and AgeI restriction endonucleases and ligated into pcDNA4C 
(Invitrogen), previously digested with EcoRV and AgeI, such that the expressed protein 
would contain a carboxyl-terminal 6× His tag. HEK293 cells at 1.8 x10
6
 cells/well of a 6-
well plate were seeded and transfected 24 hrs later with 2 µg of expression plasmid using 
MegaTran 1.0 (Origene) with a 3:1 ratio of reagent to DNA as per the manufacturer’s 
instructions. Stable cells were selected with zeocin (150 µg/mL) 48 hrs post transfection. 
Stable cells were seeded into triple flasks with OPTI-MEM (Invitrogen) and conditioned 
medium was collected every 3 days with the addition of phenylmethylsulfonyl fluoride at 
a final concentration of 1 mM to the harvest. The harvested medium was adjusted to 50 
mM phosphate buffer pH 8.0, 0.5 M NaCl, 1 mM β-mercaptoethanol, 5 mM imidazole, 
and 10% glycerol, applied to a Ni Sepharose excel (GE Healthcare) column, washed and 
eluted with 15 mM and 400 mM imidazole respectively. The eluted pool (4 column 
volumes) was extensively dialyzed against PCSK9 storage buffer (25 mM HEPES, pH 
7.9, 150 mM NaCl, 0.1 mM CaCl2, and 10% glycerol). The dialyzed samples were then 
concentrated with PEG-20,000 (Sigma) and dialyzed against storage buffer. 
Concentrations were determined through bicinchoninic acid assay (BCA assay; Pierce) 
using BSA as a standard. Purity of PCSK9 was assessed through SDS-PAGE followed by 
silver staining and stored in aliquots at -70°C until use.  
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5.3.4 Labeling of PCSK9 
Purified PCSK9 was dialyzed against 0.1 M Na2CO3 pH 8.6, 0.2 M NaCl. PCSK9 
was then incubated with a 5-fold molar excess of Alexa Fluor 488 carboxylic acid, 
succinimidyl ester mixed isomers dissolved in dimethyl sulfoxide at 10 mg/mL 
(Invitrogen). The reaction mixture was rocked for 4 hrs at 4°C to ensure complete 
labeling. The reaction was quenched with the addition of 0.01 volumes of 1 M Tris, pH 
8.0 followed by incubation for 30 min at 4°C. Free dye was removed through extensive 
dialysis against 25 mM HEPES, pH 7.5, 300 mM NaCl, 50 mM KH2PO4, 0.1 mM CaCl2, 
and 10% glycerol. PCSK9 was concentrated using an Amicon Ultra-4 centrifugal filter 
with a 10 kDa membrane cutoff (Millipore). Concentration was determined 
spectrophotometrically with a moles dye per mole protein ratio of 2.8. 
 
5.3.5 Transient Transfection 
HepG2 cells were transfected with clathrin heavy chain siRNA or scrambled 
control siRNA (Santa Cruz Biotechnology) at a concentration of 80 nM as per the 
manufacturer’s protocol. The transfection mixture was incubated on cells for 8 hrs 
followed by the addition of complete medium. Cells were assayed 48-72 hours post 
transfection. Percent knockdown was determined using qRT-PCR (see below). HepG2 
cells were transiently transfected with v5 (empty vector), LDLR, or LDLRΔCT [36] 
using MegaTran 1.0 (Origene) as per the manufacturer’s protocol. Briefly, HepG2 cells 
were seeded at a density of 2 x10
5
 cells/6-well in antibiotic free media and transfected 24 
hrs later with 1.3 µg of cDNA with a 3:1 ratio of reagent to DNA. Cells were assayed 72 
hours post transfection.  
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5.3.6 qRT-PCR 
Determination of clathrin heavy chain knockdown efficiency was determined 
through iTaq one-step RT-PCR kit with SYBR® green (Bio-Rad). The following primers 
were used: clathrin heavy chain forward: 5’-GGC CCA GAT TCT GCC AAT TCG TTT-
3’; clathrin heavy chain reverse: 5’-TGA TGG CGC TGT CTG CTG AAA TTG-3’; 
GAPDH forward: 5’-GGA GCC AAA AGG GTC ATC ATC-3’; GAPDH reverse: 5’-
GTT CAC ACC CAT GAC GAA CAT G-3’.  
 
5.3.7 Internalization Assays 
HepG2 cells (in some cases stably transfected with an expression vector for 
PCSK9) were seeded at 2 x 10
5
 cells/well in a 24 well plate (precoated with 1 mg/mL 
gelatin), in media containing 10% LPDS for 16 hours. Cells were washed twice with 
OptiMEM (GIBCO) and treated with Lp(a) purified from human plasma (5-10 µg/mL) or 
r-apo(a) variants (100-200 nM) in the presence of 0, 1, 10, or 20 µg/mL purified 
recombinant PCSK9 in Opti-MEM for 4 hours at 37°C. For experiments using LDLR-
blocking monoclonal antibodies, cells were pre-treated for 30 min with 50 µg/mL of 5G2 
or 7H2 followed by incubation with Lp(a) or apo(a) in the continued presence of 50 
µg/mL antibody for 2 hrs at 37°C. In some experiments, cells were co-treated with 10 
µg/mL lactacystin (Cayman) or 150 µg/mL E-64d (Cayman) or vehicle (dimethyl 
sulfoxide) along with Lp(a) or apo(a) for 4 hrs at 37°C. For all internalization 
experiments, HepG2 cells were extensively washed: 3× with PBS-0.8% BSA, 2× with 
PBS-BSA-0.2M ε-ACA for 5 min each, 2× with 0.2 M acetic acid pH 2.5 containing 0.5 
M NaCl for 10 min each, 2× with PBS. The cells were then lysed with lysis buffer (50 
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mM Tris pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 
0.1% SDS, 1 mM PMSF, and 150 µg/mL benzamidine).  
For experiments with fibroblasts, cells were seeded in a 24 well plate at 1.4 x 10
5
 
cells/well in medium containing 10% LPDS for 16 hrs. Cells were washed twice with 
OptiMEM and treated with Lp(a) (5 µg/mL) or apo(a) (100 nM) in the presence or 
absence of 20 µg/mL PCSK9 in OptiMEM for 4 hours at 37°C. Cells were extensively 
washed (3× with PBS-0.8% BSA, 2× with PBS containing 10 µg/mL heparin for 10 min, 
1× PBS-BSA-0.2M ε-ACA for 5 min, 2× with 0.2 M acetic acid pH 2.5 containing 0.5 M 
NaCl for 10 min, 1× with 0.5 M HEPES pH 7.5, 100 mM NaCl for 10 min, and 1× with 
PBS) then lysed with lysis buffer. Concentrations of lysate samples were determined by 
BCA assay with BSA as a standard and analyzed by Western blotting.  
 
5.3.8 Western Blotting 
Cell lysates were subjected to SDS-PAGE on 5-15% (Lp(a)-treated cells) or 7-
15% (apo(a)-treated cells) polyacrylamide gradient gels respectively. The gels were 
transferred onto PVDF membranes (Millipore) and immunoblotted with either mouse-
anti human apo(a) a5 antibody [39], mouse-anti human β-actin (Sigma), or rabbit-anti 
human LDLR (GeneTex). Bands were visualized with SuperSignal® West Femto 
Maximum Sensitivity Substrate (Thermo Scientific) and quantified using Alpha View 
software (Alpha Innotech). 
 
5.3.9 LDLR Degradation Assay 
HepG2 cells were seeded at 2 x 10
5
 cells/well in a 24 well plate in medium 
containing 10% LPDS for 16 hours. PCSK9 (20 µg/mL) with 0, 100, 250 µg/mL of 
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plasma-purified Lp(a) or LDL or 0, 100, 250 nM apo(a) was added in OptiMEM and the 
cells incubated for 4 hours. Cells were washed three times with PBS and lysed. 
Concentrations of samples were determined by BCA assay and LDLR levels were 
analyzed by Western blotting.  
 
5.3.10 Binding Study 
Saturation binding curves were generated by incubating LDL or Lp(a), at 0.5 
mg/mL, with increasing amounts of PCSK9-Alexa 488 (25-1200 nM) in binding buffer 
(25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM CaCl2, 1% BSA) for one hour at 37°C. 
Glycerol was added to the samples to a final concentration of 10% and the samples were 
subjected to electrophoresis on 0.7% agarose gels (UltraPure Agarose, Invitrogen) for 2 
hours at 40 V in 90 mM Tris pH 8.0, 80 mM borate, 2 mM calcium lactate. In-gel 
scanning and quantification of the anount of labeled PCSK9 free and bound to Lp(a) or 
LDL was achieved with a FluorChem Q imager (Alpha Innotech). Dissociation constants 
(KD) were determined by fitting the data to an equation describing a rectangular 
hyperbola by nonlinear regression using Graph Pad Prism 6.  
 
5.3.11 Purification of LDL and Lp(a) and Preparation of Lipoprotein-Deficient 
Serum (LPDS) 
Blood was collected from a healthy human volunteer (with written informed 
consent) with no detectable Lp(a) into BD Vacutainers containing sodium polyanethol 
sulfonate and acid citrate dextrose. The blood was centrifuged at 2,000 × g for 15 min at 
4°C and LDL was isolated from plasma through sequential ultracentrifugation (1.02 
g/mL < d < 1.063 g/mL); the centrifugation steps were at 45,000 × g for 18 hrs at 4°C. 
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The isolated LDL was extensively dialyzed against 150 mM NaCl, 5.6 mM Na2HPO4, 1.1 
mM KH2PO4, 0.01% EDTA (pH 7.4). Lipoprotein-depleted serum (LPDS) was prepared 
through addition of NaBr to FBS (ATCC) to a final density of 1.21 g/mL followed by 
ultracentrifugation as described above. The top fraction was removed and the infranatant 
fraction containing LPDS was extensively dialyzed against HEPES-buffered saline 
(HBS; 20 mM HEPES pH 7.4, 150 mM NaCl). Lp(a) was prepared from a single donor 
with high Lp(a) and a single 16-kringle apo(a) isoform as previously described [40]. 
Concentrations of LDL and Lp(a) were determined by BCA assay using BSA as a 
standard. 
 
5.3.12 Purification of LDLR-Blocking Monoclonal Antibodies 
Anti-human LDLR monoclonal antibodies 5G2 and 7H2 (a gift from Dr. Ross 
Milne, University of Ottawa Heart Institute) were purified from ascites fluid using 
Protein G Sepharose 4 Fast Flow affinity chromatography according to manufacturer’s 
recommendations (GE Healthcare). Concentrations of antibodies were determined using 
BCA assay with BSA as a standard.  
 
5.3.13 Statistical Methods 
Comparisons between data sets were performed using two-tail Student's t-test 
assuming unequal variances. 
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5.4 RESULTS 
 
5.4.1 PCSK9 inhibits Lp(a) and apo(a) internalization 
PCSK9 can target the LDLR for degradation in an intracellular pathway by 
targeting the LDLR from the trans Golgi network directly to lysosomes [41]. Conversely, 
extracellular PCSK9 targets the LDLR for degradation through binding of PCSK9 to the 
EGF-A domain of the LDLR and subsequently targeting the complex to lysosomes for 
degradation [42, 43].
 
Herein, we evaluated the role of both the intra- and extracellular 
PCSK9-mediated degradation of LDLR in Lp(a)/apo(a) internalization by HepG2 cells. 
Overexpression of PCSK9, which would stimulate both the intracellular and extracellular 
pathway of targeting the LDLR for degradation, resulted in a significant decrease in the 
amount of Lp(a) internalized by HepG2 cells (Fig. 5.1A). Similar results were obtained 
for the internalization of a physiologically relevant recombinant apo(a) (r-apo(a)) species 
(17K) that contains 8 identically repeated KIV2 domains (Fig. 5.1B). Addition of a lysine 
analog, ε-ACA, markedly inhibits the uptake of both Lp(a) and r-apo(a) (Fig. 5.1A, B) 
although PCSK9 still significantly reduced uptake of Lp(a). Likewise, mutating the 
strong lysine binding site present in KIV10 of 17K (17KΔLBS10 variant) results in a 
significant decrease in its ability to be internalized (Fig. 5.1B). Interestingly, however, 
PCSK9 is able to significantly decrease internalization of this variant but not 
internalization of either 17K or 17KΔLBS10 in the presence of ε-ACA (Fig. 5.1B).  
To specifically determine the role of the extracellular PCSK9 degradation 
pathway, HepG2 cells were exposed to exogenous, purified PCSK9 or a gain-of-function 
(GOF) mutant of PCSK9 (D374Y) in the presence of Lp(a) or apo(a). Treatment of 
HepG2 cells with various concentrations of wild type (WT) PCSK9 resulted in a 
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significant decrease in Lp(a) and 17K internalization (Fig. 5.1C, D). The GOF mutant 
was found to have a more robust effect on Lp(a) (at 1 µg/mL) and 17K (at 1 and 10 
µg/mL) internalization compared to WT PCSK9. 
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Figure 5.1: PCSK9 reduces the internalization of both Lp(a) and apo(a) in HepG2 
cells. A and B, HepG2 cells stably transfected with empty vector or PCSK9-v5 were 
grown for 16 hrs in LPDS media followed by treatment with either 10 µg/mL Lp(a) (A) 
or 200 nM apo(a) (B) in the presence or absence of 200 mM ε-ACA for 4 hours. The cells 
were extensively washed to remove any bound Lp(a)/apo(a) and lysed to determine the 
relative amount that was internalized, using β-actin as an internal control. Error bars 
indicate standard error of the mean (SEM) with n≥3 independent experiments. *: p<0.05 
**: p<0.01. C and D, HepG2 cells were grown in LPDS media for 16 hrs followed by 
treatment with various concentrations of PCSK9 or PCSK9 D374Y in the presence of 
either 10 µg/mL Lp(a) (C) or 200 nM 17K (D). The cells were extensively washed to 
remove any bound Lp(a)/apo(a) and lysed to determine the relative amount that was 
internalized, using β-actin as an internal control. Error bars indicate SEM with n≥3 
independent experiments. *: p<0.05; **: p<0.01.  
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5.4.2 PCSK9 does not bind to Lp(a) 
It has been previously reported that PCSK9 can bind to LDL in vitro consistent 
with a one-site binding model with a KD ~ 325 nM [44]. Furthermore, the binding of 
PCSK9 to LDL inhibits its ability to target the LDLR for degradation in HuH7 human 
hepatoma cells [44]. Hence, we determined whether Lp(a) can bind to PCSK9 in vitro 
and if Lp(a)/apo(a) can inhibit the ability of exogenous PCSK9 to target the LDLR for 
degradation. We found that LDL can bind to PCSK9 in vitro with a KD of ~ 130 nM, a 
value close to that previously reported [44] (Fig. 5.2A, B). On the other hand, little or no 
binding of Lp(a) to PCSK9 was detected (Fig. 5.2A, C). Treatment of HepG2 cells with 
exogenous PCSK9 results in a substantial decrease in LDLR levels, while co-treatment of 
PCSK9 with LDL results in recovery of LDLR levels (Fig. 5.2D). These findings are also 
in agreement with previously reported data [42]. However, co-treatment of Lp(a) or 17K 
with PCSK9 results in no significant recovery in LDLR levels (Fig. 5.2E, F). Together, 
these results suggest that Lp(a) does not bind to PCSK9 and therefore cannot block the 
ability of PCSK9 to target the LDLR for degradation.  
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Figure 5.2: PCSK9 binds to LDL in vitro but not to Lp(a). LDLR levels are recovered 
from PCSK9 degradation by treatment with LDL but not Lp(a) or apo(a). Various 
concentrations of PCSK9-Alexa 488 were incubated with 0.5 mg/mL of purified LDL or 
Lp(a) for one hour at 37°C. A and B, Samples containing PCSK9 and either LDL (A) or 
Lp(a) (B) were resolved on 0.7% agarose gels. C, Bound and free levels of PCSK9 were 
quantified and fit to a saturation curve by nonlinear regression using Graph Pad Prism 6 
to give a mean KD for LDL of 127.6 ± 39.8 nM (n= 3). D-F, HepG2 cells were grown for 
16 hrs in LPDS media followed by treatment with various concentrations of LDL (D), 
Lp(a) (E), or 17K r-apo(a) (F) in the presence or absence of 20 µg/mL PCSK9 for 4 
hours. The relative LDLR levels were determined and normalized to β-actin. Error bars 
indicate SEM with n≥3 independent experiments. *: p<0.05; **: p<0.01 compared to 
control in the absence or presence of PCSK9.  
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5.4.3 Lp(a)/apo(a) internalization involves clathrin-mediated endocytosis and 
internalized Lp(a)/apo(a) is targeted to lysosomes 
PCSK9 has been previously shown to target the LDLR for degradation via 
clathrin heavy chain-mediated endocytosis and subsequent targeting to lysosomes [45, 
46]. We therefore determined whether Lp(a) and apo(a) undergo the same degradation 
pathway. Knockdown of clathrin heavy chain in HepG2 cells results in a significant 
decrease in Lp(a) and apo(a) internalization (Fig. 5.3). In both cases, while PCSK9 
treatment results in a dose-dependent decrease in internalization in the absence of clathrin 
heavy chain knockdwon, no further decrease resulting from PCSK9 is observed in the 
presence of clathrin heavy chain knockdown (Fig. 5.3). These results indicate that the 
PCSK9-regulated internalization of Lp(a)/apo(a) is dependent on clathrin coated pits. 
The degradation pathway that Lp(a)/apo(a) undergoes was further evaluated 
through inhibitors of both the lysosomal and proteosomal pathway. Treatment of HepG2 
cells with a lysosomal inhibitor, E-64d, resulted in the intracellular accumulation of Lp(a) 
and apo(a) (Fig. 5.4). However, treatment with a proteosomal inhibitor, lactacystin, 
results in no accumulation of Lp(a) or apo(a). These results indicate that Lp(a)/apo(a) is 
internalized through clathrin-mediated endocytosis and is subsequently targeted for 
lysosomal degradation.  
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Figure 5.3: Lp(a) and apo(a) internalization is dependent on clathrin coated pits in 
HepG2 cells. A and B, HepG2 cells were transfected with control or clathrin heavy chain 
siRNA for 48 hours followed by incubation of cells in LPDS media for 16 hrs. HepG2 
cells were then treated with 5 µg/mL Lp(a) (A) or 200 nM 17K (B) in the presence or 
absence of PCSK9 for 4 hours. Internalization of Lp(a)/apo(a) was measured as in the 
Legend to Fig. 5.1. Error bars indicate SEM with n≥3 independent experiments. *: 
p<0.05; **: p<0.01. Insets: clathrin heavy chain mRNA was quantified using qRT-PCR 
following siRNA treatment to determine knockdown efficiency. 
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Figure 5.4: Lp(a) and apo(a) degradation in HepG2 cells occurs in lysosomes and not 
proteosomes. A and B, HepG2 cells were grown for 16 hrs in LPDS media followed by 
treatment with either DMSO, E-64d (150 µg/mL), or lactacystin (10 µM) in the presence 
or absence of 20 µg/mL PCSK9 as well as Lp(a) (A) or 17K (B) for 4 hours. 
Internalization of Lp(a)/apo(a) was measured as in the Legend to Fig. 5.1. Error bars 
indicate SEM with n≥3 independent experiments. *: p<0.05; **: p<0.01. 
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5.4.4 PCSK9 regulates Lp(a) internalization through the LDLR 
Previous studies have shown that apo(a) can be internalized into HepG2 cells 
through the LDLR or through lysine-dependent interactions with plasminogen receptors 
[12]. We therefore wanted to examine which of these routes might be sensitive to 
PCSK9. Apo(a) is not itself a ligand for LDLR, but r-apo(a) added to HepG2 cell 
medium binds non-covalently to apoB-containing lipoproteins secreted by the HepG2 
cells which allows it to be internalized by the LDLR in a “piggybacking” manner [12]. 
The weak LBS in KIV type 7 and 8 mediate these non-covalent interactions and 
therefore, for internalization studies, we utilized a r-apo(a) variant in which both these 
LBS were mutated (17KΔLBS7,8) [6]. We found that 17KΔLBS7,8 was poorly 
internalized in HepG2 cells (Fig. 5.5A); although its internalization did not appear to be 
affected by PCSK9, this conclusion has to be tempered by the fact that the internalization 
of this species is at our limit of detection. 
To determine more directly if the LDLR plays a role in Lp(a)/apo(a) 
internalization, the LDLR or the LDLR lacking its carboxyl tail (LDLRΔCT) were 
overexpressed in HepG2 cells. The ΔCT deletion occurs where the autosomal recessive 
hypercholesterolemia (ARH) adaptor protein binds and is important for recruiting the 
complex into clathrin-coated pits [47, 48]. Overexpression of LDLR in HepG2 cells 
results in a dramatic increase in Lp(a) internalization (Fig. 5.5B) and only a modest and 
not statistically significant increase in apo(a) internalization (Fig. 5.5C). Treatment of the 
cells overexpressing LDLR or LDLRΔCT with PCSK9 leads to a significant decrease in 
Lp(a) internalization (Fig. 5.5B).  
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Treatment of HepG2 cells with a blocking monoclonal LDLR antibody was also 
utilized to confirm that the LDLR is involved in Lp(a) catabolism and its regulation by 
PCSK9. Two LDLR-blocking monoclonal antibodies, 5G2 and 7H2, were used which 
were previously shown to specifically block the binding of LDL to the LDLR in cultured 
human fibroblasts [49]. Lp(a) internalization was markedly decreased by the addition of 
either antibody and PCSK9 had no effect on Lp(a) internalization in the presence of the 
antibodies (Fig. 5.5D). Furthermore, we found that 7H2 likewise markedly decreased 
17K internalization (Fig. 5.5E). On the other hand, PCSK9 did not decrease 17K 
internalization in the presence of the antibody, and internalization of 17KΔLBS7,8 
appeared to be insensitive to both PCSK9 and the antibody (Fig. 5.5E). These results 
indicate that the LDLR mediates internalization of Lp(a) through the LDL component 
and in a manner that is regulated by PCSK9. 
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Figure 5.5: The LDLR contributes to Lp(a) and apo(a) internalization in HepG2 cells. 
A, HepG2 cells were grown in LPDS media for 16 hrs followed by treatment with 
various concentrations of PCSK9 in the presence of 17K or 17KΔLBS7,8 (200 nM). 
Internalization of apo(a) was measured as in the Legend to Fig. 5.1. Error bars indicate 
SEM with n≥3 independent experiments. **: p<0.01. B and C, HepG2 cells were 
transfected with expression plasmids encoding either LDLR or LDLRΔCT for 48 hours 
and were then grown for 16 hrs in LPDS media. The cells were incubated with 10 µg/mL 
Lp(a) (B) or 200 nM apo(a) (C) in the presence or absence of 20 µg/mL PCSK9 for 4 
hours after which internalization of Lp(a)/apo(a) was measured. Error bars indicate SEM 
with n≥3 independent experiments. *: p<0.05; **: p<0.01. D and E, HepG2 cells were 
grown in LPDS media for 16 hrs followed by pretreatment with monoclonal LDLR 
blocking antibodies (mAb’s 5G2 or 7H2; 50 µg/mL) for 30 min. Cells were then 
incubated with 5 µg/mL Lp(a) (D) or 100 nM apo(a) (E) in the presence or absence of 10 
µg/mL PCSK9 and in continuing presence of mAb’s for 2 hours, after which 
internalization of Lp(a)/apo(a) was measured. Error bars indicate SEM with n≥4 
independent experiments. *: p<0.05 and **: p<0.01 for comparison of absence of 
antibody and PCSK9. 
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The role for the LDLR was also explored using primary fibroblasts isolated from 
individuals with or without FH. The three cell lines studied were GM01386 (fully 
functional LDLR), GM01355 (clinically affected with severe hypercholesterolemia with 
LDLR activity found to be partially negative), and GM00701 (LDLR activity <1% 
compared to normal cells). Lp(a) internalization is substantially decreased in cells 
deficient in LDLR, and the internalization was unaffected by PCSK9 in these cells (Fig. 
5.6A). Conversely, no significant difference in 17K internalization is observed between 
LDLR-deficient and normal fibroblasts and there is no effect in any cell line of PCSK9 
treatment (Fig. 5.6B). PCSK9 was able to dramatically decrease LDLR content of those 
fibroblasts that contained immunoreactive receptor (Fig. 5.6C). These findings 
underscore the requirement for apo(a) to couple to apoB-containing lipoproteins in order 
to internalize through the LDLR in a PCSK9-regulable manner as these cells do not 
express apoB-containing lipoproteins.  
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Figure 5.6: Lp(a), but not apo(a), internalization decreases in FH fibroblasts lacking 
LDLR. A and B, FH Fibroblasts used were GM01386 (fully functional LDLR), 
GM01355 (clinically affected with severe hypercholesterolemia with LDLR activity 
found to be partially negative), and GM00701 (LDLR activity <1% compared to normal 
cells). The FH fibroblasts were grown in LPDS media for 16 hrs followed by incubation 
with 5 µg/mL Lp(a) (A) or 100 nM apo(a) (B) in the presence or absence of 10 µg/mL 
PCSK9 for 4 hours. Internalization of Lp(a)/apo(a) was measured as in the Legend to Fig. 
5.1. Error bars indicate SEM with n≥5 independent experiments. *: p<0.05; **: p<0.01 
for comparison of control in the absence of PCSK9 and ε-ACA. C, The LDLR content of 
the respective fibroblast cell lines in the presence or absence of PCSK9 treatment was 
assessed by Western blot analysis using a monoclonal antibody against LDLR. 
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5.5 DISCUSSION  
Elevated plasma Lp(a) levels have been recently shown to be effectively reduced 
with the use of two different monoclonal antibodies against PCSK9 [25-29]. This therapy 
was conceived to lower LDL levels as inhibition of PCSK9 leads to upregulation of the 
LDLR. The ability of the therapy to lower plasma Lp(a) challenges the existing dogma 
that the LDLR does not play a major, if any, role in Lp(a) catabolism. Therefore, our aim 
was to directly assess the ability of PCSK9 to influence Lp(a) uptake in a cellular model 
and to explore the role of LDLR in this process.  
We found that PCSK9 was indeed able to inhibit Lp(a) internalization in HepG2 
cells (Fig. 5.1). This effect was observed whether PCSK9 was ectopically overexpressed 
(and hence active both intracellularly and extracellularly) or added as a purified protein to 
the culture medium along with Lp(a) (hence acting exclusively extracellularly). Notably, 
we also found that PCSK9 can stimulate internalization of apo(a) itself (Fig. 5.1). 
However, we conclude that the effect of PCSK9 on apo(a) internalization is dependent on 
the ability of free apo(a) to associate with apoB-containing lipoprotein particles in the 
culture medium, with internalization of the resultant complex being sensitive to PCSK9. 
This conclusion is based on the fact that internalization of apo(a) by fibroblasts, which do 
not express apoB, is insensitive to PCSK9 (Fig. 5.6). Moreover, internalization of the 
17KΔLBS7,8 variant, which cannot associate non-covalently with apoB-containing 
lipoproteins [6], appears to be insensitive to the effects of PCSK9 (Fig. 5.5). Given these 
findings, and a previous report that demonstrated that apoB-100, not apo(a), is the ligand 
in Lp(a) for LDLR [12], we suspected that the LDLR, the major target of PCSK9, is 
mediating the PCSK9-sensitive component of Lp(a) internalization.  
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Importantly, apo(a), due to its structural similarities to plasminogen, may also 
potentially bind to and be internalized by plasminogen receptors, which contain carboxyl-
terminal lysine residues [12]. Previous results have shown that removal of the strong 
lysine binding site in r-apo(a) (the 17KΔLBS10 variant) results in an inability to 
effectively bind to fibrin surfaces [7]. In the current study, 17KΔLBS10 internalization is 
significantly reduced, but not abolished, compared to wild-type 17K in HepG2 cells (Fig. 
5.1). Treatment of HepG2 cells with the lysine analogue ε-ACA resulted in a significant 
decrease in both Lp(a) and apo(a) internalization, and PCSK9 was still able to inhibit 
Lp(a) (but not apo(a)) internalization in the presence of ε-ACA. Thus, removal of the 
strong LBS in apo(a) affects its ability to be internalized through lysine-dependent 
plasminogen receptors but not through non-covalent interactions with apoB and 
subsequent binding to LDLR. However, treatment with ε-ACA abolishes both the ability 
of apo(a) or Lp(a) to bind to lysine-dependent plasminogen receptors as well as the 
ability of apo(a) to couple to the apoB component of LDL [50]; the latter effect accounts 
for the inability of PCSK9 to inhibit apo(a) uptake in the presence of ε-ACA (Fig. 5.1B).  
Recently, it has been reported that LDL can bind to PCSK9 and inhibit its ability 
to target the LDLR for degradation [44]. We therefore analyzed if Lp(a) can bind to 
PCSK9 in order to determine if (i) less Lp(a) is being internalized due to its ability to 
bind to PCSK9 and thus prevent its internalization; or (ii) Lp(a) binding to PCSK9 leads 
to a reduced ability for PCSK9 to target the LDLR for degradation, or other receptors, 
limiting the ability of Lp(a) to be internalized through those receptors. Through in vitro 
binding experiments, we have shown that PCSK9 cannot bind to Lp(a) (Fig. 5.2). As 
well, both Lp(a) and apo(a) do not inhibit the ability of PCSK9 to target the LDLR for 
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degradation in HepG2 cells. The exact site at which the apoB component of LDL binds to 
PCSK9 is currently unknown. Therefore, it is possible that the apo(a) component of Lp(a) 
is interfering with the interaction of PCSK9 and apoB.  
We also explored the degradation pathway of Lp(a)/apo(a) through PCSK9. 
Previous work has shown that PCSK9 can target the LDLR for degradation through 
clathrin-mediated endocytosis and is targeted for lysosomal degradation [43, 44]. We 
show here, through knockdown of clathrin heavy chain, that Lp(a) and apo(a) are also 
internalized through clathrin-mediated endocytosis. Treatment with PCSK9 results in no 
further decrease in Lp(a)/apo(a) internalization following clathrin heavy chain 
knockdown. This indicates that the receptors that internalize Lp(a)/apo(a) which can be 
regulated by PCSK9 are dependent on clathrin-mediated endocytosis. Furthermore, 
treatment with a lysosomal inhibitor, E-64d, but not a proteosomal inhibitor, results in a 
significant accumulation of intracellular Lp(a) and apo(a) with or without PCSK9 
treatment. Both of these inhibitors are highly selective, potent, and irreversible inhibitors 
of their respective target proteases [51, 52]. E-64d inhibits calpain and the cysteine 
proteases cathepsins F, K, B, H, and L and acts by forming a thioester bond with the thiol 
of the active site cysteine without affecting cysteine residues in other enzymes. 
Lactacystin covalently modifies the amino-terminal threonine of specific catalytic 
subunits of the proteasome. Taken together, these results indicate that Lp(a)/apo(a) 
internalization alone or through PCSK9 occurs, in part, through clathrin-mediated 
endocytosis and Lp(a)/apo(a) is subsequently targeted for lysosomal degradation. We 
next determined which receptor is involved in Lp(a) catabolism which can be regulated 
by PCSK9. 
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The role for the LDLR in Lp(a) catabolism has been controversial. Compared to 
LDL, plasma Lp(a) concentrations are much less responsive to conventional lipid-
lowering therapies including statins. Indeed, some studies have shown increased in 
plasma Lp(a) with statins, others no effect, and others decreases [53]. More recent, larger 
studies have found that statins modestly but significantly reduce Lp(a) in subjects with 
dyslipidemia or heterozygous FH [54, 55]. Moreover, in some studies of FH kindreds 
with a null LDLR, elevated plasma Lp(a) levels are observed in affected individuals [21, 
22, 56], although this result has not been unanimously observed [22, 57, 58]. Although 
overexpression of LDLR in mice significantly increased Lp(a) clearance [20], plasma 
clearance studies in Ldlr
-/- 
mice and human FH patients reported no significant difference 
in Lp(a) clearance compared to the presence of normal LDLR, although a non-significant 
decrease in fractional catabolic rate in the absence of LDLR of about 10% was reported 
in both studies [23, 24]. Plausible evidence therefore exists to indicate that the LDLR 
does participate in Lp(a) catabolism, which may account for the ability of PCSK9 
inhibitors to lower plasma Lp(a). Accordingly, we directly examined the role of the 
LDLR in regulation of Lp(a) catabolism by PCSK9. 
The following lines of evidence from our study very strongly support the concept 
of the LDLR being a PCSK9-regulable clearance receptor for Lp(a). (i) The GOF PCSK9 
mutant D374Y, which can target the LDLR for degradation more rapidly, was more 
effective than WT PCSK9 in inhibiting both Lp(a) and apo(a) internalization in HepG2 
cells (Fig. 5.1C, D). (ii) Overexpression of LDLR (and LDLRΔCT) dramatically increase 
Lp(a) clearance (Fig. 5.5B). Addition of PCSK9 in the context of LDLR overexpression 
decreased internalization, but the difference did not reach statistical significance. It is 
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possible that the dose of PCSK9 added was not sufficient to influence the very high 
concentrations of ectopically-expressed LDLR. (iii) Addition of blocking monoclonal 
antibodies against LDLR decreased Lp(a) internalization and PCSK9 had no effect in the 
setting of LDLR blockade with the antibodies (Fig. 5.5D). (iv) Human fibroblasts lacking 
LDLR showed decreased internalization of Lp(a) that was unaffected by the addition of 
PCSK9 (Fig. 5.6A).  
It is notable that the LDLR lacking the cytoplasmic tail, which interacts with the 
ARH adaptor protein to promote endocytosis, retains a considerable fraction of the wild-
type receptor’s ability to internalize Lp(a) (Fig. 5.5B). It has been previously shown that 
PCSK9 cannot target the LDLR for degradation in primary hepatocytes isolated from 
Arh
-/-
 mice [59]. However, PCSK9 can target the LDLR for degradation upon removal of 
the cytoplasmic tail in CHO cells [60], and the ARH adaptor protein is not necessary in 
PCSK9 mediated LDLR degradation in fibroblasts [46]. These results suggest a potential 
PCSK9-interacting partner in mediating endocytosis of the LDLR-PCSK9 in HepG2 
cells.    
Less of an increase is observed with apo(a) internalization following LDLR 
overexpression (Fig. 5.5C) indicating the requirement for apo(a) coupling to apoB for 
recognition by this receptor. Although HepG2 cells were deprived of LDL by growth in 
LPDS, these cells do express apoB and secrete apoB-containing lipoprotein particles in 
the LDL density range [12]. Formation of non-covalent complexes between these 
particles and apo(a) could be rate-limiting and therefore may account for why less of an 
increase in internalization is observed for apo(a) compared to Lp(a) with LDLR 
overexpression. Our results also show that Lp(a) internalization is significantly reduced 
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in human FH fibroblasts with a defective LDLR compared to fibroblasts with WT LDLR 
function (Fig. 5.6A). Fibroblasts do not express apoB and, not surprisingly therefore, the 
internalization of apo(a) is not affected by PCSK9 in either the control or LDLR 
defective fibroblast cells (Fig. 5.6B). Collectively, these results definitively indicate a 
role for the LDLR in internalization of Lp(a) through the apoB component rather than 
apo(a).  
PCSK9 has been reported to downregulate other members of the LDLR, 
specifically the VLDLR and the apoE2 receptor [35]. It is not known if these are ligands 
for Lp(a) in vivo, but it does not appear that they are playing a role in Lp(a) 
internalization in our experiments, at least with respect to the PCSK9-dependent 
component. This conclusion stems from our observations that Lp(a) internalization is 
insensitive to PCSK9 in the presence of antibodies that block the LDLR (Fig. 5.5D) or in 
fibroblasts lacking functional LDLR (Fig. 5.6A).  
It is notable that Lp(a) lowering by PCSK9 inhibitory antibodies is of a lower 
magnitude (~30%) compared to LDL (~70%) [25-29]. Because LDL concentrations are 
higher than Lp(a) on a particle number basis, LDL can compete with Lp(a) for binding to 
the LDLR. Considering the concentration of plasma LDL is generally far greater than that 
of Lp(a), it increases its likelihood of clearance through the LDLR compared to Lp(a). It 
is also notable that all study subjects receiving PCSK9 inhibitory antibodies were also 
receiving an optimal dose of statin [27], and an Lp(a) lowering effect was still observed. 
In this setting, by increasing hepatic LDLR to supraphysiological levels, there is a 
profound lowering of LDL levels which may in turn allow for the clearance of Lp(a) 
through the LDLR. This was also observed in vivo in which Lp(a) catabolism 
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significantly increased in mice overexpressing LDLR [20]. Our results clearly suggest 
that the effects of PCSK9 inhibitory antibodies on Lp(a) levels in vivo are the 
consequence of greater LDLR-mediated catabolism of Lp(a). Therefore, although the 
LDLR may not be a major route of clearance of Lp(a) under most circumstances, its 
importance increases in the setting of therapy to increase LDLR numbers, particularly by 
the use of inhibitory antibodies against PCSK9.  
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 Elevated levels of Lp(a) have been identified as an independent risk factor for 
CHD [1, 2]. However, the pathophysiological mechanisms by which Lp(a) mediates its 
harmful effects are not entirely understood. The aim of this work was to identify the 
mechanism of how Lp(a) can effect pericellular plasminogen activation, and to extend 
our understanding of Lp(a) catabolism. The role of Lp(a)/apo(a) in pericellular 
plasminogen activation was evaluated in vascular and blood cells. In addition, the role of 
novel apo(a) receptors in the context of plasminogen activation was assessed. 
Furthermore, the mechanism by which Lp(a)/apo(a) is catabolised and how this may 
potentially be regulated by PCSK9 was investigated. We found that Lp(a)/apo(a) can 
inhibit pericellular plasminogen activation through attenuating Glu- to Lys-plasminogen 
conversion. As well, a variety of receptors- uPAR, αMβ2, and αVβ3- were implicated in 
regulating plasminogen activation and mediating the ability of apo(a) to inhibit 
plasminogen activation on vascular and blood cells. Finally, we determined that Lp(a) 
catabolism can be regulated by PCSK9 through LDLR-dependent uptake of Lp(a).  
 
6.1 LP(a)/APO(a) INHIBITS PERICELLULAR PLASMINOGEN ACTIVATION  
Previous reports have established that apo(a) inhibits tPA-mediated fibrin clot 
lysis [3] and tPA-mediated plasminogen activation on the fibrin surface [4-7]. Apo(a) 
was found to inhibit fibrin clot lysis with tPA-mediated activation of Glu-plasminogen 
and to a less extent with either uPA as a plasminogen activator or with Lys-plasminogen 
[3]. These findings illustrate that the key inhibitory ability of apo(a) is to attenuate the 
conversion of Glu- to Lys-plasminogen on fibrin clots. Apo(a) was reported by our group 
to inhibit plasminogen activation through what was described as an equilibrium template 
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model with tPA, plasminogen, apo(a), and fibrin interacting in a quaternary complex [4]. 
Additionally, apo(a) was shown to attenuate the conversion of Glu-plasminogen to Lys-
plasminogen on the fibrin surface [8]. Apo(a)-mediated inhibition of fibrinolysis, as well 
as Glu- to Lys-plasminogen conversion, was not dependent on apo(a) isoform size [4, 8]. 
Critical roles for the KV domain and the strong LBS in KIV10 were shown for both 
optimal inhibitory effects of apo(a) on fibrin mediated plasminogen activation as well as 
Glu- to Lys-plasminogen conversion [4, 8]. A N-terminally truncated version of apo(a) 
(missing KIV types 1-4) was unable to inhibit tPA-mediated Glu-plasminogen activation 
on the fibrin surface to the same extent as the full length version indicating that KIV 
types 1-4 of apo(a) are required for maximal inhibition of plasminogen activation [4]. 
However, the N-terminal domain of apo(a) was not required for apo(a) mediated 
inhibition of Glu- to Lys-plasminogen conversion on the fibrin surface [8]. Removal of 
the protease domain of apo(a) did not affect its ability to inhibit tPA-mediated Glu-
plasminogen activation on the fibrin surface indicating that the interaction between 
apo(a) and plasminogen in solution is not required for this process [4]. Together these 
findings illustrate that there are common domains necessary for the ability of apo(a) to 
inhibit both plasminogen activation and Glu- to Lys-plasminogen conversion on the 
fibrin surface, although there are contrasting roles for some apo(a) domains in these two 
processes. This may reflect the fact that different enzymes are required in catalyzing the 
reactions for plasminogen activation (tPA) and for Glu- to Lys-plasminogen conversion 
(plasmin). A corresponding level of understanding of the ability of apo(a) to inhibit 
plasminogen activation and Glu- to Lys-plasminogen conversion on cell surfaces is 
critical as this is one of the potential pathophysiological roles for Lp(a). Plasmin 
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generated via cell surface receptors contributes not only to fibrinolysis and thrombolysis 
[9-11], but also to events involved in atherogenesis, cell migration and proliferation, 
angiogenesis, inflammation, wound healing, and cancer [12-20].  
 As a result, the role of apo(a) in potentially inhibiting pericellular plasminogen 
activation was explored in Chapter 2. As we report for the first time, the addition of 
apo(a) resulted in a significant dose-dependent decrease in plasminogen activation. A 
greater than 50% decrease in plasminogen activation was observed in the presence of the 
maximum concentration of apo(a) utilized on HUVECs, THP-1 monocytes, and THP-1 
macrophages; the extent of the ability of apo(a) to inhibit plasminogen activation was 
similar in the three cell lines utilized. Critical roles for the KV domain and the strong 
LBS in KIV10 were required for optimal inhibitory ability of apo(a). These findings are in 
agreement with previous studies conducted on the fibrin surface with regard to the role of 
apo(a) isoform size and critical domains necessary for optimal inhibition of plasminogen 
activation and Glu- to Lys-plasminogen conversion on fibrin surface [4, 8].  
We have shown that low concentrations of Lp(a) are effective at reducing 
plasminogen activation on HUVECs and THP-1 monocytes but not on THP-1 
macrophages. Apo(a) was found to be more potent than Lp(a) for inhibition of 
plasminogen activation on THP-1 macrophages and HUVECs suggesting that the apo(a) 
component of Lp(a) is responsible for the inhibitory ability. These results are expected as 
apo(a) shares homology with plasminogen [21] and thus may compete with plasminogen 
for binding sites on cellular receptors. Similar to THP-1 monocytes, Lp(a) was able to 
inhibit plasminogen activation to the same extent as apo(a) on the fibrin surface [4]. This 
indicates that the differences in the receptors present on distinct cell types directly play a 
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role in the potency of Lp(a) for inhibition of plasminogen activation. For example, Lp(a) 
may potentially bind to non-plasminogen receptors through its LDL component to 
different extents on various cell types thereby diluting the effect of the apo(a) component 
of Lp(a) to inhibit  plasminogen activation. In addition, different cell surfaces may bind 
and internalize Lp(a) to greater extents. For example, rapid uptake of Lp(a) has 
previously been shown in THP-1 macrophages [22]. This may explain the variation in the 
ability of Lp(a) to inhibit plasminogen activation on different cell surfaces. Although, 
higher concentrations of Lp(a) may have the ability to decrease plasminogen activation 
on THP-1 macrophages but were restricted to the relatively low concentration of the 
preparation.  
The inhibitory ability of plasminogen activation by apo(a) in the current study 
was examined using the plasminogen activator tPA and not uPA. tPA was used as it is 
expressed in ECs and has been previously shown to bind to various cell types including 
monocytes, platelets, and monocytoid cells [23-26]. It would be interesting to determine 
if apo(a) is able to inhibit pericellular plasminogen activation using uPA as an activator. 
The uPAR plays a key role in uPA-mediated plasminogen activation [27] and it is 
possible that apo(a) not only interferes with plasminogen/uPA binding to cell surface 
receptors (such as uPAR) but also in the positive feedback mechanism of converting sc-
uPA to its active tc-uPA form. Previous findings illustrated that apo(a), plasminogen, 
tPA, and fibrin interact as a quaternary complex which can attenuate the rate of 
plasminogen activation [4]. However, the current study did not quantitatively evaluate if 
the same mechanism occurs on the cell surface. Therefore, future experiments are needed 
to determine if apo(a) inhibits pericellular plasminogen activation through either: (i) 
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binding as a quaternary complex on the cell surface, (ii) simply competing with 
plasminogen for cell-surface binding sites, (iii) binding of apo(a) to plasminogen in 
solution and prevention of its subsequent activation, or (iv) a combination of the 
aforementioned events. If in fact inhibition of plasminogen activation is occurring 
through binding as a quaternary complex, than differences may be observed based on the 
cell-type (dependency of certain receptors such as uPAR) and the enzyme catalysing the 
reaction (tPA versus uPA). If apo(a) and plasminogen are exclusively competing for cell 
surface receptors, than the ability of apo(a) to inhibit plasminogen activation will be 
dictated by the receptors present on different cell types and not necessarily the type of 
plasminogen activator. If inhibition is occurring through simply binding of plasminogen 
and apo(a) in solution than no difference in the enzyme catalyzing the reaction or cell-
type should dictate the ability of apo(a) to inhibit plasminogen activation.  
 The mechanism of how apo(a) can inhibit pericellular plasminogen activation was 
explored in Chapter 3. The native circulating form of plasminogen, Glu-plasminogen, is 
in a closed conformation that does not allow for rapid activation to plasmin by 
plasminogen activators [28, 29]. However, binding of Glu-plasminogen to cell surface 
receptors results in a more open conformation and accessibility to plasminogen activators 
or plasmin [30]. Cleavage of Lys
77
-Lys
78
 by plasmin results in the removal of the N-
terminal tail domain and formation of Lys-plasminogen [31]. Unlike Glu-plasminogen, 
Lys-plasminogen adopts a more extended, open conformation [28, 29]. This open form is 
a much better substrate for plasminogen activators. Previous results have identified that 
Glu- to Lys-plasminogen conversion is the primary driver of plasminogen activation on 
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ECs [32]. As well, our group has shown that apo(a) can inhibit Glu- to Lys-plasminogen 
conversion on the fibrin surface [8].  
The inhibitory effect of apo(a) on pericellular plasminogen activation may 
potentially occur through attenuating Glu- to Lys-plasminogen conversion. In the current 
study, we have shown that apo(a) is a potent inhibitor of Glu- to Lys-plasminogen 
conversion on both HUVECs and SMCs. Isoform size of apo(a) did not affect its ability 
to inhibit Glu- to Lys-plasminogen conversion. The domains of apo(a) that are required to 
inhibit Glu- to Lys-plasminogen conversion are similar to that observed in Chapter 2 with 
respect to the ability of Lp(a)/apo(a) to inhibit pericellular plasminogen activation as well 
as to previous findings of Lp(a)/apo(a)-mediated inhibition of plasminogen activation and 
Glu- to Lys-plasminogen conversion on the fibrin surface [4, 8]. We have shown that 
removal of the strong LBS in KIV10 abolished the ability of apo(a) to inhibit Glu- to Lys-
plasminogen conversion on vascular cells. The protease domain as well as the KV 
domain were also identified as necessary for the maximal ability of apo(a) to inhibit Glu- 
to Lys-plasminogen conversion on vascular cells. The importance of these domains was 
also illustrated with respect to their requirement for apo(a)-mediated inhibition of 
pericellular plasminogen activation on fibrin [4], as well as vascular and blood cells 
(Chapter 2). The KV domain was also required for the ability of apo(a) to inhibit Glu- to 
Lys-plasminogen conversion on the fibrin surface [8]. However, it is unknown if the LBS 
present in KV is required for the ability of apo(a) to inhibit this process. Apo(a) partially 
retained the ability to inhibit Glu- to Lys-plasminogen conversion in the absence of the 
protease domain on vascular cells. Previous results have shown that apo(a) can bind to 
plasminogen through the protease domain of apo(a) in solution [33]. As a result, the 
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predominant mechanism for which apo(a) inhibits Glu- to Lys-plasminogen conversion 
on vascular cells may not be through the binding of apo(a) to plasminogen in solution.  
 Binding of Lp(a)/apo(a) to cell surface receptors is assumed to occur 
predominantly through LBSs in apo(a) KIV types 5-8, KIV type 10, or KV in a similalr 
manner as plasminogen. Plasminogen has previously been shown to bind to cell surface 
receptors containing a carboxyl-terminal lysine residue [12]. Carboxyl-terminal lysines 
present on cell-surface receptors are responsible to a greater extent for plasminogen 
activation than for plasminogen binding. A previous study that removed carboxyl-
terminal lysine residues on monocytoid cells resulted in a ~60% decrease in plasminogen 
binding and >95% decrease in plasminogen activation [26]. However, a previous report 
illustrated that apo(a) can effectively bind to ECs even with removal of the strong LBS 
present in KIV10 [34]. It has generally been assumed that Lp(a)/apo(a) can potentially 
disrupt the physiological functions of plasminogen by virtue of the high level of 
homology between the two, including the lysine-binding function. Nevertheless, apo(a) 
may bind to different cell surface receptors than plasminogen, or to receptors proximal to 
plasminogen receptors that result in steric hindrance of the ability of plasminogen to bind 
to cell surface receptors. The role of carboxyl-terminal lysine-containing receptors on the 
ability of apo(a) and plasminogen to compete for binding sites on vascular and blood 
cells was therefore explored.  
 As described in Chapter 2, removal of carboxyl-terminal lysines, through 
treatment with CpB, resulted in a small decrease in plasminogen activation on HUVECs, 
THP-1 monocytes, and THP-1 macrophages. A concomitant decrease in plasminogen 
binding was observed using these three cell lines. The addition of the lysine analogue ε-
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ACA resulted in almost complete abolishment of the ability of plasminogen to bind to the 
cell surfaces. Conversely, apo(a) binding slightly decreased following CpB treatment in 
THP-1 monocytes and THP-1 macrophages, but not on the surface of HUVECs. Apo(a) 
binding was abolished by the addition of ε-ACA to THP-1 monocytes and THP-1 
macrophages; this was not observed using HUVECs. These results suggest that apo(a) 
binding to ECs is most likely not dependent on receptors containing a carboxyl-terminal 
lysine residue, but that internal lysines in receptors may play a role.  
  Competition binding experiments were also conducted in order to determine if 
apo(a) or plasminogen can compete with one another for binding sites on vascular and 
blood cells. It is important to note that apo(a) and plasminogen can bind to each other in 
solution and may result in a “piggy-back” effect whereby apo(a) can still bind to cell or 
fibrin surfaces when plasminogen is bound to it, or vice versa [33]. The potential 
confounding effects of piggy-backing complicates the interpretation of competition 
experiments. We found that unlabelled plasminogen was unable to compete for binding 
of fluorescently labelled apo(a) to vascular and blood cells. However, unlabelled apo(a) 
effectively competed with fluorescently labelled plasminogen for binding to the cell 
surface. These results suggest that apo(a) can bind to plasminogen in solution, and that 
the complex retains the ability to bind to the cell surface through apo(a), but not through 
plasminogen. This may be a potential mechanism by which apo(a) interferes with both 
plasminogen activation and Glu- to Lys-plasminogen conversion. The lack of 
competition for one another may also indicate that apo(a) and plasminogen bind to 
different receptors. A previous study has shown that Lp(a) can compete with 
plasminogen for binding sites on monocytes and endothelial cells [35]. Plasminogen and 
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Lp(a) have similar affinities for plasminogen receptors (KD~1-3 µM), but plasminogen 
can bind to approximately 10 times more binding sites than Lp(a) [35]. These results 
indicate that Lp(a) has the potential to compete with plasminogen for binding to cellular 
receptors, but Lp(a)/apo(a) can only bind to a subset of plasminogen receptors. Further 
experiments are required in order to convincingly determine if apo(a) and plasminogen 
are competing for the same cellular receptor(s) or if they are predominantly binding to 
independent receptor(s). In vitro experiments can be conducted to determine if apo(a) can 
bind to known plasminogen receptors such as Plg-RKT and/or annexin II S100A10 [22, 
36]. 
 In conclusion, Lp(a)/apo(a) can inhibit pericellular plasminogen activation on 
vascular and blood cells through attenuating Glu- to Lys-plasminogen conversion. Apo(a) 
can potently inhibit tPA-mediated conversion of plasminogen to plasmin as well as 
plasmin mediated Glu- to Lys-plasminogen conversion, a key mechanism in accelerating 
the rate of plasminogen activation. The KV domain and the strong LBS in KIV10 were 
necessary for optimal inhibitory effect of apo(a) on plasminogen activation and Glu- to 
Lys-plasminogen conversion. The protease domain of apo(a) was required for maximal 
inhibition of Glu- to Lys-plasminogen conversion on vascular cells.  
These findings extend our knowledge on the effect of Lp(a)/apo(a) on 
antifibrinolytic/prothrombotic and atherosclerotic processes. The ability of Lp(a)/apo(a) 
to inhibit pericellular plasminogen activation can ultimately lead to a prothrombotic state 
through inhibition of fibrinolysis in vivo. Lp(a)/apo(a) mediated inhibition of pericellular 
plasminogen activation can have additional implications within the vasculature. For 
example, plasmin generated on the surface of vascular and blood cells play a key role in 
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the dissolution of mural thrombi [10]. Mural thrombi are formed following plaque 
disruption and subsequent exposure of thrombogenic components within the plaque 
architecture to that of the blood within the lumen. The thrombus formed can then remain 
attached to the damaged endothelium and contribute to the development of 
atherosclerosis [10]. Ideally, the mural thrombus forms a plug at the site of the weakened 
fibrous cap and damaged endothelium and is subsequently dissolved by plasmin. 
However, the mural thrombus can also be incorporated into the atherosclerotic plaque 
through reorganization of the vascular cells if the thrombus is not dissolved [10]. This 
would ultimately result in plaque growth and further progression of atherosclerosis. We 
have shown here that Lp(a)/apo(a) can significantly reduce the formation of plasmin on 
vascular and blood cells which potentially has significant implications in promoting the 
stability of a mural thrombus and ultimately leading to the progression of atherosclerosis.  
 
6.2 RECEPTORS INVOLVED IN APO(a) MEDIATED INHIBITION OF 
PLASMINOGEN ACTIVATION  
Plasminogen receptors are expressed on many cell types with no single receptor 
responsible for binding of plasminogen on the cell surface [12]. Plasminogen binding 
occurs with low affinity to these cellular receptors (Kd ~ 1 µM) but with high capacity, 
ranging from ~10
4
 sites on platelets to >10
7
 sites on ECs [12]. Various plasminogen 
receptors have been identified which accelerate the rate of plasminogen activation [12]. 
The uPAR assists in uPA-mediated plasminogen activation by clustering uPA on the cell 
surface in close proximity to plasminogen receptors [37]. Binding of sc-uPA to uPAR 
allows for cleavage of sc-uPA by plasmin to its active two-chained form (tc-uPA) [38, 
39]. As well, uPAR can also bind to vitronectin and β3 integrins [40, 41]. uPAR does not 
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contain a transmembrane domain and therefore transmits intracellular signals through 
interacting with various integrins, such as αVβ3 [41]. The role of uPAR in the context of 
tPA mediated plasminogen activation and the ability of Lp(a)/apo(a) to inhibit this 
process was explored in Chapter 4. Knockdown of uPAR in HUVECs resulted in a 
significant decrease in plasminogen activation as well as plasminogen and apo(a) 
binding. The ability of apo(a) to inhibit plasminogen activation was partially attributable 
to the interaction with uPAR. Importantly, the KV domain and the strong LBS in KIV10 
were required for apo(a) to bind to uPAR and to inhibit plasminogen activation. Similar 
to the results in Chapter 2, ε-ACA did not decrease binding of apo(a) on the cell surface 
of HUVECs, but did so on THP-1 monocytes and THP-1 macrophages.  
Overexpression of uPAR was also conducted in HUVECs, THP-1 monocytes, and 
THP-1 macrophages to validate the role of uPAR in tPA-mediated plasminogen 
activation. Overexpression of uPAR in these cells resulted in an increase in plasminogen 
activation. Interestingly, apo(a) was able to inhibit uPAR-mediated plasminogen 
activation on HUVECs, but not on THP-1 monocytes or THP-1 macrophages. These 
results underscore the variation in the identity and role of plasminogen/apo(a) receptors 
on various cell types. Apo(a) and plasminogen binding increased with uPAR 
overexpression in HUVECs, THP-1 monocytes, and THP-1 macrophages. The KV 
domain and strong LBS in KIV10 of apo(a) were required for maximal binding of apo(a) 
to uPAR on HUVECs and THP-1 monocytes, but not on THP-1 macrophages. 
Interestingly, apo(a) did not inhibit plasminogen activation via uPAR on THP-1 
monocytes or THP-1 macrophages even though an increase in apo(a) binding was 
observed following uPAR overexpression. These findings suggest that the ability of 
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apo(a) to inhibit plasminogen activation through uPAR is dependent on uPAR interacting 
with another cell-type specific protein such as an integrin. However, these findings do not 
directly address whether uPAR can in fact bind directly to tPA, plasminogen, or apo(a). 
Future experiments are needed to identify whether plasminogen or apo(a) can bind 
directly to uPAR or through interaction with another protein to which uPAR is bound. A 
more direct approach, using in vitro binding experiments, should be conducted with 
purified uPAR and apo(a) or plasminogen to determine if in fact they can bind with each 
other. 
As noted above, uPAR can also interact with different integrins. Previous studies 
have shown that apo(a) can stimulate EC growth and migration through integrin αVβ3 
[42], and that Lp(a) can bind to αMβ2 integrin and recruit inflammatory cells [43]. Based 
on these observations, the role of integrins αMβ2 and αVβ3 was explored in the ability of 
apo(a) to modulate the plasminogen activation system (Chapter 4). Plasminogen 
activation was reduced in the presence of a monoclonal antibody targeting either integrin 
αM or integrin β2 on THP-1 monocytes and HUVECs. A monoclonal antibody targeting 
αVβ3 also resulted in a minor decrease in plasminogen activation on HUVECs with a 
more substantial decrease observed using THP-1 monocytes. Addition of the highest 
concentration of apo(a) with THP-1 monocytes or HUVECs resulted in no difference in 
plasminogen activation in the absence or presence of monoclonal antibodies targeting αM, 
β2, or αVβ3 integrins. The collective data indicate that apo(a) may inhibit plasminogen 
activation to an extent through these receptors. In general, these findings confirm 
previous reports that indicate that a large subset of receptors contributes to plasminogen 
activation on various cell types. The receptors tested in the present study contributed to 
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plasminogen activation and the ability of apo(a) to inhibit this process; however, there is 
no single plasminogen receptor responsible for plasminogen activation or the ability of 
apo(a) to inhibit this process. 
As mentioned above, the ability of apo(a) to inhibit pericellular plasminogen 
activation not only contributes to inhibition of fibrinolysis and thrombolysis [9-11], but 
also to events involved in atherogenesis, cell migration and proliferation, angiogenesis, 
inflammation, wound healing, and cancer [12-20]. This provides a basis for the suggested 
link between Lp(a) and atherosclerotic and thrombotic processes as well as nonvascular 
diseases such as cancer. The direct role of Lp(a)/apo(a) in these cellular processes, with 
respect to plasminogen activation, has yet to be fully elucidated, either in 
pathophysiological contexts (at high Lp(a) concentrations) or as a protective agent in 
normal physiology (at low Lp(a) concentrations). It would be interesting to determine if 
Lp(a)/apo(a) can directly inhibit plasminogen activation leading to attenuation of cancer 
metastasis and invasion. Recent intriguing evidence suggest that Lp(a) levels <80 mg/dL 
are a significant risk factor for different forms of cancer including hepatocellular 
carcinoma, pancreatic cancer, and leukemia with no association of Lp(a) levels as a risk 
factor for lung cancer [44]. It is possible that apo(a) can inhibit plasminogen activation on 
cancer cells. This would lead to less plasmin formation and subsequently delay 
degradation of the ECM, thereby preventing uncontrolled tissue remodelling. 
Considering that the uPAR plays a critical role in uPA-mediated plasminogen activation 
in the context of cell remodelling [41] and that apo(a) may regulate plasminogen 
activation via uPAR (Chapter 4), it is tempting to speculate that Lp(a)/apo(a) may play a 
role in impeding cancer progression. This may present a novel mechanism and potential 
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therapeutic option to delay cancer metastasis and invasion by the ability of Lp(a)/apo(a) 
to inhibit plasmin formation. This may present a protective physiological function of 
Lp(a). Future work should explore the potential ability of Lp(a)/apo(a) to inhibit cancer 
metastasis and invasion.  
 
6.3 PCSK9 MEDIATED LP(a) CATABOLISM AND THE ROLE FOR THE LDLR 
 The most commonly used therapeutic option for treatment of individuals with 
elevated plasma Lp(a) has been through niacin therapy  [45]. However, treating patients 
with niacin has been associated with often intolerable side effects [46]. Additionally, 
recent evidence suggests that niacin therapy may not further decrease cardiovascular risk, 
including that associated with elevated Lp(a) levels, compared to administration of statin 
therapy alone [47, 48]. Nevertheless, niacin can lower Lp(a) levels by 20-30% and is still 
recommended for administration to high-risk patients with elevated Lp(a) levels over 50 
mg/dL [45].  
A recent therapeutic approach to lowering Lp(a) levels is through blocking the 
function of PCSK9 [reviewed in ref. 49], although the mechanism by which PCSK9 may 
regulate Lp(a) levels is unknown. In Chapter 5, we present strong evidence that PCSK9 
can decrease Lp(a) internalization in HepG2 hepatic cells and human primary fibroblasts 
through the LDLR. In this study, we showed that exogenous treatment of HepG2 cells 
with PCSK9 effectively and potently reduced the extent of Lp(a) and apo(a) 
internalization. These results are intriguing in that they corroborate in vivo findings 
demonstrating a role for PCSK9 in lowering Lp(a) levels [49]. Blocking PCSK9 with a 
monoclonal antibody results in ~30% and ~70% decrease in Lp(a) and LDL levels in 
humans respectively [50-52]. Clearly, LDL is a better ligand for the LDLR compared to 
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Lp(a). As a result, the decrease in Lp(a) levels observed through PCSK9 inhibition may 
be due in part to a drastic decrease in LDL levels and subsequently less competition for 
Lp(a) clearance via the LDLR. It is important to note that niacin treatment and blocking 
PCSK9 function is not specific in lowering Lp(a) as a significant decrease in LDL levels 
are also observed [46, 49].  
The decrease observed for Lp(a) and apo(a) internalization in HepG2 cells 
following PCSK9 treatment may be the result of binding of Lp(a) to PCSK9 in solution, 
thereby preventing catabolism through the LDLR. This follows from a recent report that 
the apoB-100 component of LDL can bind to PCSK9 in solution, preventing the complex 
from catabolism through the LDLR [53]. As such, we conducted in vitro experiments to 
determine if PCSK9 can bind to Lp(a) and prevent the ability of Lp(a) to be catabolised 
through the LDLR similar to that observed for LDL. We found that Lp(a) does not bind 
to PCSK9 in vitro, nor does it protect the LDLR from degradation unlike what was 
observed for LDL suggesting that the apo(a) component of Lp(a) may interfere with the 
ability of PCSK9 to interact with apoB-100. It would be interesting to determine if the 
inability of Lp(a) to bind to PCSK9 is isoform size-dependent. Lp(a) has been previously 
shown to display differences in affinity to mononuclear cells with larger isoforms binding 
to the cell surface with lower affinity than small isoforms suggesting that smaller 
isoforms may potentially bind to other ligands such as PCSK9 [54]. Future work should 
be invested into determining if smaller Lp(a) isoforms can bind to PCSK9 in vitro. If 
binding of smaller isoforms of Lp(a) to PCSK9 does occur than it may prevent the 
function of PCSK9 to target the LDLR for degradation, which would lead to increased 
levels of LDL and potentially Lp(a).  
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The next step was to determine which receptor is responsible for the ability of 
PCSK9 to regulate Lp(a) catabolism. The GOF D374Y PCSK9 mutant is more active 
than wild-type PCSK9 at targeting the LDLR complex for degradation [55]. Interestingly, 
treatment with the GOF PCSK9 mutant D374Y resulted in a more robust effect in 
reducing Lp(a) and apo(a) internalization in HepG2 cells suggesting a role for the LDLR. 
Three other independent experiments were conducted in order to determine if the LDLR 
does in fact play a role in the effect of PCSK9 in Lp(a)/apo(a) catabolism. We found that 
overexpression of the LDLR in HepG2 cells resulted in a significant increase in Lp(a) 
internalization with a non-significant increase observed using apo(a). PCSK9 did not 
significantly reduce Lp(a) or apo(a) internalization with LDLR overexpression, possibly 
attributed to the significant enhancement in LDLR protein levels without increasing the 
concentration of PCSK9. These results suggest that the apoB-100 component of Lp(a) is 
responsible for the ability of Lp(a) to be catabolised by the LDLR. In another experiment, 
monoclonal antibodies targeting the LDLR were used to block the receptor to determine 
if an effect on Lp(a) catabolism is observed. A significant decrease in both Lp(a) and 
apo(a) internalization in HepG2 cells was observed using two different LDLR 
monoclonal antibodies, again suggesting a role for the LDLR. As a third line of evidence, 
human fibroblasts with either defective or no LDLR activity were utilized to determine 
the contribution of the LDLR to Lp(a) catabolism. We showed that Lp(a) internalization 
was significantly reduced in human primary fibroblasts with a defective or null LDLR 
compared to fibroblasts with normal LDLR activity. Crucially, apo(a) internalization was 
not affected by PCSK9 using either fibroblasts with normal LDLR or defective LDLR 
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activity. These results demonstrate conclusively that the effects of PCSK9 on Lp(a) 
catabolism are specifically attributable to the effect of PCSK9 on the LDLR.  
The inability of apo(a) internalization to be modulated by PCSK9 in fibroblasts 
may indicate the importance for the non-covalent attachment of apo(a) to LDL. Unlike 
HepG2 cells, fibroblasts do not endogenously express apoB-100 and apo(a) is therefore 
unable to “piggy-back” on LDL in fibroblasts. The results indicate the importance for 
apo(a) to associate with apoB-100 in order for internalization through the LDLR to occur. 
Interaction between apo(a) and apoB-100 secreted by HepG2 cells is required to 
modulate apo(a) internalization by either PCSK9 treatment or the addition of monoclonal 
LDLR blocking antibodies. The importance of the apo(a) interaction with apoB-100 for 
LDLR-dependent uptake was further illustrated utilizing the 17KΔLBS7,8 variant which 
has been previously shown to be unable to associate with apoB-100 [56]. Removal of the 
weak LBS in each of the KIV type 7 and 8 domains resulted in a significant decrease in 
the ability of this variant to be internalized compared to wild-type apo(a). Together, these 
results suggest that the non-covalent interaction between apo(a) and apoB-100 is 
necessary for internalization to occur through the LDLR and hence to be modulated by 
PCSK9.  
The mechanism by which Lp(a)/apo(a) degradation occurs through PCSK9 was 
also explored in Chapter 5. The results indicate that Lp(a)/apo(a) internalization occurs 
through clathrin-mediated endocytosis in hepatic cells. Treatment of HepG2 cells with a 
lysosomal inhibitor, but not a proteasomal inhibitor, resulted in intracellular accumulation 
of Lp(a)/apo(a) consistent with a lysosomal degradation pathway. Collectively, these 
results suggest that Lp(a)/apo(a) internalization occurs through clathrin-coated pits and is 
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subsequently targeted for lysosomal degradation consistent with the LDLR 
internalization pathway. Future work should be conducted in order to determine if a co-
receptor or protein is required for binding to the Lp(a):LDLR complex in order to target 
Lp(a) into clathrin coated pits for subsequent lysosomal degradation. This is suggested 
based on a report that a PCSK9 mutant lacking the M2 domain is unable to target the 
PCSK9:LDLR complex for degradation, but can still effectively bind to the LDLR [57]. 
It would also be interesting to determine if the LDLR is recycled following 
internalization with Lp(a) similar to the LDL:LDLR complex, or if the Lp(a):LDLR 
complex is targeted for degradation as has been described for the PCSK9:LDLR 
complex.   
 There still remain many questions with regard to how Lp(a) is catabolised in 
humans. The results in Chapter 5 indicate that PCSK9 can mediate Lp(a) catabolism 
through the LDLR, at least in a cell culture model. The LDLR may not necessarily 
represent the main Lp(a) receptor responsible for its clearance in vivo. Traditional statin 
therapy, which results in an increase in hepatic LDLR number, generally has minimal or 
no effect on Lp(a) levels. However, the LDLR may play a role in Lp(a) clearance in 
situations in which LDLR levels are furthere elevated, such as with the use of PCSK9 
inhibitors with statins [49]. The role of the LDLR and PCSK9 must be explored in Lp(a) 
catabolism utilizing in vivo models. Currently, the role for the LDLR remains 
controversial with many studies conducted indicating a role for this receptor on Lp(a) 
catabolism [58-67], while others showing no role for this receptor [68-72]. A potential 
reason for the contradictory findings is that commonly used animal models, such as mice, 
do not contain the LPA gene, and may not be equipped with the optimal tools for Lp(a) 
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catabolism [73]. Therefore, caution must be used when studying Lp(a) catabolism using 
in vivo models other than in humans and Old World monkeys, which have the LPA gene 
[73]. Future experiments are required to determine if mouse models are appropriate for 
examining the role of the LDLR in Lp(a) clearance. For example, the role of the LDLR in 
binding and degradation of Lp(a) can be determined through ex vivo experiments using 
wild-type and LDLR
-/- 
mice in the presence or absence of PCSK9. The findings can then 
be compared to those in Chapter 5 to determine if mice are an appropriate model for 
evaluating Lp(a) catabolism.  
It would be interesting to study Lp(a) clearance in mice overexpressing human 
apo(a) and apoB-100 with or without the addition of either purified PCSK9 or a 
monoclonal antibody targeting the endogenous PCSK9. Additionally, determination of 
the role of the LDLR, or other receptors that can be targeted by PCSK9 in Lp(a) 
catabolism using knockout mouse models of these receptors. In this regard, PCSK9 has 
been shown to target not only the LDLR but also VLDLR, ApoER2, and LRP-1 for 
degradation [74, 75]. Since the liver has been shown to be the primary route for Lp(a) 
clearance [68, 76], study of the role of ApoER2 and LRP-1 should be prioritized since 
these receptors are expressed in the liver, unlike VLDLR.  
Additional novel receptor(s) that are not regulated by PCSK9 may also be 
responsible for Lp(a) clearance. A more substantial decrease in LDL compared to Lp(a) 
levels is observed following PCSK9 inhibition which suggests that other receptors, in 
addition to the LDLR, can contribute to the clearance of Lp(a); these receptors would not 
be regulated by PCSK9. If in fact the LDLR, or other receptors targeted by PCSK9, are 
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the sole receptor(s) responsible for Lp(a) clearance, than similar lowering results should 
be observed to that of LDL for PCSK9 based therapies, which is not the case.  
Owing to the high degree of homology between apo(a) and plasminogen [21], it is 
therefore possible that Lp(a) can be cleared from the circulation by plasminogen 
receptors via the apo(a) component of Lp(a). Previous studies have shown that 
Lp(a)/apo(a) can compete for binding to plasminogen receptors [77, 78]. Additionally, 
apo(a) has been shown to be taken up by FH fibroblasts through plasminogen receptors 
[58]. There may potentially be a role for the receptors identified in Chapter 4- uPAR and 
integrins αMβ2 and αVβ3- in Lp(a) clearance. However, the role for this class of 
plasminogen receptors in Lp(a) binding and potentially its clearance from plasma in vivo 
is unknown. Previous work has shown that uPAR can interact with LRP and undergo 
clathrin-mediated endocytosis [79]. It may therefore be possible that Lp(a) interacts with 
uPAR and the Lp(a):uPAR:LRP complex is subsequently catabolised. Future work is 
needed to explore the possibility that Lp(a) is cleared through the apo(a) component by 
plasminogen receptors or other yet to be identified receptors. These findings will enable 
the generation of more specific therapeutic targets for lowering elevated Lp(a) plasma 
levels through modulation of Lp(a) catabolism.   
 
6.4 CONCLUDING REMARKS 
Lp(a) has been identified as an independent, causal risk factor for CHD, although 
the pathophysiological and physiological roles of Lp(a) remain elusive [1, 2]. The roles 
of Lp(a) isoform size, independent of Lp(a) concentration, and the impact on CHD still 
remain controversial. Lp(a) contains multifunctional properties attributable to both the 
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LDL and apo(a) components that result in a multitude of different mechanisms dependent 
on the vascular setting. For example, we have shown in the current study that elevated 
levels of Lp(a)/apo(a) can inhibit plasmin formation on vascular cells, which may 
promote atherosclerosis in the context of a mural thrombi. Conversely, a decrease in 
plasmin formation on cancer cells may be beneficial as it can potentially play a role in 
inhibiting cancer metastasis and invasion [44]. Lp(a) therefore possesses the ability to 
promote atherosclerosis and thrombosis as well as nonvascular processes, such as cancer, 
depending on the concentration and vascular setting. 
Lp(a) is a challenging lipoprotein to study as it is only present in humans and Old 
World monkeys, which questions the validity of common in vivo models used to study 
Lp(a) [73]. The physiological role of Lp(a) is difficult to determine as knockout models 
are not feasible. The harmful effects of Lp(a) may be significantly reduced with the 
proper management for individuals with elevated plasma levels. Blocking the function of 
PCSK9 may present an effective method for reducing elevated levels of Lp(a) through 
increasing Lp(a) catabolism. Future work at reducing the rate of apo(a) synthesis, through 
ASO therapy, may offer a strategy to specifically lower Lp(a) levels at the rate of 
production and may provide an attractive therapeutic option. Many questions remain in 
determining the mechanisms of action and deciphering the harmful and potential 
protective roles of Lp(a). Further elucidation of the multiple roles of Lp(a) will allow for 
the evaluation the effects of targeting Lp(a) levels on cardiovascular and nonvascular 
outcomes.  
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